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Abstract 
 
Innate-like T cells, including invariant natural killer T (NKT), mucosal associated 
invariant T (MAIT) cells or γδ T cells are associated with regulation of anti-tumour 
responses in humans and mice, although their exact role remains controversial. We have 
studied innate-like T cells from tumour infiltrating lymphocytes (TILs), peripheral blood 
mononuclear cells (PBMCs) and bone marrow (BM) derived cells from patients 
undergoing treatment for cancer and compared their characteristics to cells from healthy 
donors. We identified that the overall frequency of innate-like T cells was variably 
deficient in patients with blood or solid cancers. Interestingly, the deficiency of innate-
like T cells appeared to be more severe than that of other T cells suggesting a specific 
impact. An increased proportion of activated γδ T cells and MAIT cells suggested they 
could have a functional role in responses to cancer cells. Despite the deficiency of these 
subsets in patient tissue samples, we showed that anti-tumour capacity of innate-like T 
cells was intact as innate-like T cells in most patient groups had a similar cytokine 
response to stimulation as cells from healthy donors. Finally, we also showed that innate-
like T cells appeared not to broadly recognize cancer cells, as no direct impact was 
identified in their overall frequency or cytokine expression when exposed to autologous 
tumour cells, cancer lysates or lipids extracted from patient tumours, or colorectal cancer 
cell lines. This project was aimed at providing an overview of potential defects in innate-
like T cells based on my analysis of a wide range of samples in the Fiona Elsey Cancer 
Research Institute (FECRI) Tissue Bank. As a result of my studies, we have established a 
clear understanding of innate cells in cancer, which provides a basis for future studies. 
Our novel findings include analysis of frequency distribution and functional capacity of 
MAIT cells in solid tumours other than colorectal cancer and in patients with blood 
cancers such as chronic lymphocytic leukaemia (CLL), non-Hodgkin’s lymphoma (NHL), 
multiple myeloma (MM) or other haematological malignancies, something not previously 
reported. Taken together, we showed that a deficiency of innate- like T cells is common 
in patient groups with cancer and could be a risk factor for disease and possibly a target 
for immunotherapies, but the functional capacity was intact for cytokine responses. 
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Chapter 1: Literature review 
1.1. Introduction 
Our immune system provides defence against foreign pathogens, such as bacteria, 
parasites and viruses, which may be harmful to our body. The immune system can also 
respond to cancer, although the effectiveness of anti-cancer immunity varies between 
forms of cancer and between individuals. Cancer cells sometimes express antigens that 
can be recognized by immune cells, but they can also escape the immune system by 
mutations and establishing immune-suppressive microenvironments 1–3.  
Immune cells can sometimes promote cancer 4 by releasing immune-regulatory 
factors, such as transforming growth factor (TGF-β) and interleukin 10 (IL-10) 5, but 
there are many types of immune cells with different function.  More research is needed to 
understand their dynamics and function in cancer, but one interesting group of cells 
linked to cancer in mice and humans that have only been identified relatively recently are 
innate-like T cells, which include NKT, γδ T and MAIT cells. Innate-like T cells have the 
capacity to induce or suppress anti-cancer immune responses in mice, but there have been 
conflicting findings in patient studies that suggest more studies are required to understand 
their importance. We have conducted a detailed analysis of innate-like T cells isolated 
from blood, tumours and bone marrow of patients and compared them to cells from 
healthy donors and to conventional T cells to better understand their importance in 
regulating the immune response against cancer in human patient groups.  
 
1.2. Immune system organisation  
The immune system contains innate and adaptive arms. The innate immune system is 
evolutionarily conserved and provides the first line of defence against pathogens such as 
viruses and bacteria 6–8. The adaptive immune system provides a more specific response 
and can adapt or respond to new or changed pathogens 4,6,9. The innate and adaptive 
immune systems often interact with each other to maximise immune response efficiency 
and prevent damage to the host from prolonged inflammation 6. Innate-like T cells are 
part of the adaptive immune system, but they express some antigens and display some 
functions that are more often associated with innate cells. This thesis is focused on 
developing a better understanding of the importance of innate-like T cells in human 
cancer. 
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1.2.1. Innate immune system 
The innate immune system provides the first line of defence against pathogens and is 
orchestrated by an array of different cells, including natural killer (NK) cells, 
macrophages, mast cells, neutrophils, eosinophils and innate lymphoid cells (ILCs) 7,10,11. 
Innate immune cells usually respond rapidly to foreign or abnormal material recognized 
by receptors for conserved antigens expressed by pathogens. These pathogen-associated 
molecular patterns (PAMPs) are recognised through a variety of receptors collectively 
known as pathogen recognition receptors 12.  
Major histocompatibility complex (MHC) molecules are normally expressed by 
all human nucleated cells and act as a means to ‘present’ antigen to T cells, and an 
‘identification tag’ for the innate immune system to recognise ‘self’ cells 2,5. Cells that do 
not express MHC molecules (e.g. bacteria and some virally infected and/or abnormal self, 
such as cancerous cells) are recognized and destroyed by innate cells through cell lysis, 
phagocytosis and release of soluble messenger molecules such as interleukins and 
chemokines 6–8. 
 
1.2.2. Adaptive immune system 
The adaptive immune response is mobilised by T and B cells, which possess an enormous 
diversity of antigen receptors to recognise pathogens 20. B cells recognise antigens 
directly 13, whereas T cells require the antigen to be ‘presented’ to them by MHC 
molecules expressed by antigen-presenting cells (APCs) 7,14. The polymorphic structure 
of MHC helps to ensure variety of pathogen derived proteins can be presented 15. Thus, 
the adaptive immune system can recognise more diverse antigens than the innate immune 
system; however, the adaptive response normally takes longer to develop 4,7,14,16. When T 
and B cells recognise specific antigens, they rapidly proliferate to increase the number of 
cells capable of recognising that antigen 13,14,17. Following an adaptive immune response, 
a proportion persist as ‘memory’ T or B cells to provide a more rapid response if the 
pathogen is encountered again 17–19. I will provide an overview of the biology of the main 
adaptive cells and then a more detailed description of their importance in cancer. 
 
B cells. B cells develop in the bone marrow (BM) and when stimulated can produce 
antigen-specific antibodies 13,20. There are five distinct isotypes of antibodies with unique 
functions produced by B cells (IgM, IgD, IgG, IgA and IgE) 21. Key functions of these 
antibodies include;  binding target pathogens to prevent pathogenic mode of actions (i.e. 
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entry into healthy cells), activation of other immune cells by FC receptors or activation of 
complement system 21. 
 
T cells. T cells are adaptive immune cells that develop in the thymus 22–24. They are 
defined by co-expression of CD3 and T cell receptors (TCR) 26 that recognize antigen 
presented by MHC molecules expressed on the surface of other cells. The highly 
polymorphic MHC and TCRs allows for responses against a broad variety of antigens. 
The main T cell subsets express CD4 or CD8. CD4+ T cells release cytokines to regulate 
immune responses 27,28. CD4+ T cells have different subsets with different distinct 
functions. For example, Th1 response is characterized by expression of transcription 
factor T-bet 25,26. In contrast, Th2 responses are characterized by transcription factor 
GATA-3 and release of cytokines including IL-4 25,27. In contrast, CD8+ T cells release 
perforin and granzyme B that can lyse abnormal or infected cells 29,30.  
Smaller subsets of functionally distinct T cells are found within CD4+ and CD8+ 
lineages. For instance, CD4+ T cells include FoxP3+ regulatory T cells (Treg) that can 
suppress nearby immune cells by direct contact or by releasing cytokines such as TGF-β 
or IL-10 28–30,31. Other subsets of CD4+ T cells include the innate-like T cells that co-
express receptors that are usually expressed by NK cells 31,32 and have distinct functions 
and distribution. For example, T cells co-expressing CD161 or CD56 often localise to 
human liver and gut in higher proportions than in blood 31,33. CD161+ and CD56+ T cells 
can be cytotoxic and produce prodigious amounts of cytokines 31,33,34; however, their 
exact functional roles are not fully understood, especially in humans.  
Innate-like T cells often have TCRs restricted to non-MHC molecules, including 
MR1 (MAIT cells) and CD1d (NKT cells) 35–37. Innate-like T cells are often described as 
being a mixture of between conventional innate and adaptive immunity. 
 
1.2.3. Innate-like T cells 
NKT cells. A key feature of innate-like T cells is their expression of semi-invariant TCRs 
restricted by non-MHC antigen-presenting molecules 38,39 (Table i). For example, natural 
killer T (NKT) cells in mice and humans are restricted by CD1d 39 and have a semi-
invariant TCR that recognises the alpha galactosylceramide (αGal-Cer) glycolipid 37,39,40 
(Figure i). NKT cells also recognize some bacterial glycolipids including 
isoglobotrihexosylceramide, a mammalian glycolipid 41. The fact that NKT cells can 
respond to different glycolipids may be a factor in the diverse functional roles that are 
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reported 36. A defect in function or frequency of NKT cells is associated with cancer, 
however, the mechanisms remain unclear and there have been contradicting results. 
There are a group of CD1d-restricted NKT cells with more diverse TCR called 
Type 2 NKT cells that doesn’t respond to αGal-Cer 42. Type 2 NKT cells probably 
respond to naturally occurring self glycolipids, including sulfatide 42 and have also been 
associated with cancer 37, but this thesis will focus on Type 1 NKT cells (NKT cells). 
  NKT cells often co-express NK cell markers such as CD161 or CD94 37,43 as well 
as conventional T cell markers such as CD4 and CD8 44 (Table 1).  Most NKT cells are 
CD4+CD8- (CD4+) or CD4-CD8- (DN), with a small proportion CD4-CD8+ (CD8+). 
The CD4+ and CD4- subsets are reportedly functionally distinct with CD4- NKT cells 
associated with a Th1-type response of primarily IFNγ and TNF whereas CD4+ NKT 
cells have a Th0 type response that also includes IL-4 and IL-13 39,45. The cytokine profile 
of NKT cells is associated with expression of transcription factors such as T-bet and 
GATA3 as shown in mice studies 15. One intriguing characteristic is that NKT cells can 
rapidly produce cytokines within 1-2 hr of stimulation 46 due to their expression of pre-
formed mRNA for production of cytokines 47. NKT cells can also be stimulated in an 
antigen independent manner by IL-12, meaning they can become activated without TCR 
mediated antigen recognition.   
 
MAIT cells. Similar to NKT cells, mucosal-associated invariant T (MAIT) cells are 
characterised by semi-invariant TCRs consisting of a Vα7.2-Jα33 (TRAV1-2) chain, 
which is restricted by the MHC-like molecule MR1 48,49 (Figure i). In humans, early 
studies on MAIT cells used expression of surrogate markers such as CD161 or CD8 in 
combination with Vα7.2TCR 50,51, but more recently, an MR1 tetramer has been 
developed for specific detection of MAIT cells. Studies have confirmed that MAIT cells 
can also be identified on the basis of Vα7.2TCR and CD161 expression. Most MAIT cells 
are predominantly CD8+ or CD4-CD8- with a small population of CD4+ 52 (Table i). 
Like NKT cells, MAIT cells respond to stimulation with rapid release of cytokines such 
as IFNγ, IL-4 and IL-17 53, although it is not yet clear if there are distinct subsets. In 
regards to distinct functional subsets, more recent study reported using mouse model that 
expression of retinoic acid orphan receptor γt (RORγt) altered cytokine profile produced 
by MAIT cells 54. 
Production of IFNγ, TNF and IL-17 cytokines is associated with anti-cancer and 
anti-microbial responses 55,56. Indeed, MAIT cells are associated with anti-microbial 
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responses, especially in the gut, where MAIT cells were first discovered. The microbes to 
which MAIT cells respond include Escherichia coli, Mycobacterium tuberculosis and 
Mycobacterium bovis, among others. Antigen presentation to MAIT cell TCRs via MR1 
plays an important role in generating antigen-specific anti-microbial response 55,57,58. 
MAIT cells could respond to a broad range of microbes by recognition of vitamin B 
metabolites.  
MAIT cells have undergone clinical investigation in various patient groups, 
including M. tuberculosis in HIV patients, in which reduced cytotoxic capacity and 
increased programmed death 1 protein (PD-1) expression indicate exhaustion of MAIT 
cells 59,60. In another clinical study, patients with severe bacterial infections exhibited 
reduced frequency of MAIT cells compared with healthy individuals 61,62. Interestingly, a 
similar reduction in MAIT cell frequency was found in blood from patients with 
inflammatory bowel disease, but when inflammatory tissue and healthy tissue were 
compared, MAIT cell frequency was higher in the affected tissue 63.  
Changes to MAIT cells have also been reported in autoimmune diseases, with two 
studies showing that MAIT cell frequency was lower in blood of patients with multiple 
sclerosis than for healthy individuals 64,65. MAIT cells have similar functional capacities 
as NKT cells, and are thus considered likely to have a role in cancer regulation, despite 
there being few studies of MAIT cells in cancer patients. 
There are no reports of MAIT cells responding to viruses but MAIT cells can 
respond to bacteria and yeast. There is evidence of MAIT cells trafficking to disease sites 
as acute infection of M. tuberculosis reduced the frequency of MAIT cells in blood and 
increased in patient lung 66,67. Compared to other innate-like T cells such as NKT cells, 
there are relatively fewer studies conducted in context to cancer but there is increasing 
evidence that the frequency and function of MAIT cells are impacted in patients. 68,69.  
 
γδ T cells. Unlike NKT cells and MAIT cells, it is unclear whether γδ T cell TCRs are 
restricted by antigens presented by specific antigen-presenting molecules such as CD1d 
or MR1 70. What is unique about γδ T cell TCRs is that they do not comprise alpha (α) 
and beta (β) TCR chains like most T cells (including NKT cells and MAIT cells). Instead, 
they are comprised of gamma (γ) and delta (δ) TCR chains. γδ T cells have variable γ or δ 
TCR chains and this is often used to distinguish different γδ T cell subsets and are 
associated with specific tissue locations 71. For example, In humans, γδ T cells expressing 
δ1 TCR are found in epithelial sites such as skin and intestine while γδT cells 
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expressing γ9δ2TCR are mostly found in peripheral blood and lymphoid tissues 72. 
Furthermore, γδT cells expressing γ9δ2 TCR rapidly respond to nitrogen-containing 
bisphosphates such as zoledronic acids 73–75 (Table i). γ9δ2 TCR+ γδ T cell subsets can 
also be identified by differential CD4 or CD8 expression, much like conventional T cells 
or other innate-like T cells 76,77. Functionally, γδ T cells are reported to produce range of 
cytokines including IFNγ, IL-4 and IL-17 71.  
While γδ T cell subsets expressing different γ and δ TCR chains may be expected 
to recognize different antigens, few such antigens have been identified. γ9δ2 TCR 
expressing γδ T cells are reportedly activated by a wide range of microbes, indicating the 
possibility that the common antigen shared by different microbes 78.  
 NKT cells γδ T cells MAIT cells 
Restricted TCR 
repertoire 
Yes (ref 36,37,44) Yes (ref 79–81) Yes (ref 50,82,83) 
Subsets defined by 
expression of CD4 
and CD8 
Predominantly, 
CD3+CD4+ and 
CD3+ CD4–CD8– 
(ref 36,39,44,84) 
Predominantly 
CD3+CD8+ and 
CD3+CD4-CD8- 
(ref 77) 
Predominantly 
CD3+CD8+ and 
CD3+CD4-CD8- 
(ref 52) 
Expression of 
innate immune cell 
markers 
CD161, CD56, 
CD16 and NKR 
(i.e. NKG2D) (ref 
36,44,85,86) 
CD161, CD56 and 
NKR (i.e. 
NKG2D, NKp44) 
(ref 77,86–90) 
CD161, CD56, 
NKR (i.e.NKG2D) 
(ref 91). 
Table i. Phenotypic traits of the innate-like T cells invariant natural killer T cells 
(NKT), gamma delta T cells (γδ T) and mucosal-associated invariant T (MAIT) cells in 
humans. 
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Figure i. Specificity of antigen and antigen presenting molecules for innate-like T cells. 
The figure above describes the some of the defining traits of innate-like T cells and 
conventional T cells.  
 
1.3. Cancer immunology 
For the immune system to eliminate cancer cells, coordination of innate and adaptive 
immunity is required. There are many complex interactions between innate and adaptive 
immune cells when responding to malignant cells. For example, when NK cells kill 
cancer cells with low MHC I expression 92,93, antigen can be phagocytosed by 
macrophages or dendritic cells, which then present the tumour associated antigens to T 
cells to induce a specific response 92,93. 
In a healthy individual, the immune system can detect and eliminate most cancer 
cells 92. But clearly, the cancer cells sometimes evade immune surveillance. This can be 
achieved by cancer cells expressing inhibitory ligands such as programmed death ligand 1 
(PD-L1), which can interact with programmed death 1 protein (PD-1) expressed by T 
cells and B cells 94. Cancer cells sometimes also have increased expression of 
gangliosides, which are glycosphingolipids shed by cancer cells into the surrounding 
microenvironment that can suppress anti-cancer responses 95,96.  In addition, the presence 
of immune suppressing Treg or myeloid derived suppressor cells (MDSC) such as 
macrophages, can inhibit anti-cancer responses by NK and T cells 92,97. Furthermore, 
tumours often establish a microenvironment of stromal cells and fibroblasts that 
establishes an immune suppressed environment 98. As mentioned, the exact role of innate-
like T cells in this setting is not known, but past studies in animal models indicate they 
could contribute to both pro-tumour or anti-tumour responses 99,100. In the following 
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sections, we will describe the immune cells that are known or hypothesised to be 
important factors in immunity to cancer.  
 
1.3.1. Innate immune cells 
Natural killer (NK) cells can directly kill cancer cells through perforin dependent or death 
receptor ligand responses 101. Cancer cells often downregulate expression of MHC I to 
evade CD8+ T cell responses, or they express molecules such as MHC I polypeptide 
related sequence A or B (MICA or MICB), but these characteristics are both detected by 
NK cells 92. The potential therapeutic use of NK cells was investigated using adoptive 
transfer of NK cells to patients with cancer 102,103. However, the clinical response was 
inconsistent and hampered by impaired killing functions, homing and lack of expansion 
104. ILCs are another group of innate immune lymphocytes with several functionally 
distinct subsets105,106. ILCs are not only able to induce cytotoxic response like NK cells. 
Broadly speaking, NK cells are part of ILC1 subset as both populations express CD127 
(IL-7R). ILC1 cells are reported to have anti-tumour activity based on their production of 
IFNγ and TNF upon stimulation with cytokines such as IL-12, IL-15 or IL-18 105. 
However, other ILC subsets such as ILC2 and ILC3 are can inhibit anti-tumour responses 
by releasing IL-4, IL-13 (by ILC2) or IL-17/ IL-22 (by ILC3). Of note,  the frequency of 
circulatory ILC2 cells in patients with gastric cancer was significantly higher than in 
blood of healthy individuals, while increased IL-22 production by ILC3 was identified in 
patients with hepatocarcinoma 105. Despite these findings, the role of ILCs in patients 
with cancer is not well established and requires further investigation. 
Other innate immune cells such as macrophages and dendritic cells (DC) also play 
crucial roles in cancer immunity. Macrophages are commonly found in tumours and are 
sometimes a dominant population 107. Interestingly, macrophages can alternate between 
two functionally distinct activated states called macrophage 1 (M1) and macrophage 2 
(M2) 93. Macrophages develop from monocytes when exposed to certain factors such as 
granulocyte macrophage colony stimulating factor (GM-CSF), lipopolysaccharides (LPS) 
or TNF to name few to become M1 while exposure to IL-4 or IL-13 induce M2 108. 
Functionally, M1 is associated with anti-tumour response and high production of 
inflammatory cytokines such as TNF, IL-1 and IL-6 are reported while M2 are associated 
with suppression of anti-tumour response and typically high for IL-10 production and low 
on IL-12 108. While their functional roles are not clearly established in tumour 
development, both subsets are considered to be important factors and increased 
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infiltration of macrophages is often correlated with poor prognosis 93,107.   
Dendritic cells (DC) are important for priming T cell responses via antigen 
presentation 92. Therefore, play a significant role in inducing anti-cancer response, and it 
is detrimental that tumours often show an abnormal balance between  mature and 
immature DCs in patients with cancer 93,109. This indicate that DC differentiation is 
abnormal in tumours and antigen presentation to T cells is impaired. Treatments that 
target or involve DCs have been tested in patients with cancer, but impairment of DC 
functions, lack of selectivity of DCs with anti-tumour capacity and the labour intensive 
nature of the approach have all contributed to relatively disappointing clinical responses 
in patients with cancer 110,111. 
 
1.3.2. Adaptive immune cells 
T cells are considered to play a more significant role in immunity to cancer than B cells, 
although B cells still play important roles in some patient groups. Interestingly, B cells 
can sometimes suppress as well as promote anti-cancer responses, but their function is 
often dependent on receiving help from T cells, which highlights the importance of T 
cells. Examples showing a role for B cells include an animal model of melanoma where 
production of IFNγ and TNF by CD4 and CD8 T cells were reduced when mice were 
depleted of B cells using CD20 monoclonal antibody 112. A clinical study also reported 
that B cell frequency is positively correlated with overall survival in patients with 
melanoma 113,114.  In contrast, past study also indicated that B cells infiltrating tumours 
are also associated with development of tumours via their secretion of lymphotoxin, a 
TNF family cytokine that can promote the survival of cancer cells 115. Furthermore, 
certain B cell subsets characterised by IL-10 production were reported to be important for 
generating regulatory T cells with anti-tumour suppressing capacity in vitro 116.  
Conventional CD4+ or CD8+ T cells have been extensively studied in cancer. The 
early evidence of T cell surveillance of cancer cells came from mouse studies which 
showed that T cell deficiency was associated with spontaneous and chemically induced 
cancers 117–119. Supporting these results were studies showing that increased T cell 
infiltration of tumours is correlated with improved survival of patients with difference 
cancers, such as colorectal cancer, gastric cancer and glioma 120,121. Functionally, anti-
tumour response by CD4+ T cells are characterized by induction of Th1 response, which 
generates cytokines such as IFNγ and TNF 27,117 while Th2 responses are often anti-
inflammatory and have been correlated with tumour growth in animal study 128. CD8+ T 
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cells can mediate a cytotoxic response against cancer cells following recognition of 
tumour-derived antigens presented by tumour cells, or APCs such as DCs.  
There are evidences suggesting that anti-tumour response is enhanced when both 
CD4+ and CD8+ T cells are present. For instance, in a mouse study injected with 
B16BL6 melanoma tumour cell line, it was shown that separate single adoptive transfer 
of tumour specific CD4+ T cells or IL-2 and CD3 stimulated CD8+ T cells showed weak 
anti-tumour response but injection of both CD4+ and CD8+ T cells enhanced anti-tumour 
response and elimination of tumour was observed 123. In a clinical study, it was reported 
that the increased frequency of CD4+ and CD8+ T cells in tumours of patients with breast 
cancer showed more favourable clinical outcome 124. 
Ideally, T cells will mount an anti-cancer response after recognition of tumour 
antigens presented by antigen presenting cells, resulting in cytokine release and 
cytotoxicity toward cancer cells 6,125,126–128. Indeed, in human cancer, there are many 
examples where T cells have the capacity to induce an anti-tumour response. For instance, 
CD4+ T cells and CD8+ T cells from PBMCs of patients with multiple myeloma can 
recognize and produce IFNγ in response to  the cancer antigen MAGE-C2 126. In another 
study, CD8+ T cells mounted a specific cytotoxic response after engaging with monocyte 
derived DCs pulsed with neuroblastoma cell line derived antigen 129. These types of study 
indicate that it is feasible to target cancer cell antigens with the host’s immune cells.  
Defects of conventional T cells that appear to affect cancer immunity include 
deficiencies and reduced or abnormal cytotoxic and cytokine responses. These defects are 
all linked with poor prognosis in cancer 96,121,125,130–132, although in many instances the 
underlying mechanisms and causes of the defects are poorly defined.  In addition to 
defects within the overall T cell pool, there are specific defects of regulatory immune 
subsets that can also potentially impact anti-tumour responses. These subsets include 
important T cell lineages such a such as Th17 cells and Tregs that already have well 
defined roles in cancer 133,134.  
The key trait of Th17 cells is their capacity to produce IL-17 and both animal and 
human studies have shown these cells can promote or inhibit cancer 133. For example, in 
mice, the development of B16 melanoma and MB49 bladder carcinomas is reduced in IL-
17-/- mice, and adoptive transfer of IL-17 producing CD4+ T cells from IFNγ-/- mice 
increased tumour growth, suggesting that IL-17 from CD4+ T cells promoted tumour 
growth 135. In another study, stimulation of non small lung cancer cell (NSCLC) with IL-
17 enhanced the angiogenic potential of NSCLC compared to non IL-17 stimulated cells 
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and mice injected with NSCLC lines transfected with IL-17 cDNA showed enhanced 
development of tumours compared to controls 136.  In humans, increased IL-17 mRNA in 
circulating CD4+ T cells correlated with poor prognosis in patients with colorectal cancer, 
and CD4+ T cells from tumours of patients with gastric cancer had increased IL-17 
expression compared to CD4+ T cells from non affected tissues 137,138. 
In contrast are reports of anti-tumour activity by Th17 cells in cancer. IL-17 
deficient mice injected with MC38 (adenocarcinoma cell line) into had increased tumour 
growth and lung metastasis, and RORγt knockout mice showed a decrease in tumour 
growth after  adoptive transfer of Th17 cells increased recruitment of Th1 cells, despite 
this not affecting the frequency or function of other immunosuppressing cells, such as 
myeloid derived suppressor cells 139. These findings show diverse functional roles of 
Th17 cells but the mechanisms that determine their role in human cancers are not clear 
and further investigation is required. 
In some instances, T cells may not be defective, but still suppress immune 
responses.  An obvious example is the FoxP3+ Treg subset, which can promote tumour 
growth and suppress anti-cancer T cell responses cells. Tregs can be produced in thymus, 
or tolerance-inducing conditions can cause CD4+ T cells to differentiate and express in 
peripheral sites, including the tumour microenvironment 140.  An increased frequency of 
Tregs in tumours is associated with poor clinical outcomes 141–143. Tregs can also affect 
DCs and NK cells through release of TGFβ and IL-10 144–146. 
 
1.3.3. Innate-like T cells in cancer patients 
T cells expressing innate immune cell markers such as CD161, CD56 and CD94 are often 
innate-like T cells, however, conventional T cells expressing these markers are also 
reported in cancer patients. There are reports of increased frequency of CD161+CD4+ T 
cells in blood of cancer patients than those without cancer 31. However, MAIT and other 
lineages were not separated before measuring the frequency so it is unclear whether this 
increase reflected a change to innate-like T cells, which may have been present in the 
population of cells studied. Broadly, T cells expressing CD161 and CD56 have 
sometimes been found to have an immune-suppressing function 31, although again these 
are difficult  to interpret given it is now clear that there are many lineages that fall within 
the broader CD161+ or CD56+ classification. However, these studies do indicate that 
need for more detailed identification system that helps to distinguish the proportion of 
innate-like T cells (if any) and conventional T cells so that impact of each population 
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could be measured. In our project, we will be separating innate-like T cells from 
conventional T cells with innate immune cell marker so that we have better view on how 
different T cell populations are impacted and more importantly whether impact on innate-
like T cells are specific or reflects the systemic impact on all of T cell populations in 
patients with cancer. 
 
1.3.4. Innate-like T cells and cancer 
Studies of innate-like T cells in patients with cancer have shown they can be impacted in 
a variety of ways and this can enhance the promotion or suppression of anti-tumour 
responses. These effects have mostly been demonstrated in animal models, so it is not 
clear how this applies in humans. Thus, it is important to directly investigate the 
importance of innate-like T cells in cancer patients.  
 
NKT cells in cancer. The importance of NKT cells in anti-tumour responses was first 
identified in Jα281 gene targeted (NKT deficient) mice, which showed NKT cells protect 
against methylcholanthrene-induced tumours 147. Importantly, this protection was 
mediated without additional administered stimulants like αGal-Cer 147, although the 
precise mechanism remains poorly understood. Other studies have also showed the 
capacity of NKT cells to induce anti-tumour response, often in conjunction with αGal-Cer 
to elicit an NKT specific response. NKT cells are capable of cytotoxic killing of cancer 
cells when stimulated with αGal-Cer 148,149, but are thought to primarily act by regulating 
the function of other immune cells through cytokine release. Some studies have shown 
that protection in some animal models is IFNγ dependent, although this may be linked to 
NK cell activity 150–152. 
Immune regulation by NKT cells is complex and involves other immune cells to 
induce anti-tumour immunity. For instance, the methylcholanthrene induced fibrosarcoma 
model showed that NKT cells are important but also relied on NK cells and CD8+ T cells 
to produce IFNγ for effective tumour immunity 99. Similarly, in models using αGal-Cer, 
the use of dendritic cells to present αGal-Cer to NKT cells was often required for anti-
tumour responses 153. 
There is also evidence that NKT cells can suppress tumour immunity. CD1 
deficient mice injected with NKT cells showed reduced immune surveillance, suggesting 
they were inhibiting the activity of other cells 154. Wild type mice are also reported to 
show a reduced cytotoxic response and IFNγ production by liver NK cells compared to 
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CD1 deficient mouse. This attributed to the presence of NKT cells and their capacity to 
recruit IL-10 producing bone marrow derived myeloid cells 100. Similarly, NKT cell-
deficient mice can reject adoptively transferred lymphoma cells, but introduction of NKT 
cells partially reversed the rejection and suppressed anti-tumour responses by CD8+ T 
cells 155.  
The capacity for NKT cells to induce or suppress anti-tumour responses has 
sometimes been attributed to distinct functional subsets. This was supported in a study 
where NKT deficient Jα18-/- mice injected with sarcoma cell line were protected by co-
transfer of liver CD4- NKT cells but not CD4+ NKT cells 156. Furthermore, when CD4– 
NKT cells and CD4+ NKT cells from healthy individuals were exposed to cancer cell 
lines, CD4– NKT cells showed a stronger anti-tumour response than CD4+ NKT cells 157. 
In vitro studies have shown that human CD4- NKT cells produce Th1 cytokines such as 
IFNγ and TNF, whereas CD4+ NKT cells produced both Th1 and Th2 cytokines 45,158 
(they are human studies, not mice) . These cytokine profiles are consistent with the more 
potent anti-tumour effect of CD4- NKT cells in animal models, although surprisingly, the 
cytokine differences are not as distinct in mice as they are in humans.   
 
NKT cells and cancer in human. Clinical studies also report that NKT cells may have a 
role in regulating immune responses to cancer, however, the findings are inconsistent. 
This may be due in part because humans have a significantly lower NKT cell frequency 
compared to mouse 36, and because it is often difficult to access sufficient patient tissue 
samples, especially tumours. Nevertheless, there are now many reports of reduced NKT 
cell frequency in patients with hepatocarcinoma 159, colorectal carcinoma, breast cancer, 
head and neck cancer, renal cell carcinoma, melanoma and several blood cancers 160. In 
contrast, there are some reports of reduced NKT cell frequency in primary tumours of 
patients with colorectal carcinoma and intrahepatic tumours 157,161.  
 Aside from overall frequency, cytokine production and proliferation is also 
sometimes impaired in the NKT cell pool of cancer patients 162,163. It is important to note, 
however, that there are contradicting findings about NKT cells in cancer that at least 
partly reflect the technical changes about how these cells are identified. For example, in 
separate studies of patients with multiple myeloma (MM), one study reported that NKT 
cells have reduced capacity to produce IFNγ while another showed no significant 
differences compared to NKT cells from healthy donors 164,165. These conflicting findings 
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demonstrate the need for more detailed investigations to determine the importance of 
NKT cells in these patient groups.  
Overall, past findings suggest that NKT cells can play important roles in inducing 
or suppressing tumour development. The functional capacity of NKT cells are relatively 
well defined in animal models and in vitro studies, however, direct assaying of NKT cells 
in humans with cancer would greatly improve our understanding of defects that may be 
associated with cancer and the role of NKT cells in these patient groups.  
 
Clinical application of NKT cells. The promising findings in animal models and clinical 
studies have led to several clinical trials targeting NKT cells in patients with cancer. The 
premise of several trials has been that NKT cells would act as adjuvant to induce anti-
tumour responses by regulating the immune response of NK cells, CD8+ T cells and DCs 
166,167. The approaches included administration of αGal-Cer, in vitro stimulation and re-
administration of collected NKT cells and administration of αGal-Cer pulsed DCs168.  
In solid cancers, there have been trials for lung cancer, colorectal cancer and breast cancer, 
which results mostly showing the treatments were safe but lacking efficacy 169–172. In 
hematologic malignancies, αGal-Cer loaded DC therapy against myeloma reduced 
tumour-associated monoclonal immunoglobulin levels 173, and a separate study using 
monocyte derived DC pulsed with αGal-Cer produced no significant clinical results 174. 
The findings suggest that NKT cell targeted therapy is mostly well tolerated by 
patients with cancer, but the minimal impact on the disease itself indicates that further 
investigation is required if NKT cell-targeted treatments are to be effective. One of reason 
for limited clinical response could be the 10-fold lower frequency of NKT cells in 
humans compared to mice 36,  and the deficiency and functional defects reported for NKT 
cells in several patient groups. It is also possible that the use of a broad agonist such as 
αGal-Cer could result in activation of NKT cell subsets with conflicting roles, resulting in 
minimal overall impact. More detailed information about the behaviour of NKT cells and 
their subsets in patients may help identify specific targets for treatments. 
 
γδ T cells in cancer. The function of γδ T cells is still not fully understood, but there are 
reports of tumours developing and progressing in animal models when γδ T cells are 
reduced or depleted suggesting γδ T cells are sometimes important for inducing anti-
tumour responses 175,176. Furthermore, in an ex vivo mouse model of human breast cancer, 
expanded γδ T cells injected as an adaptive transfer treatment migrated to tumour sites 
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and induced an anti-tumour response 177. In a different study, an anti-tumour response by 
γδ T cells was generated against grafted tumour cell line B16F10 and production of IFNγ 
by γδ T cells and NK cells may regulate MHC 1 expression on some tumour cells 175. In 
another animal study, γδ T cells increased the tumour killing and optimize anti-tumour 
response following αGal-Cer treatment 70. 
γδ T cells may also suppress anti-cancer responses by direct contact with immune 
cells and release of cytokines such as IL-4 178. Interestingly, γδ T cells are impacted by 
the function of NKT and NK cells because culturing those cells with tumour infiltrating 
γδ T cells reduces the cytotoxic activity and IL-4 and IL-10 production of γδ T cells 179. 
While not definitive, these findings indicate γδ T cells can influence anti-tumour 
responses and require further investigation in anti-tumour immunity. 
 
γδ T cells in human cancer. γδ T cells have been reported to infiltrate tumours in human 
breast, colorectal, renal and lung cancers, among others 90,179–183. However, like NKT 
cells, there are conflicting views about their overall frequency in patients with cancer. 
Breast cancer patients reportedly exhibit a higher frequency of γδ T cells in blood 90 
compared to healthy counterparts, while melanoma patients had a lower frequency of γδ 
T cells 180. In another study involving patients with advanced-stage cancer, the frequency 
of γδ T cells was no different to healthy controls 182; however, the frequency of γδ T cells 
in tumours increased with disease progression 90. While the reasons for the mixed reports 
are not clear, it appears the frequency of γδ T cells can increase or decrease in patients 
with cancer and this could indicate a role for these cells in associated immune responses.  
In vitro studies have shown that γδ T cells can induce cytotoxicity to cancer cells 
including primary multiple myeloma cells 184,185. They also produce cytokines that could 
potentially affect other immune cells. Interestingly, γδ T cells isolated from blood of 
patients with breast cancer produce significantly more amount of TNF than cells from 
blood of healthy donors 186.  
γδ T cell subsets have been identified based on expression of surface markers such 
as CD8, and more recently according to their TCR gene usage. An experiment using γ9δ2 
T cell subset of γδ T cells from human PBMCs have been intensively studied in context 
of cancer due to their capacity to specifically respond to microbial derived (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate (HMB-PP) to induce anti-tumour response 187. This is 
akin to using αGal-Cer to stimulate NKT cells because when γ9δ2 T cells are stimulated, 
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they mediate cytotoxicity directly to cancer cells but also produce large amount of IFNγ 
and TNF to regulate immune responses of other immune cells 188.  
γδ T cells in human cancer have also been associated with immune suppression. 
For example, breast tumour infiltrating γδ T cells can suppress effector T cell function 
and the maturation of dendritic cells 189. In addition, γ9δ2 T cells can produce cytokines 
such as IL-4 and IL-10 when exposed to immune suppressing factors such as 
transforming growth factor (TGF-β) 190. Also like NKT cells, defects in IFNγ production 
and cytotoxic function by γδ T cells has been reported in melanoma patients 180 and 
patients with nasopharyngeal carcinoma 90,191.  
 These studies suggest that γδ T cells may impact tumours in humans, but their role 
and importance remains poorly understood. Clinical trials of adoptively transferring 
expanded γδ T cell have reported mixed results in cancer patient groups. The trials 
suggested the transferred γδ T cells may directly respond to cancer cells or to enhance 
anti-tumour response via Th1 cytokines 73,75,192,193. A complicating factor is that the γ9δ2 
subset is found in humans and other higher primates but not in mice, so these cells have 
not been able to be tested in established mouse models 187. It is therefore important to 
obtain as much information as possible from different patient groups with cancer to better 
understand if γδ T cells are defective in these patients, or play an important role in anti-
tumour immunity. 
 
MAIT cells and cancer. Compared with NKT cells or γδ T cells, there are fewer studies 
of MAIT cells in the context of cancer. This is likely due to MAIT cells being discovered 
later and also because were difficult to identify until the relatively recent development of 
specific reagents. As MAIT cells possess similar characteristics to NKT cells, including 
potent cytokine production and semi-invariant TCRs, several studies have now been 
conducted in patients with cancer. The MAIT cell Vα7.2-Jα33 TCR is expressed in 
tumours from cancerous brain, liver and kidney tissue, indicating that MAIT cells could 
be part of the tumour-infiltrating lymphocyte population 194, but in more recent findings, 
the frequency of MAIT cells has been found to be deficient in blood from patients with B 
cell malignancies such as chronic lymphoid leukaemia 195. Interestingly, the frequency of 
MAIT cells in adenocarcinoma and colorectal tumours was higher than in non-affected 
tissue taken from the same patients 68,196. Few studies have been conducted and it is not 
clear whether MAIT cells would promote or suppress tumour immunity, but an increased 
frequency of MAIT cells in colorectal tumours and statistically similar level of MAIT 
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cells in patient blood has been correlated with poor prognosis 196. However in other 
studies, MAIT cell deficiencies have been reported in blood of patients with colorectal 
cancers, lung cancers and gastric cancers, so the impact of these cells is still uncertain 
69,197. Few functional analyses have been conducted for MAIT cells in patients with 
cancer, but there are fewer IFNγ-producing MAIT cells in adenocarcinoma tumours 68  
One aspect of MAIT cells that has not been investigated is MR1 expression in 
cancer cells as this may directly affect the capacity of MAIT cells to respond to cancer 
cells. Currently to our knowledge, there are no clinical reports of MR1 expression in 
cancer cells. However, given that increased expression of CD1d antigen-presenting 
molecules in chronic lymphocytic leukaemia (CLL) patients is correlated with poor 
prognoses 198, it is worth investigating MR1 to determine whether a similar trend could be 
identified and if MAIT cells can potentially recognize tumour cells.  
As there are limited studies of MAIT cells in solid cancers or haematological 
cancers, more studies are needed. We are investigating several kinds of solid and blood 
cancers to develop a better understanding of MAIT cells in these settings. 
 
1.4. Conclusion 
Our understanding of innate-like T cells has come a long way in cancer immunology. 
Both NKT cells and γδ T cells have been introduced in early phase clinical trials based on 
their potential to induce anti-tumour responses. However, the role of innate-like T cells in 
cancer remains unclear. For example, the frequency of NKT and γδ T cells is abnormal in 
some patient groups, but not others, but few forms of cancer have been studied in depth 
and often only blood has been examined. It is therefore crucial to investigate innate-like T 
cells in many different forms of cancer and ideally, to study their frequency and function 
in tumours as well as in blood.  NKT and γδ T cells also have a range of subsets with 
varied functional roles, many of which have not been directly studied in patients with 
cancer and it will be important to investigate them separately.  
Detailed studies of innate-like T cells in patients with cancer have been limited by 
difficulties obtaining patient tissue samples, and the rarity of these cell types, but an 
improved understanding of these cells may help to improve treatments and clinical 
outcomes. This thesis studies innate-like T cells isolated from many different patient 
groups to better understand their importance in cancer. As well as direct analysis of their 
phenotype ex vivo, we have sometimes tested the response of innate-like T cells to 
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established cancer cell lines such as LIM adenocarcinoma cell lines199. These cell lines 
are well characterized and were used to address whether innate-like T cells have the 
capacity to directly respond to cancer cells.  
In this project, our goal is to identify patient groups where innate T cell lineages 
are abnormal, or show signs of activation, as these will be candidates for later studies in 
our group to develop these cells as targets for new treatments and as biomarkers to allow 
for better disease prevention and treatment.  
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Chapter 2 Materials and methods 
 
2.1.1. General Materials  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2. Cell lines 
 
Name of Cell line Disease Type 
LIM2407 Colon adenocarcinoma 
LIM2412 Colon adenocarcinoma 
LIM2538 Colon adenocarcinoma 
DK-1 Mouse hybridoma 
 
Name of materials used  Supplier 
BD Cytofix BD Biosciences Pharmingen  
BD CytoPerm BD Bioscience Pharmingen  
Fetal Calf Serum Sigma Aldrich 
Bovine calf serum Sigma Aldrich 
Penicillin Streptomycin x100 concentration Sigma Aldrich 
Vybrant CFDA SE Cell Tracer Kit Invitrogen 
10 x Phosphate Buffered Saline (10X PBS) Sigma Aldrich 
Histopaque Sigma Aldrich 
RPMI Medium 1640 Gibco 
Dimethyl Sulfide (DMSO) Sigma Aldrich 
Cryotube (1ml) Nunc 
45μm Filter Millipore 
50μM 2-β mercaptoethanol ICN Biomedicals 
GlutaMAX-1 Gibco 
Non essential amino acids Gibco 
HEPES Gibco 
1mM sodium pyruvate Invitrogen 
96 well plates Costar 
10ml Falcon Tubes Globe Scientific 
50ml Falcon Tubes Corning 
Tumour dissociation cocktails Miltenyl 
CO2 Incubator Sanyo Biomedical 
FACS tube round bottom Corning 
FACS tube v-bottom Thermo Fisher Scientific 
PCR tubes Edwards Instrument Co 
Micro centrifuge tubes (1.5ml) Global Science 
Acetic acid Sigma Aldrich 
Chloroform Sigma Aldrich 
Methanol Sigma Aldrich 
Ammonium Sigma Aldrich 
Sulfuric acid Sigma Aldrich 
Dichloromethanol Sigma Aldrich 
TLC plates Merck 
Glass chambers Sigma Aldrich 
Heat gun Makita 
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2.1.3. Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4. Stimulation Reagents 
 
 
 
 
 
 
 
 
 
 
Fluorochrome attached antibodies Clone Supplier 
γδTCR FITC B1.1 eBioscience 
γδTCR PeCy7 11F2 BD Biosciences Pharmingen  
Vα7.2TCR FITC 3C10 Biolegend 
Vα7.2TCR APC-Cy7 3C10 Biolegend 
CD1d tetramer with α-
galactosylceramide PE/BV450/APC 
 Kindly donated from Godfrey 
Lab (Microbiology 
Department, University of 
Melbourne) 
CD14 PeCF594 MΦP9 BD Biosciences Pharmingen  
CD14 BV605 M5E2 BD Horizon 
CD56 Percp-Cy5.5 HCD56 Biolegend 
7AAD PeCy5 Nil BD Biosciences Pharmingen  
CD4 PeCy7 A161A1 Biolegend 
CD4 BV711 L200 BD Bioscience Pharmingen 
CD161 APC HP-3G10 Biolegend 
CD94 APC HP-3D9 BD Biosciences Pharmingen  
CD3 APC-Cy7 HIT3a Biolegend 
CD3 BV650 SK7 BD Biosciences Pharmingen  
CD25 BV450 M-A251 BD Horizon 
CD25 PeCF594 M-A251 BD Biosciences Pharmingen  
CD8 BV510 SK1 BD Biosciences Pharmingen  
IL-4 PE 8D4-8 BD Biosciences Pharmingen  
IL-13 PE JES10-5A2 BD Biosciences Pharmingen  
IL-17 PE N49-653 BD Biosciences Pharmingen  
IL-17 BV786 N49-653 BD Biosciences Pharmingen  
IFN PeCF594 XMG1.2 BD Biosciences Pharmingen  
IFN FITC 4S.B3 eBioscience 
TNF Percp-Cy5.5 MAb11 Biolegend 
TNF FITC MAb11 eBioscience 
Anti-FC receptor  HM14-1 BD Biosciences Pharmingen  
Stimulation Reagents Supplier 
Leukocyte Activation Cocktail BD Bioscience Pharmingen 
Ionomycin Sigma 
Phorbol 12-myristate 13-acetate (PMA) Sigma  
IL-2 Biolegend 
Anti-CD3 UCHT BD Bioscience Pharmingen 
Anti-CD28 NA/LE BD Bioscience Pharmingen 
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2.1.5. Other materials 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.6. Solutions used in the project 
I. Cell culture media. For maintaining most cells, media consisting of RPMI with 10% 
FCS, 1 x GlutaMAX-1, 15 mM HEPES, 0.1 mM non-essential amino acids, 100 μg/mL 
streptomycin sulfate, 1mM sodium pyruvate and 50 μM 2-β mercaptoethanol was used. 
Cells were typically maintained in 96 well round bottom culture plates with lid (sterile, 
nonpyrogenic polystyrene) in an incubator set to 37 °C, 5 CO2. 
 
II.  Other solutions.  
i. Sterile milliQ water was used at 1:10 volume ratio using stock 10X PBS solution 
to bring the final concentration to 1x PBS.  
ii.  FACS buffer was prepared by adding 1% BCS into 1x PBS.  
iii. Acidic solvent was used to run TLC plates spotted with extract (lipid) from 
colorectal cancer cell lines. Acidic solvent was made up of chloroform, 
methanol, acetic acid, water at volume ratio of 20:60:4:5. Solution was mixed 
thoroughly to make sure there was no phase separation.  
iv.  Basic solvent was used to run TLC plates spotted with extracts (lipid) from 
colorectal cancer cell lines. Basic solvent was made up of chloroform, 
methanol, ammonium* (* made up of 7ml ammonium and 18 ml of water) at 
Name of other materials used Supplier 
BD Cytometric Bead Array Master Buffer Kit BD Biosciences Pharmingen  
BD Flex Set TNF BD Biosciences Pharmingen  
BD Flex Set IFN BD Biosciences Pharmingen  
BD Flex Set IL-13 BD Biosciences Pharmingen  
BD Flex Set IL-17 BD Biosciences Pharmingen  
BD Flex Set IL-4 BD Biosciences Pharmingen  
Qubit Protein Assay Kit Life Technologies 
Qubit Assay tubes Thermo Fisher Scientific 
Qubit Flurometer Thermo Fisher Scientific 
FACS ARIA II BD Biosciences 
Automated Cell Counter Invitrogen 
Tissue dissociator Miltenyi 
Flowjo   Flowjo, LLC 
Lipid Extraction kit CELL BIOLABS, INC 
Fixable Viability Stain 450 BD Horizon 
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volume ratio of 65:25:5. Solution was mixed thoroughly to make sure there 
was no phase separation.  
v. Orcinol was used to spray TLC plates after solvents were used to separate the 
extracts. Solution was made up of acetone and sulfuric acid* (volume ratio of 
1:1). *exothermic reaction takes place upon mixing solution. 
 
2.1.7. Tissue samples 
In order to identify potential differences between healthy individuals and patients with 
cancer, we used tissue samples collected from healthy individuals and patients with blood 
or solid cancer (Table ii). Where possible, patient tissue samples were often compared as 
groups based on the type of cancer. If not enough patient tissue samples were available to 
be grouped into a specific disease, they were grouped as ‘other’ solid or blood cancers.  
The information below describes where and how these samples were obtained.  
 
I. Blood from healthy donors. Buffy coats from healthy donors were provided from Red 
Cross Blood Bank. (Information regarding age and gender of healthy donors was 
provided.) 
 
II. Patient samples. Cancer patients were recruited in accordance with ethics governance 
from St John of God Hospital, Ballarat. Typically, 20 ml blood, tumour (any size 
available, usually < 2 cm3) and 1ml of bone marrow were collected by medical 
collaborators. 
Disease Blood (M F) 
Tumour 
(M/F) 
Bone Marrow 
(M/F) 
Age 
range 
Colon 39 (17/22) 38 (17/21) NA 24-97 
Lung 4 (2/2) 7 (4/3) NA 31-68 
Other Solid 8 (3/5)  13 (7/6) NA 48-84 
CLL 39 (21/18) NA 8 (5/3) 51-92 
NHL 13 (7/6) NA 17 (8/6) 34-87 
MM 20 (14/6) NA 17 (14/3) 43-89 
Other Blood 27 (20/7) NA 16 (8/10) 45-82 
Healthy Control 39 (16/23) NA NA 16-68 
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Table ii Patient Demography. The table describes the demography of tissue samples 
investigated in this PhD project from patient groups with different cancers, and healthy 
donors (Healthy Control). Broadly, we used blood samples from healthy donors, blood 
and tumours from patients with solid cancers, and blood and bone marrow from patients 
with blood cancers. Other solid cancers (i.e., ‘Other Solid’) included ovarian, melanoma, 
stomach and breast, while other blood cancers (Other Blood) included T cell lymphoma, 
ALL, AML, hairy cell leukaemia, or NK leukaemia.  The age range, total number of tissue 
samples used in the project and gender distribution of respective tissue samples are 
shown. 
 
2.1.8. Lymphocyte isolation from patient tissue samples 
Methods indicated below were used to process human tissue samples into a viable single 
cell suspension. Single cell suspensions from healthy individuals or patients with cancer 
were used to measure changes to frequency and functional capacities of different innate-
like T cells. 
 
I. Blood. Blood samples were centrifuged at 500 g for 10 min and serum was collected 
for storage at -80 °C. Blood was mixed with PBS at 1:1 volume ratio before the solution 
was overlayed on histopaque at 2:1 volume ratio. After centrifuging at 500g with break 
off at room temperature for 30 min, the buffy layer containing lymphocytes was collected 
and subsequently washed with PBS and a cell count was conducted. The sample was 
centrifuged at 500 g for 5min, supernatant was removed and freezing media mix 
consisting of 50% RPMI media, 40% FCS and 10% DMSO was used to resuspend the 
cell pellets. The cryovials were placed in a -80 °C freezer overnight before storing in 
liquid nitrogen tank for long term. 
 
II. Bone marrow. Bone marrow samples were mixed with PBS at 1:1 volume ratio 
before the solution was overlayed on histopaque at 2:1 volume ratio. After centrifuging at 
500 g with break off at room temperature for 30 min, a buffy layer of lymphocytes was 
collected and subsequently washed with PBS and a cell count was performed. Once the 
sample was centrifuged at 500 g for 5 min, the supernatant was removed and resuspended 
in freezing media mix consisting of 50% RPMI media, 40% FCS and 10% DMSO. The 
final cell mixture was stored in cryovials at -80 °C overnight before storing in a liquid 
nitrogen tank.  
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III. Tumour. Tumour samples from patients were chopped using surgical forceps into 
small parts before using tumour dissociation kit according to company instructions. 
Tumour sample mixture was overlayed on histopaque at 2:1 volume ratio. After 
centrifuging at 500 g with break off at room temperature for 30 min, a buffy layer 
consisting lymphocytes was collected and subsequently washed with PBS and cell count 
was performed. Once the sample was centrifuged at 500 g for 5 min, supernatant was 
removed and the pellet was resuspended in freezing media mix consisting of 50% RPMI 
media, 40% FCS and 10% DMSO and stored in cryovials at -80 °C over night before 
storing in a liquid nitrogen tank. 
 
2.1.9. Tissue screening 
We have used established methods to identify different innate-like T cell populations 
from human tissue samples. For NKT cells, we used anti-αGal-Cer-loaded CD1d tetramer 
in combination with anti- CD3 mAb while anti-Vα7.2 TCR was used along with anti-
CD3, anti-CD161 and anti-CD8 to help identify MAIT cells. We also investigated γδ T 
cells using anti-γδTCR in combination with anti-CD3. Technical limitations restricted the 
number of markers that could be used for flow cytometry analysis, although where 
numbers allowed, in some instances we used 2 separate antibody cocktails to stain for 
additional surface markers relevant to innate-like T cells (e.g., anti-CD14, natural killer 
cell markers such as CD94 and activation markers CD25). Collectively, our aim was to 
identify and quantify changes to the relative frequency of different innate-like T cell 
subsets (refer to chapter 3) to better understand the distribution of these cells in patients 
with cancer. The table below indicates typical cocktails that were used to identify innate-
like T cells when screening patient tissue samples (Table iii). 
Fluorochrome Cocktail 1 Cocktail 2 
FITC Vα7.2TCR γδTCR 
PE αGal-Cer loaded 
CD1d Tetramer 
CD45RA 
PI 7AAD 7AAD 
PeCy5 CD56 CD14 
PeCy7 CD4 CD4 
APC CD161 CD94 
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APCCy7 CD3 CD3 
BV450 CD25 CD25 
BN510 CD8 CD8 
Table iii. Antibody cocktails used for screening patient tissue samples. In Chapter 3, the 
following antibody cocktails were used to screen patient tissue samples. Briefly, cocktail 
1 was used to identify MAIT or NKT cells and their subsets among other immune cells 
while cocktail 2 was used to identify γδ T cells and their subsets among other immune 
cells. 
 
I. Surface staining. Cell suspensions stored in a liquid nitrogen tank were thawed gently 
using a water bath at 37 °C before centrifuging with 1% BCS PBS at 4 °C for 5 min at 
500 g. Thawing was done carefully to retain maximal viability for the subsequent assays 
and viability was routinely checked at the end of each experiment. Supernatant was 
removed and resuspended in 1% BCS PBS before a cell count was conducted. The cell 
mixture was centrifuged again in v-bottom FACS tubes with 1% BCS PBS at 4 °C and 
stained for surface antigens with fluorochrome labelled antibodies for 10 min at 4 °C. The 
cell mixture was washed with 1% PBS/FBS the supernatant discarded after centrifuging 
before the pellet was resuspended using 1% PBS for analysis on the FACSAria II.  
 
II. Screening. A FACSAria II was used for screening samples by flow cytometry. In 
brief, the lymphocyte population was identified based on FSC-A and SSC-A after 
exclusion of doublets and dead cells based on viability staining (i.e.7AAD or fixable 
viability stain) as indicated in plots below (Figure ii). In most instances, viability was 
over 70% and where lower viability was identified, we used stringent gating to exclude 
non- viable cells. 
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Figure ii. Gating strategy to identify viable, single cell lymphocytes. The representative 
facs plots illustrate the gating strategy used to identify viable lymphocytes (A-C). The 
viable lymphocyte population was subsequently analysed the frequency (including subsets 
or activated population in chapter 3), cytokine expression (Chapters 4 and 5) or 
proliferation (Chapter 5) of different innate-like T cells such as NKT, γδ T or MAIT cells 
from blood, bone marrow or tumours. 
 
2.1.10. Identification and quantification of cytokines released by lymphocytes 
Once the frequency and distribution of innate-like T cells and their subsets were 
established in chapter 3, we used the FACS ARIA II to sort innate-like T cells of interest 
to measure their intracellular cytokine expression pre or post stimulation (in chapter 4) to 
understand the functional capacity of these cells in patients with cancer. Sorting meant the 
downregulation of TCR-related antigens after stimulation did not affect our ability to 
identify these cells. In chapter 5, however, we did not sort the T cells before culture 
because antigen presenting cells (APCs) were needed to present antigens. 
Downregulation of markers following activation meant that careful gating was required to 
identify different cell types. More detailed information is provided at chapter 4 and 5.  
 
I. Surface staining. Cell suspensions stored in liquid nitrogen were collected and thawed 
in a 37 °C water bath before washed with 1% BCS PBS and centrifuged at 4 °C for 5 
minutes at 500 g. Supernatant was removed and cells resuspended with 1% BCS PBS 
before a cell count was conducted. The cell mixture was stained in for surface markers in 
v-bottom FACS tubes using mAbs diluted in 1% BCS PBS for 10 min at 4 °C. The cell 
mixture was washed in 1% PBS and centrifuged at 500 g for 5 min and supernatant 
discarded. Cells were resuspended in 1% BCS PBS before analysis. 
 
II. Cell sorting. In chapter 4, a FACSAria II flow cytometer was used for sorting cell 
populations of interest. Due to the size and quality of tissue samples received, the number 
of sorted cells (i.e. MAIT cells, NKT cells or γδ T cells) was often relatively low. Typical 
range of cell numbers sorted from respective patient tissue samples is listed in the table 
below (Table iv). 
 
Tissue Samples MAIT cells γδ T cells NKT cells 
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Blood 500 - 3000 400 - 4000 50 - 1500 
Tumours 200 – 1500 100 -  2000 50 - 1000 
Bone Marrows 50 - 2000 NA NA 
Table iv. Typical number of innate-like T cells sorted from patient tissue samples. The 
typical range of cell numbers from sorted patient tissue samples for MAIT cells, NKT 
cells and γδ T cells. Due to small amounts of patient tissues samples or low cell numbers, 
NKT cells or γδ T cells in bone marrows were not sorted. If the number or sorted cells 
was too low, no further analysis was conducted. 
 
III. Leukocyte activation cocktail (LAC). A LAC mix consisting of PMA, ionomycin  
and golgi plug (brefeldin A) was used to stimulate innate-like T cells to measure the 
intracellular cytokine expression (chapter 4). The final concentration of each product was 
as follows; 1 PMA (50 ng/ml), 2 ionomycin (1 µg/ml), 3 golgiplug (10 µg/ml). The LAC 
was used for stimulation of enriched innate-like T cells for 6 hours to induce intracellular 
cytokine expression according to company instructions . For measuring cytokines 
released by sorted innate-like T cells into culture supernatants, stimulation (12 h) without 
golgi plug was used. 
 
2.1.11. Intracellular staining 
BD Cytofix/ Cytoperm Plus Fixation/Permeabilisation Kit was used to fix and stain cells 
for intracellular antigens after staining for surface markers. Staining took place at room 
temperature for 30 min in dark. Stained cells were washed with BD Perm/Wash buffer 
before resuspension in 1% BCS +PBS for analysis using FACSAria II. The list of 
cocktails used to measure intracellular cytokine staining is indicated for each innate-like 
T cell population (Table v). The fixable viability stain was used according to the protocol 
provided by the company to distinguish live and dead cells. 
 
I. Identification and quantification of extracellular cytokines in supernatants. 
Cytometric Bead Array (CBA) kit was used according to manufacturer’s instructions to 
identify and quantify cytokines released into culture supernatants. Briefly, the CBA 
master protein kit was used to set up cytokine bead cocktail which was added to 
supernatant and left for 1 h at 4 °C in dark. The antibody cocktail corresponding to 
cytokine bead cocktail was prepared and added to the supernatant pre-exposed to cytokine 
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bead cocktail for 1h at room temperature in dark. The mixture was then washed with 
wash buffer from Master protein kit and resuspended in wash buffer and run on the 
FACSAria II for analysis. 
Fluorochrome Cocktail 1 Cocktail 2 Cocktail 3 
FITC Vα7.2TCR TNF γδTCR 
PE IL-4 αGal-Cer loaded 
CD1d Tetramer 
IL-4 
PI IFNγ IFNγ IFNγ 
PeCy5 TNF IL-4 TNF 
PeCy7 CD4 CD4 CD4 
APC CD161 CD161 CD94 
APCCy7 CD3 CD3 CD3 
BV450 FIXABLE 
VIABILITY STAIN 
FIXABLE 
VIABILITY STAIN 
FIXABLE 
VIABILITY STAIN 
BV510 CD8 CD8 CD8 
Table v. Antibody cocktail used for intracellular cytokine assay. In chapter 4, these 
antibody cocktails were used to measure the functional capacity of sorted innate-like T 
cells from patient tissue samples. Briefly, cocktail 1 was used to measure cytokine 
expression of MAIT cells and their subsets, cocktail 2 was used to study cytokine 
expression of NKT cells and their subsets while cocktail 3 was used for the cytokine 
expression of γδ T cells and their subsets. 
 
2.1.12. Measuring the functional capacity of innate-like T cells to cancer cells 
derived antigens 
In the Chapter 5, we asked whether innate-like T cells in patient tissue samples have the 
capacity to respond to antigens derived from cancer cells, including autologous viable 
tumour cells from patients with colorectal cancer. To do this, we extracted protein lysates 
or lipids from patient tumour cells or colorectal cancer cell lines using well established 
methods. Where possible, autologous tumour cells from patients with colorectal cancer 
was also used to measure the functional response of innate-like T cells to viable tumour 
cells. 
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I. Tissue sample preparation for protein extraction. Frozen tissue (usually tumour) 
samples were transferred from liquid nitrogen and chopped into small parts using sterile 
forceps on sterile petri dish. 1-2 mL of sterile PBS was added to further mash the tissue 
before transferring the mix into a cryotube.  The tumour mix was rapidly frozen using 
liquid nitrogen 1-2 min and thawed for 4 min in 37°C water bath. Please refer to ‘IV. 
Protein extraction and concentration quantification’ for further information. 
 
II. Colorectal cancer cell lines. Three colon cancer cell lines (LIM2408, LIM2412 and 
LIM2537) were used for preparation of cancer cell antigens using a conventional freeze 
and thaw approach.  
 
III. Peripheral blood mononuclear cells (PBMCs). In order to measure the response 
against tumour cells derived antigens by immune cells, protein lysates from tumour cells 
equivalent to protein extracted from 1x10^6 viable PBMCs were used. PBMCs from 
healthy donor were processed using a freeze and rapid thaw technique as previously 
described. 1x10^6 viable cells were typically used. The protein concentration from the 
processed PBMCs was measured and the solution used in an assay to measure anti-
tumour response using patient cell samples.  
 
IV. Protein extraction and concentration quantification. Single cell suspensions 
prepared from patient tissue, cancer cell lines or PBMCs from blood of healthy donors 
were used to extract protein using a established method involving freezing and thawing. 
Freezing and thawing was repeated 6 times. The samples were then centrifuged at 1800 
rpm for 6 min. Supernatant was collected and filtered using 45 μM filter with a syringe 
into an eppendorf tube. 20-30 μl of this mix was frozen into 200 µl PCR tubes. 
For protein concentration quantification, Qubit Protein kit, Qubit Fluorometer and 
Qubit assay tubes were used according to the company protocols. In brief, standard 
controls were prepared and 10 µl of test samples or standard controls were added into 190 
µl of detection reagent mix in Qubit assay tubes. The Qubit assay tubes were stored at 
room temperature in dark for 15 min after vortexing the sample mix. Qubit Fluorometer 
was used according to company protocol to quantify protein concentration. Protein lysates 
were used in cell culture at 200 µg / ml for up to 1x10^6 cells. 
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V. Lipid extraction. Cancer cell lines were used to extract lipids using a lipid extraction 
kit. Briefly, 100 µl of cell suspension was added into a 10 mL falcon tube with following 
pre-mixed reagents and vortexed.  
 
1. 500 µl of Reagent A for 10 min 
2. 250 µl of Reagent B for 5 min,  
3. another 250 µl of Reagent B for 5 min and  
4. 500 µl of Reagent C for 5 min.  
5 After spinning down using centrifuge for 5 min at 1000 rpm, top organic layer 
containing lipid was collected into new 10 ml falcon tube. 530 µl of Reagent B was added 
to left over aqueous solution and vortexed for 5 min. Step 5 was repeated to further 
collect lipid layer. 420 µl of Reagent B was added to left over aqueous solution and left 
on vortex for 5 min and step 5 was repeated.  
6. Collected lipid layer was dried using vacuum concentrator overnight. Once dried, the 
lipid was measured and stored in DMSO (0.1%) for use in cell culture at eventual final 
concentration of 200 ug for up to 1x10^6 cells. 
 
VI. Lipid identification. Dried, extracted lipids from samples and reference points were 
dissolved in dichloromethanol and chloroform solution (1:1 volume ratio) at room 
temperature and spotted onto 2 x TLC plates at a concentration of 10 -100 mg/mL 
depending on quantity of extracts. Once TLC spotted was with reference points and 
testing samples were dried, each TLC plates was placed inside two separate glass 
chambers consisting of different solvents. The lid was securely placed to seal the chamber 
while running the TLC plates. Solvents used for running TLC plates were either basic 
solvents or acidic solvents (refer to ‘II Other solutions’). Once the solvent front was 2cm 
below the top of TLC plates, we removed the TLC plates from the glass chamber and 
used a heat gun to dry the solvents. Once dried, TLC plates were sprayed with orcinol. 
One sprayed, TLC plates were dried using a heat gun before highlighting spots using 
pencil where necessary. 
 
2.1.13. Preparation for measuring the response of innate-like T cells to cancer cell 
antigens or autologous tumour cells  
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I. Cell sample preparation. Stored cell suspensions from patient tissues (blood, bone 
marrow tumour) were thawed in a 37 °C water bath and washed in 10 ml 1% BCS PBS at 
4 C°. The sample was centrifuged for 5 min at 500 g and supernatant was removed, with 
the pellet resuspended using 1% BCS PBS. A cell count was conducted to measure 1x106 
cells for culturing with antigens from cancer cells (refer to chapter 5).   
The same cell number was used to measure the response of innate-like T cells co-
cultured with autologous tumour cells. Initially, tumour infiltrates consisting of innate-
like T cells and autologous viable tumour cells were stimulated with IL-2 for 10 days 
(100 U/ml) before being re-challenged with freshly thawed autologous tumour cells for 
further 5 days in cell culture media supplemented with IL-2 (20 U/ml) at 37 °C with 5% 
CO2. 
All cultures of innate-like T cells with lipids from colorectal cancer cell lines were 
conditioned with or without a low concentration of IL-2 (20 U/ml) regardless of exposure 
to cancer cells derived lipids. Innate-like T cells were derived from PBMCs from healthy 
donors due to lack of patient tissue samples with sufficient number innate-like T cells. 
 
II. Media supplements. IL-2  was used at different concentration (ranged between 10 U 
to 100 U/ml) in cultures of T cells. For intracellular cytokine staining, Golgi plug was 
used according to company instruction. 6 hours before harvesting. 
 
III. Measuring cell proliferation. Vybrant CFDA SE Cell Tracer Kit was used where 
necessary to detect cells of interest. Briefly, 5 μM of Vybrant CFDA SE Cell Tracer Kit 
was used to stain viable single cell suspension in 2 ml of PBS while mixing, incubated for 
10 min at 37 °C with 5% CO2 and the reaction quenched with cold 20% FCS cell culture 
media at 2:1 ratio. The cells were and centrifuged at 500g for 5min before supernatant 
was discarded and cells resuspended with 10% FCS cell culture media for culturing. The 
antibody cocktails used to identify innate-like T cells and their cytokine expression is 
indicated in the table below (Table vi). 
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Fluorochrome Cocktail 1 
FITC CFSE 
PE αGal-Cer loaded CD1d Tetramer 
PI CD25 
PeCy5 TNF 
PeCy7 γδTCR 
APC CD161 
APCCy7 Vα7.2TCR 
BV450 FIXABLE VIABILITY STAIN 
BV510 CD8 
BV605 CD14 
BV650 CD3 
BV711 CD4 
BV786 IL-17 
Table vi. Antibody cocktail used to measure cancer cell antigen response. In chapter 5, 
the following list of fluorochrome attached surface, cytokine or proliferation markers 
were used to measure the response of innate-like T cells from patient tissue samples to 
antigen derived from cancer cells. 
 
2.1.14. Data Analysis 
The data collected using FACSAria II was exported from the FacsDIVA software in the 
flow cytometers and analysed using Flowjo software version 10.1r5 or FCAP Array 
Software version 3.0.  The following programs were used according to company 
protocols. 
PRISM version 6 was used to produce graphs and conduct statistical tests of data 
from assays. Mann-Whitney t-test with Bonferroni correction, Wilcoxon matched-pair 
signed test for comparing paired patient samples or Pearson correlation coefficients were 
conducted depending on the nature of the data set. Significance was defined as p<0.05. 
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Chapter 3: Innate-like T cells in patients with cancer 
Innate-like T cells are part of the adaptive immune system, but they possess some 
phenotypic and functional features of innate immune cells. They often express a semi-
invariant T cell receptor (TCR), which identifies them as T cells, but also NK markers 
such as CD161 56,199, and they have the capacity to respond rapidly to stimulation like NK 
cells 52,200,201. While innate-like T cells such as NKT cells, γδ T cells and MAIT cells are 
well characterized in healthy individuals, their prevalence and functional roles in patients 
with different forms of cancer are not well defined.  
In cancer, one common way to investigate innate-like T cells has been to quantify 
the frequency of the various lineages 39. Cells isolated from patient blood have been 
primarily studied, although other tissue samples (e.g. tumours) have also been 
investigated in some instances. There are many examples where patients with cancer have 
been shown to have defects or deficiencies affecting innate cell lineages. For instance, the 
frequency of NKT cells in blood of patients with multiple myeloma (MM) was reported 
to be significantly lower than in blood of healthy individuals 202. However, there are also 
conflicting findings where no significant frequency of NKT cells or increased functional 
capacity to proliferate upon antigen specific stimulation has been reported 203,204. Previous 
studies of NKT cells, γδ T cells and MAIT cells have utilised different approaches to 
identify the same cell lineages, which may have contributed to inconsistent findings 
between studies regarding changes or defects in the frequency of innate-like T cells in 
patients with cancer 160,196,205,206.  This makes the direct comparison of results from these 
studies difficult to interpret and the role of innate-like T cells in anti-tumour immunity 
and the potential targeting of these cells in treatments for clinical benefit remain poorly 
defined. 
Aside from assaying the frequency of innate-like T cells, few reports have 
assessed the function of innate-like T cells from patients, such as their cytokine 
production, or rate of proliferation in response to different stimuli. It is important to study 
the function as well as the frequency of these cells because innate-like T cells have the 
potential for directly or indirectly impacting on anti-cancer immune responses by 
regulating other immune cells 207–209. Therefore, there is a need to better define the 
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frequency of these cells and investigate their functional capacity in patient tissue samples 
to decipher their importance.  
In this chapter, our aim is to understand whether the frequency and function of 
innate-like T cells in cancer patients is altered compared to healthy donors and whether 
their phenotype suggests the cells are responding to cancer. We have the advantage of 
access to samples from many patient groups, including blood, tumours and bone marrow, 
which will allow us to assess whether there are differences in different tissues of patients 
with cancer. For example, changes in relative frequency of cells in the tumour compared 
to blood may indicate selective activation, migration or suppression of these cells in the 
tumour microenvironment. 
We investigated innate-like T cells in many patient groups with different forms of 
cancer and have presented our data in several ways. For example, we have compared 
innate-like T cells isolated from blood of patients to cells from the blood of healthy 
donors, and also to tissues from the same patient group. Where feasible we have also 
compared tissues from the same individual (i.e., patient-matched data). Patient data was 
examined collectively as solid or blood (haematological) and where numbers allowed, in 
groups of specific cancer types. For example, for solid cancers, we had sufficient donors 
to separately analyse some cell types from patients with colorectal cancer (labelled ‘colon 
cancer’ in Figures) or lung cancer, but low sample sizes or cell yield sometimes meant 
other patient samples were pooled into one group classified as ‘other’ solid cancers. 
‘Other’ solid cancers included ovarian cancer, breast cancer, melanoma and stomach 
cancer.  
For blood cancers, separate patient groups were studied for chronic lymphocytic 
leukaemia (CLL), non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) while 
the less frequent samples from patients with acute leukaemia (AL), T cell leukaemia 
(TCL), hairy cell leukaemia (HCL), natural killer cell leukaemia (NCL) and acute 
myeloid leukaemia (AML) were pooled and classified as ‘Other’ blood cancers. To 
simplify the description of results and figures in the thesis, samples described as ‘blood’, 
‘bone marrow’ and ‘tumour’ can be assumed to refer to viable lymphocytes processed 
from these samples, unless otherwise stated.  
 
3.1.1. MAIT cells in patients with cancer 
MAIT cells are a recently identified lineage of innate-like T cells that are often compared 
with NKT cells because they possess similar traits. MAIT cells have a semi restricted 
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TCR that specifically recognizes vitamin B metabolites via the MR1 antigen presenting 
molecule to induce rapid production of cytokines 38. These features are similar to NKT 
cells, which have a semi invariant TCR that can interact with lipids presented by the 
CD1d antigen-presenting molecule.  
MAIT cells are identified in several ways, including with a MR1 tetramer loaded 
with riboflavin metabolite, or by co-expression of Vα7.2TCR, CD161 and sometimes 
CD8 56. The means of identifying MAIT cells is somewhat controversial, although recent 
findings show that the MR1 tetramer identifies a similar group of cells to that identified 
as Vα7.2TCR+, CD161+ and CD8+ 52. 
In recent clinical studies of patients with cancer, MAIT cells were found to be 
present in blood and tumours, with strong indications that the both frequency and function 
was significantly impacted in some patient groups with cancers 68,69,196,194. However, not 
many forms of cancers have been investigated. For example, most tumour studies were 
done in colorectal cancer patients, but other solid cancers, such as breast cancer or lung 
cancer have not been studied at all 68,196,197. Furthermore, relatively few reports have 
described MAIT cells in context of haematological malignancies such as multiple 
myeloma. In this project, we will investigate MAIT cell frequency in other forms of 
cancer and investigate their functioning in those and in colorectal cancers.  
 
3.1.2. Characterization and identification of MAIT cells  
In this project, viable MAIT cells were defined as CD161+Vα7.2TCR+CD3+. This 
definition has been used to identify MAIT cells in previous studies including patients 
with cancer 197. Where appropriate, MAIT cell subsets were categorized by differential 
expression of CD8 (i.e. CD161+CD8+Vα7.2TCR+ CD3+) with the CD8+ compartment 
especially enriched for MR-1 tetramer positive MAIT cells. One important question was 
to determine whether MAIT cells are activated in patients with cancer because this would 
be consistent with MAIT cells playing a role in anti-tumour immunity and perhaps 
recognizing tumour antigens. To examine the activation of MAIT cells, expression of 
CD25 and cytokines were measured ex vivo from patients. The frequency of MAIT cell 
subsets was measured relative to viable lymphocytes, T cells and Vα7.2TCR+CD3+ T 
cells as indicated (Figure 1).  
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Figure 1. Identification and quantification of MAIT cells and their subsets. Using 
tissue samples from patients with cancer, Vα7.2TCR+CD3+ T cells were identified 
among lymphocytes isolated from blood, tumours and bone marrow (A), followed by 
identification of MAIT cell subsets based on CD161 and CD8 expression (B).  
 
3.1.3. MAIT cells in solid cancer 
The frequency of MAIT cells in peripheral blood mononuclear cells (PBMCs) of patients 
with cancer has been reportedly lower than in PBMCs of healthy donors, while the 
frequency of MAIT cells in tumours was significantly higher than in unaffected tissues 
68,69,196. These studies examined MAIT cells in patients with colorectal cancer, lung 
cancer and liver cancer, but were mostly limited to analysis of patient blood, with the 
exception of one study of colorectal cancer 68,69,196,197. Thus, there is still a relatively poor 
understanding of the role of MAIT cells in tumour infiltrating lymphocytes (TILs) of 
patients with solid cancer, including the phenotype and frequency of these cells. In this 
section, we compared MAIT cells from PBMCs and TILs of patients with solid cancers to 
PBMCs of healthy individuals.  
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CD161 is usually regarded as an innate immune cell marker, but can also be 
expressed by innate-like T cells such as MAIT and NKT cells. Both lineages are reported 
as having abnormal frequency in patients with cancer. Other T cell populations 
expressing CD161 have also been reported to have an abnormal frequency in patients 
with cancer. For instance, a previous report showed that the frequency of CD161+CD4+ 
T cells in PBMCs of patients with cancer was significantly higher than in PBMCs of 
healthy donors 31. Thus, in addition to assaying MAIT and NKT cells, we assayed the 
frequency of CD161+ T cells to better understand whether changes affected MAIT cells, 
CD161+ cells or the overall T cell compartment.  
 
I. The frequency of MAIT cells in blood of patients with cancer  
i. MAIT cells. We found that the frequency of MAIT cells was lower in PBMCs of 
patient groups with solid cancer compared to healthy donors, irrespective of whether 
frequency was measured relative to viable lymphocytes (mean range 0.3% - 0.4% in 
patient PBMCs cf 2.27% in healthy PBMCs), T cells (0.6%-1.4% cf 4.9%) or 
Vα7.2TCR+CD3+ T cells (14.2% - 38.2 cf 60.1%) (Figure 2 A-C).  
 
Figure 2. The frequency of MAIT cells in patients with solid cancer. The frequency of 
MAIT cells was expressed relative to total lymphocytes (A), T cells (B) or 
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Vα7.2TCR+CD3+ T cells (C) in PBMCs (Bl) and TILs (Tu) of patients with solid cancer. 
The frequency in healthy controls was compared to collective patient samples, and then to 
each patient group (see comparison indicators above graphs). Each symbol represents 
one patient sample. Mann-Whitney test was conducted to determine statistical difference 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cells. To determine whether the MAIT cell deficiency reflected a broader 
impact on T cells in patients with solid cancer, CD161+ T cells were also assayed. 
Interestingly, the frequency of CD161+ T cells in patient PBMCs, which excluded MAIT 
cells, was also significantly lower than healthy donors in each patient group (mean range 
1.1% - 6.5% cf 12.7%) (Figure 3A). This suggests that the loss of MAIT cells may have 
been part of a wider deficiency affecting other T cell populations. However, it is 
important to highlight that the frequency deficiency for MAIT cells was greater than 
CD161+ T cells in patient PBMCs, suggesting there could be a MAIT cell specific effect 
in addition to the deficiency of CD161+ T cells. 
The frequency of overall T cells as a proportion of viable lymphocytes in PBMCs 
of patients with lung cancer or ‘other’ solid cancers was similar to PBMCs of healthy 
individuals, despite trending lower (40.1% ± 6.9 or 37.6% ± 7.8 cf 54.5% ± 2.3) whereas 
T cell frequency was significantly lower in patients with colorectal cancer (36.9% ± 2.8 cf 
54.5% ± 2.3) (Figure 3 C). This indicates that MAIT cell deficiency is probably impacted 
by effects on the overall T cell pool, but that the effect differs between patient groups and 
does not fully account for the more severe effects on MAIT cells.  
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Figure 3. The frequency of T cell populations in patients with solid cancer. The 
frequency of CD161+T cells (A) and CD3+ T cells (C) was measured in PBMCs (Bl) and 
TILs (Tu) from patients with solid cancer, and PBMCs from healthy controls (Ctrl) (A). 
Each symbol represents data from a single sample. Statistical significance was 
determined by Mann–Whitney analysis (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). Donor-matched PBMCs and TILs from patients with colorectal cancer 
were also compared (B, D).  Statistical significance was tested by Wilcoxon analysis 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
II.  The frequency of tumour infiltrating MAIT cells 
i. MAIT cells. We assayed the frequency of MAIT cells in tumours from patients with 
colorectal, lung and breast cancer. When compared to PBMCs of healthy donors, the 
frequency of MAIT cells in patient TILs was significantly lower, irrespective of whether 
we expressed the data relative to viable lymphocytes (mean 0.07% - 0.4% in patient TILs 
cf 2.27% in healthy PBMCs), T cells (mean 0.4% - 3.2% in patient TILs cf 4.9% in 
healthy PBMCs) or Vα7.2TCR+CD3+ T cells (14.2% - 31.7% in patient TILs cf 60.1% in 
healthy PBMCs) (Figure 2 A-C). 
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ii. Non MAIT T cells. To determine whether the deficiency of MAIT cells reflected an 
impact on broader T cells, the frequency of CD161+ T cells was compared for patient 
TILs and PBMCs of healthy donors. We found that the frequency of CD161+ T cells 
infiltrating patient TILs varied between groups (Figure 3 A). For instance, the frequency 
in patient tumours was significantly lower than in PBMCs of healthy donors for patients 
with lung cancer or ‘other’ solid cancers (12.7% ± 1.6  in healthy PBMCs cf 3.2% ± 1.2 in 
lung cancer or 8.6% ± 2.7 in ‘other’ solid cancer) (Figure 3 A). However, there was no 
significant difference between TILs of patients with colorectal cancer and PBMCs of 
healthy donors (refer to Figure 3 A).  
We also identified a deficiency of overall T cells infiltrating tumours compared to 
PBMCs of healthy donors (mean ranged between 15.2% to 38.9% in patient TILs cf 
54.5% in healthy PBMCs) (Figure 3 C), which may have contributed to the MAIT cell 
deficiency although the deficiency of MAIT cells was far more severe.  
Collectively, the deficiency of MAIT cells in patient TILs appears to be partly 
specific as it was greater than other T cell populations. The frequency of CD161+ T cells 
was more variable, which could be due to the heterogeneity of this population leading to 
differences in frequency movements from MAIT cells, as shown in tumours of patients 
with colorectal cancer.  
 
III. Comparing between TILs and PBMCs within patient groups  
i. MAIT cells. We next compared TILs and PBMCs of patients and found no significant 
frequency difference within patient groups (refer to Figure 2 A-C). This indicates that the 
frequency of MAIT cells in TILs was similar to that in PBMCs of the same patient group 
with solid cancer. 
 
ii. Non MAIT T cells. The frequency of CD161+ T cells relative to viable T cells in 
tumours of colorectal or ‘other’ solid cancers was significantly higher than in PBMCs of 
same patient group (17.2% ± 3.6 in patient TILs cf 6.5% ± 1.1 in patient PBMCs for 
colorectal cancer; 8.6% ± 2.7 cf 1.1% ± 0.2 in ‘other’ solid cancer) (Figure 3 A). This 
was interesting given there was no significant difference between TILs and PBMCs in the 
frequency of MAIT cells within colorectal cancer or ‘other’ solid cancers within the same 
patient group, which indicates that MAIT cells are impacted differently to some other T 
cell populations (Figure 2 A-C). However, no difference was seen in patients with lung 
cancer as per our results for MAIT cells. 
  
41 
Interestingly, the overall frequency of T cells was similar in TILs and PBMCs in 
most patient groups with the exception of colorectal cancer, where it was lower in 
tumours than in PBMCs (36.9% ± 2.3 cf 15.5% ± 2.2) (Figure 3 C) 
 
IV. Patient matched TILs and PBMCs from patients with colorectal cancer 
i. MAIT cells. In addition to comparing PBMCs and TILs within patient groups, we 
conducted a patient-matched analysis for MAIT cells in TILs and PBMCs of the 
colorectal cancer group, but found no difference in MAIT cell frequency (Figure 4 A-C).  
 
Figure 4. The frequency of MAIT cells in patient matched tissue samples. Patient 
matched PBMCs and TILs from patients with colorectal cancer were compared for MAIT 
cell frequency in proportion to lymphocytes (A), T cells (B) or Vα7.2TCR+CD3+ T cells 
(C). Each symbol represents one patient sample. Wilcoxon test was used to determine 
statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cells. We found a significantly lower frequency of CD161+ T cells in 
TILs than in patient matched colorectal PBMCs (6.6% ± 1.2 cf 18.4% ± 4) (Figure 3 B), 
and similar deficiency was also found for overall T cells in TILs of 
patients with colorectal cancer compared to patient matched PBMCs (14.6% ± 
3.2 cf 37.1% ± 3.4) (Figure 3 D). These findings indicate that the frequency of CD161+ T 
cells infiltrating patient TILs is impacted differently to MAIT cells (Figure 4 A-C). 
 
3.1.4. Summary on MAIT cells in patients with solid cancer 
In this section, we conducted a series of comparisons between lymphocytes from the 
PBMCs and TILs of patient groups and PBMCs of healthy donors and revealed that the 
frequency of MAIT cells in PBMCs and TILs of patient groups with solid cancer was 
deficient compared to healthy donors.  
However, the MAIT cell deficiency was no greater in patient TILs than in PBMCs 
of patient groups with solid cancer, or for matched TILs and PBMCs samples from 
patients with colorectal cancer. Our findings showed that MAIT cells are similarly 
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deficient in TILs and PBMCs of patients with solid cancer compared to PBMCs of 
healthy donors, suggesting a systemic effect instead of tumour specific. 
 
3.1.5. CD8+ and CD8- MAIT cell subsets in patients with cancer 
MAIT cells co-expressing CD161, Vα7.2TCR, CD3 and sometimes CD8 56,86. The 
significance of CD8 expression is not clear, although the relative frequency of CD8+ 
MAIT cells in tumours of patients with colorectal cancer is reportedly different than non 
tumour affected tissues of the same patients 68,69,196.  
Different studies report that the frequency of MAIT cells (defined as 
CD161+Vα7.2TCR+CD3+CD8+) in blood was similar in patients with colorectal cancer 
and healthy donors 68. However, a different study where MAIT cells were defined as 
CD161+Vα7.2TCR+CD3+ reported a deficiency in blood of patients with colorectal 
cancer 6. These contradictory reports suggest that MAIT cell analysis may yield different 
results based on how they were identified. 
The earlier studies examined two distinct MAIT cell phenotypes 
(CD161+Vα7.2TCR+CD3+ and CD161+CD8+Vα7.2TCR+CD3+), but not both in the 
same study 68,69,197. In this section, we studied CD8+ and CD8- MAIT cells from blood 
and tumours of patients with different forms of solid cancer. In addition, we analysed 
CD161-Vα7.2TCR+CD3+ T cell (MAIT-like T cells) subsets to establish if changes were 
specific to the MAIT cell compartment.  
 
Proportion of CD8+ and CD8- MAIT cell subsets 
We first asked how the proportions of CD8+ and CD8- MAIT cell subsets in patients with 
solid cancer compared to PBMCs of healthy donors. In PBMCs of healthy donors, CD8+ 
MAIT cells were the dominant subset over CD8- MAIT cells (74.1% ± 2.9 in CD8+ 
subset cf 25.9% ± 2.9 in CD8- subset) (Figure 5). Consistent with this, patient PBMCs 
and TILs also showed CD8+ MAIT cells were the dominant subset across different 
patient groups with solid cancers. A possible exception was in TILs of patients with lung 
cancer, which showed no significant difference between CD8+ and CD8- MAIT cell 
frequency, although these had low n values (e.g. in colorectal cancer; 75.3% ± 2.5 CD8+ 
cf 24.6% ± 2.5 CD8- for patient PBMCs; 67.8% ± 5.5 CD8+ cf 32.2% ± 4.6 CD8- subset 
for patient TILs; for remaining patient groups, refer to Figure 5). Collectively, our results 
suggest that PBMCs and TILs of patients with solid cancer have CD8+ MAIT cells as a 
dominant subset over CD8- MAIT cells much like healthy controls. 
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Figure 5. The frequencies of CD8+ and CD8- MAIT cells in patients with solid cancer. 
The frequency of CD8+ and CD8- MAIT cells was compared for PBMCs and TILs of 
patients with solid cancer and PBMCs of healthy donors. Mann-Whitney test was used to 
determine statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****).  
 
3.1.6. Summary on MAIT cell subsets 
We asked whether the proportion of MAIT cell subsets among overall MAIT cells was 
different in patients with solid cancer compared to PBMCs of healthy donors. As for 
PBMCs of healthy donors, our results revealed that CD8+ MAIT cells are most dominant 
subset among overall MAIT cells and we saw a similar trend in patient PBMCs or TILs. 
Therefore, it appears that cancer does not significantly alter MAIT cell subset proportions 
from what is seen in healthy individuals. 
 
3.1.7. Activated MAIT cells in patients with solid cancer 
If MAIT cells participate in anti-tumour responses, they may have an activated phenotype 
in patients with cancer, especially within the tumour microenvironment. To assess this, 
we measured the frequency of activated (CD25+) MAIT cells (CD161+Vα7.2TCR+CD3) 
and of their CD8+ and CD8- subsets in PBMCs and TILs of different patient groups. We 
also assayed CD161-Vα7.2TCR+CD3+ T cells (MAIT-like T cells) and T cells from 
PBMCs or TILs of patients with solid cancer.  
 
I. The frequency of activated MAIT cells from patients with solid cancer. 
i. MAIT cells. The frequency of activated (CD25+) MAIT cells in PBMCs from patient 
groups with solid cancer was significantly higher than for PBMCs of healthy donors 
(mean ranged between 2.5% to 4.5% in patient PBMCs cf 0.48% in healthy PBMCs) 
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(Figure 6 A). Similar to PBMCs, we found a consistently higher frequency of activated 
MAIT cells in TILs of patient groups compared to PBMCs of healthy donors (mean 
ranged between 7.4% to 24.9% in patient TILs cf 0.48% in healthy PBMCs) (Figure 6 A). 
 
ii. Non MAIT T cells. To establish if this trend was specific to MAIT cells, we measured 
CD25 expression on overall T cells (CD3+) in patient and healthy donor PBMCs. The 
frequency of activated T cells increased to a similar extent as for MAIT cells and the 
frequency of activated T cells was significantly higher in patients than in healthy donors 
(mean 0.82% - 1.6% in patient PBMCs cf 0.13% in healthy PBMCs for overall T cells) 
(Figure 7 A). 
Interestingly, MAIT-like (CD161-Vα7.2TCR+CD3+) T cells were mostly similar 
in patient and healthy donor PBMCs (Figure 6 C). While this finding makes it harder to 
interpret whether the impact is specific to MAIT cells, our data does indicate that despite 
varying impacts on other T cells, the frequency of activated MAIT cells is consistently 
increased in patient PBMCs. 
In patient TILs, the frequency of CD25+ T cells was significantly higher than in 
PBMCs of healthy donors (mean ranged between 2.6% to 4.6% in patient TILs cf 0.13% 
in healthy PBMCs) (Figure 7 A). Consistent with earlier, the frequency of activated 
MAIT-like T cells was also significantly higher than in PBMCs of healthy donors (mean 
ranged between 5.6% to 8.6% in patient TILs cf 1.7% in healthy PBMCs) (Figure 6 C). 
However, it is important to highlight that the proportion of activated MAIT cells in 
patient TILs was higher than both MAIT-like T cells or T cells, even though they 
somewhat reflected the trend of other T cells. 
Collectively, we showed that MAIT cells were generally more activated in tissue 
samples from patients compared to healthy donors. This was also true for other T cell 
populations but the increase was greater for MAIT cells indicating different factors may 
have been impacting on different populations. 
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Figure 6. The frequency of activated MAIT cells or MAIT-like T cells in patients with 
solid cancer. (A) CD25 expression by MAIT cells and (C) MAIT-like T cells from PBMCs 
(Bl) and TILs (Tu) of patients with solid cancer were compared to PBMCs from healthy 
donors. Frequencies were also compared between PBMCs (Bl) and TILs (Tu) of patient 
groups. (A) 0.001% includes <0.001%, (B) 0.01% includes <0.01%. Mann-Whitney test 
was conducted to determine statistical significance (P<0.05*/ P<0.01**/ 
P<0.001***/P<0.0001****). (B, D) The frequency of CD25+ MAIT cells or MAIT-like T 
cells was also compared in patient matched PBMCs and TILs from colorectal cancer. 
Each symbol represents one sample. (C) 0.001% includes <0.001%, (D) 0.01% includes 
<0.01%. Wilcoxon test was used to determine statistical significant of the frequency 
change (P<0.05*/P<0.01**/P<0.001***/P<0.0001****).  
 
Figure 7. The frequency of CD25+ T cells in patients with solid cancer. (A) The 
frequency of activated (CD25+) T cells) in PBMCs (Bl) or TILs (Tu) from patients with 
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solid cancer was compared among each patient group or with PBMCs from healthy 
controls (Ctrl). Statistical significance was determined by Mann–Whitney analysis 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). (B) PBMCs and TILs in same 
patients with colorectal cancer was measured to determine the frequency difference 
between patient PBMCs and TILs. Each symbol represents one sample. Wilcoxon test was 
carried to determine statistical significant of the frequency change (P<0.05*/ P<0.01**/ 
P<0.001*** / P<0.0001****). 
 
II. Comparison of patient group matched TILs and PBMCs  
i. MAIT cells. The frequency of activated MAIT cells in TILs of patients with colorectal 
cancer, and ‘other’ solid cancers, was significantly higher than in PBMCs of same patient 
group (12.4% ± 2.6 cf 2.7% ± 0.8 in colorectal cancer; 24.9% ± 9 cf 4.5% ± 1.2 in ‘other’ 
solid cancers) (Figure 6 A). No significant difference was found in patients with lung 
cancer, although expression was trending higher in patient TILs (Figure 6 A). These 
findings indicate that some patient groups with solid cancers show evidence of 
significantly increased MAIT cell activation in TILs that may indicate a tumour-specific 
response. 
 
ii. Non MAIT T cells. The frequency of activated MAIT-like T cells (CD161-
Vα7.2TCR+CD3+) and T cells in TILs was significantly higher than in PBMCs for 
patients with colorectal cancer (7.89% ± 2.2 cf 0.65% ± 0.12; 4% ± 0.78 in patient TILs cf 
1% ± 0.77 in patient PBMCs) (Figures 6 C and 7 A), but no difference was seen for 
patients with lung cancer or ‘other’ solid cancers.  
 
III. Patient matched TILs and PBMCs within patients with colorectal cancer 
There were sufficient donors for a patient matched analysis of activated MAIT, MAIT-
like (CD161-Vα7.2TCR+CD3+) T cells and T cells in TILs and PBMCs in the colorectal 
cancer group (Figure 6 B, D & 7 B). For all three, the frequency of CD25+ cells was 
significantly higher in TILs than in matched PBMCs (13.6% ± 3.3 cf 1.7% ± 0.76 in 
MAIT cells, 8.1% ± 2.9 cf 0.4% ± 0.15 in MAIT-like T cells or 4.4% ± 1.3 cf 0.28% ± 0.11 
in overall T cells). These findings demonstrate that the increase in activation was higher 
for MAIT cells than for other T cell populations such as MAIT-like T cells and overall T 
cells.  
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Taken together our findings indicate that MAIT cells are more activated than other 
T cell populations investigated and this may indicate a role for these cells in the tumour 
microenvironment.  
 
IV. Proportion of activated CD8+ and CD8- MAIT cell subsets in MAIT cells 
We next asked whether CD8+ or CD8- MAIT cell subsets in patient PBMCs or tumours 
were more activated (CD25+). 2 of 3 patient groups showed no significant difference but 
CD8+ MAIT cells in PBMCs and TILs of patients with colorectal cancer were 
significantly more activated (CD25+) than CD8- MAIT cells (4.3% ± 1.4 cf 1.4% ± 0.65 
or 21.8% ± 5 cf 3.6% ± 0.93) (Figure 8). The results suggest more studies are required of 
these subsets in patients with colorectal cancers and possibly in lung cancer, where CD8+ 
subset trended higher than CD8- subset for CD25 expression. 
 
Figure 8. The comparison between activated CD8+ and CD8- MAIT cells in blood or 
tumours of patients with solid cancers. The frequency of CD25+ CD8+ and CD8- MAIT 
cells was compared for PBMCs (Bl) and TILs (Tu) of patients with solid cancer. As a 
control, PBMCs of healthy donors was also assayed. 0.001% includes <0.001%. Mann-
Whitney test was conducted to determine statistical difference (P<0.05* / P<0.01** / 
P<0.001*** / P<0.0001****). 
 
3.1.8. Summary 
Collectively, our data supports the hypothesis that MAIT cells may be responding to 
cancer because we see higher levels of MAIT cell activation in patients than in PBMCs of 
healthy donors and the extent of the increase was often higher for MAIT cells than other 
T cell subsets. One of the other highlights in this section was that MAIT cells were more 
activated in TILs than in PBMCs of respective patient group. This applied in several 
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patient groups, as well as analysis of matched TILs and PBMCs from patients with 
colorectal cancer. The increase in frequency of activated MAIT cells in the TILs and 
PBMCs of patients raises the possibility they can participate in anti-tumour responses.  
It was interesting that more CD8+ MAIT cells were activated than CD8- MAIT 
cells in TILs of patients with colorectal cancers, which may indicate that there are subset 
differences in the response of MAIT cells. 
 
3.1.9. MAIT cells in patients with blood cancer 
In patients with solid forms of cancer, MAIT cells in PBMCs and TILs were deficient 
compared to PBMCs of healthy donors. Here, we assayed the frequency of MAIT 
(CD161+Vα7.2TCR+CD3+) cells in PBMCs or bone marrow (BM) derived cells of 
patient groups with different blood cancers, including CLL, NHL and MM. Where 
relevant, we assayed the frequency of other T cells such as CD161+ T cells or overall T 
cells to identify changes affecting all T cells and to determine whether MAIT cells 
followed a similar pattern. 
 
I. PBMCs of patients with blood cancers compared to healthy PBMCs 
i. MAIT cells. As for patients with solid cancer, the PBMCs of patient groups with blood 
cancers were consistently deficient for MAIT cells (Figure 9 A-C). The range across 
patient groups compared to the PBMCs of healthy donors was as follows: 0.13% to 
0.23% cf 2.2% (relative to viable lymphocytes), 0.53% to 1.5% cf 4.9% (relative to T 
cells) or 20.9% to 31.4% cf 61.42% (relative to Vα7.2TCR+CD3+ T cells) (Figure 9 A-
C).  
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Figure 9. The frequency of MAIT cells in patients with blood cancer. The frequency of 
MAIT cells in viable lymphocytes (A), T cells (B) or Vα7.2TCR+CD3+ T cells (C) was 
measured in PBMCs (Bl) and BM derived cells (BM) of patients with blood cancer and 
PBMCs of healthy donors (Ctrl). The frequency in patient samples was compared to that 
of PBMCs from healthy controls, and we also made patient group specific comparisons of 
PBMCs and BM derived cells as indicated by brackets above each column. Each symbol 
represents one sample. Mann-Whitney tests were conducted to determine statistical 
significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cells. To determine whether the lower frequency of MAIT cells in 
PBMCs of patient groups with blood cancer reflected broader changes affecting the 
overall T cell population, we measured the frequency of other T cells in these patient 
groups. The frequency of CD161+ T cells (excluding MAIT cells) among T cells was 
significantly lower than in PBMCs of healthy donors (mean ranged between 4% to 9.7% 
in patient PBMCs cf 12.7% in healthy PBMCs) (Figure 10 A).  
The frequency of T cells in PBMCs of patients with blood cancers was 
significantly lower than in PBMCs of healthy individuals (mean ranged between 16.4% 
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to 39.3% in patient PBMCs cf 54.9% in healthy PBMCs), apart from patients with NHL, 
which were statistically similar to healthy donors (Figure 10 C). 
Our findings therefore suggest that the deficiency of MAIT cell was mostly at 
least partly reflecting the impact on broader T cell frequency in PBMCs of each patient 
group with blood cancer. However, the difference in frequency was greater for MAIT 
cells than CD161+ T cells and therefore, MAIT cells may have a specific deficiency not 
seen in other T cells.  
  
Figure 10. The frequency of CD161+ T cells and CD3+ T cells in patients with blood 
cancer. (A) The frequency of T cells expressing CD161 (A) or CD3+ T cells (C) in 
PBMCs (Bl) and bone marrow (BM) derived cells from patients with blood cancer was 
compared with PBMCs from healthy controls (Ctrl), or used in patient group specific 
comparisons between PBMCs and BM derived cells. Each symbol represents one sample. 
Statistical significance was determined by Mann–Whitney analysis (P<0.05* /P<0.01**/ 
P<0.001***/ P<0.0001****). (B, D) Patients with CLL were assayed for the frequency 
difference of CD161+ T cells or CD3+ T cells between patient matched PBMCs and BM 
derived cells.  Statistical significance was determined by Wilcoxon analysis (P<0.05*/ 
P<0.01**/ P<0.001***/ P<0.0001****). 
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II. BM derived cells of patients with blood cancers compared to healthy PBMCs 
i. MAIT cells. We next examined patient bone marrow (BM) to see if the impact on 
MAIT cell frequency was specific to patient PBMCs. The majority of patient groups 
showed a significantly lower frequency of MAIT cells in BM derived cells compared to 
PBMCs of healthy donors (e.g. among viable Vα7.2TCR+CD3+ T cells; mean range 
18% - 26% in patient BM cf 61.4% in healthy PBMCs; for frequency among T cells or 
lymphocytes, refer to Figure 9 A-B). However, a few exceptions were also found, 
depending on which immune cell population was used to relate the frequency of MAIT 
cells. For instance, relative to viable T cells, the MAIT cell frequency was slightly higher 
in BM of patients with NHL (6.1% ± 5.2 cf 4.9% ± 0.9), whereas for patients with CLL, 
the frequency was similar to healthy controls, relative to viable lymphocytes and T cells 
(Figure 9 A-B). 
 
ii. Non MAIT T cells. To assess changes affecting overall T cell populations, the 
frequency of CD161+ T cells in patient BM was measured. Patients with NHL showed 
significantly lower frequency of CD161+ T cells than in PBMCs of healthy donors (8.4% 
± 4.2 cf 12.7% ± 1.6), but were statistically similar to CLL or MM patient groups (Figure 
10 A). These findings different to the data on MAIT cells, suggesting a MAIT-specific 
defect.  
In contrast to CD161+ T cells, T cells (relative to viable lymphocytes) in BM 
from different patient groups with blood cancer were deficient in PBMCs of healthy 
donors and this was similar to MAIT cells (mean ranged between 9.7% to 35.9% cf 
54.9%) (Figure 10 C). This may indicate that the MAIT cell deficiency reflected trends 
affecting T cells overall, but the magnitude of deficiency was far greater in MAIT cells, 
which suggests a specific impact not found in other T cells. 
Despite variable results from different T cell populations, the MAIT cell 
deficiency in BM seems to be consistent across different patient groups with blood cancer 
and was mostly more extreme, indicating aspects were MAIT cell specific.  
 
III. Comparing PBMCs and BM derived cells in same patient group   
i. MAIT cells. Patient PBMCs and bone marrow (BM) derived cells were consistently 
deficient for MAIT cells compared to PBMCs of healthy donors. We next compared 
PBMCs and BM derived cells within the same patient group to determine if the frequency 
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of MAIT cells is impacted differently between tissues, but we found identified no 
significant difference between patient group matched PBMCs and BM derived cells 
(Figure 9 A-C).  
We also conducted patient matched comparisons of PBMCs and BM derived cells 
from patients with CLL and again found no significant difference in MAIT cell frequency 
(Figure 11 A-C). Low sample numbers for patient matched tissues prevented similar 
analysis of other patient groups. 
 
Figure 11. The frequency of MAIT cells in matching tissue samples from patients with 
CLL. Patient matched PBMCs and BM derived cells from patients with CLL were 
assayed for MAIT cell frequency relative to viable lymphocytes (A), T cells (B) or to Vα
7.2TCR+CD3+ T cells (C). Each dot represents one sample. Wilcoxon test was used to 
measure statistical significance (P<0.05*/ P<0.01**/P<0.001***/P<0.0001****). 
 
ii. Non MAIT T cells. The frequency of CD161+ T cells (Figure 10 A) in PBMCs and 
BM of different patient groups with blood cancer was similar for every patient group. 
Patient matched blood and BM in patients with CLL also showed no noticeable frequency 
difference for CD161+ T cells (Figure 10 B).  
In contrast to CD161+ T cells, the frequency of overall T cells sometimes differed 
between tissues. For instance, the frequency in PBMCs of patients with NHL or MM was 
significantly higher than in respective BM derived cells (45.5% ± 4.7 cf 26.2% ± 4.2 in 
NHL or 39.8% ± 3.2 cf 24.3% ± 3.2 in MM), but no difference was seen for patients with 
CLL or ‘other’ blood cancers (Figure 10 C). Curiously, no significant difference was 
found when we compared patient matched PBMCs and BM derived cells in the CLL 
patient group (Figure 10 D). 
Collectively, our data showed that MAIT cells didn’t usually have a tissue specific 
deficiency. This was also similar for CD161+ T cells. Further study is required though as 
differences for overall T cells could suggest that other T cell populations not investigated 
in this section could have a tissue specific changes in patients with NHL or MM. 
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3.1.10. Summary on MAIT cells in patients with blood cancer 
In PBMCs of patients with blood cancer, the frequency of MAIT cells relative to viable V
α7.2TCR+CD3+ T cells, lymphocytes or T cells was significantly lower than in PBMCs 
of healthy donors. These findings identify a MAIT cell specific deficiency in patient 
PBMCs compared to PBMCs of healthy individuals.  Other T cell populations, such 
CD161+ T cells often also showed a deficiency, but the deficiency of MAIT cells in 
patient blood was more severe, which suggests a MAIT cell specific effect.  
Consistent with the pattern observed in PBMCs, MAIT cells in patient BM 
derived cells were also deficient compared to PBMCs of healthy donors. This was not 
seen for CD161+ T cells, again suggesting that the MAIT cell deficiency in patient BM is 
not the result of changes affecting different T cell populations.   
Interestingly, when PBMCs and BM derived cells were compared within patient 
groups, there was no significant difference in MAIT cell frequency, indicating that 
PBMCs and BM derived cells are similarly MAIT cell deficient and that the cause of the 
deficiency is systemic.   
 
3.1.11. MAIT cell subsets in patients with blood cancers 
In the previous section, we established that the overall frequency of MAIT 
(CD161+Vα7.2TCR+CD3+T) cells was significantly lower in PBMCs and bone marrow 
(BM) cells of patient groups with blood cancer than in PBMCs of healthy donors. In this 
section, we examined CD8+ and CD8- MAIT cell and MAIT-like (CD161-
Vα7.2TCR+CD3+) T cells to determine whether deficiencies were specific to CD8+ or 
CD8- MAIT cell subsets. 
 
Proportions of CD8+ and CD8- MAIT cell subsets in patient tissue samples 
We showed that the CD8+ MAIT cell subset was dominant over CD8- subset in healthy 
donors (74.1% ± 2.9 in CD8+ subset cf 25.9% ± 2.9 in CD8- subset) (Figure 12) and in 
patient PBMCs or BM cells for all patient groups (e.g. in patients with CLL; 69.6% ± 3.6 
in CD8+ subset cf 30.2% ± 3.6 in CD8- subset among patient PBMCs; 84.1% ± 4.5 in 
CD8+ subset cf 15.8% ± 4.5 in CD8- subset for patient BM; for remaining patient groups, 
refer to Figure 12). These findings indicate that patients with blood cancer have a similar 
ratio of CD8+ and CD8- MAIT cell subsets in PBMCs and BM derived cells as for 
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PBMCs of healthy donors. This implied that the overall deficiencies we had observed 
were affecting both subsets. 
 
Figure 12. The frequency of CD8+ and CD8- MAIT cell subsets in patients with blood 
cancer. The frequency of CD8+ (+) and CD8- MAIT cells (-) was compared in PBMCs 
or BM derived cells of patients with solid cancer. PBMCs of healthy donors (Healthy 
Blood) were also investigated. Wilcoxon test was carried to determine statistical 
significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
3.1.12. Summary of MAIT cell subsets in patients with blood cancer 
In patient PBMCs and BM derived cells, the frequency of CD8+ MAIT cells was 
significantly higher than CD8- MAIT cells among overall MAIT cells, which is 
consistent with PBMCs of healthy donors. Therefore, our data suggests that cancer does 
not impact on the proportion of CD8+ and CD8- MAIT cells in PBMCs or BM derived 
cells. 
 
3.1.13. Activation of MAIT cells in patients with blood cancers 
To determine whether MAIT cells (CD161+Vα7.2TCR+CD3+ T cells) were activated in 
patients with blood cancers, we measured expression of CD25 on cells isolated from 
blood or bone marrow (BM). We also asked whether CD8+ or CD8- MAIT cell subsets 
were more likely to be activated and assayed other T cells including CD161-
Vα7.2TCR+CD3+ T cells (MAIT-like T cells) and their CD8+ or CD8- subsets as a point 
of comparison. 
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I. Activated MAIT cells in PBMCs and BM of patients and healthy donors 
i. MAIT cells. We assayed blood and found that each patient group showed a significantly 
higher frequency of activated MAIT cells compared to PBMCs of healthy donors (mean 
ranged between 4.7% to 9.4% in patient PBMCs cf 0.48% in healthy PBMCs) (Figure 13 
A).   
In patient BM derived cells, the frequency of activated MAIT cells in patients 
with NHL or ‘other’ blood cancers was significantly higher than in PBMCs of healthy 
donors (17% ± 7.7 or 9.6% ± 3.3 cf 0.48% ± 0.13), but comparable to patients with CLL 
(Figure 13 A). Due to low cell numbers, we were not able to quantify the frequency of 
activated MAIT cells in BM of patients with MM. 
 
ii. Non MAIT T cells. As a point of comparison, we examined other T cells in patient 
PBMCs and also found a significantly higher frequency of activated (CD25+) T cells 
compared to PBMCs of healthy donors (mean ranged between 0.62% to 1.1% in patient 
PBMCs cf 0.13% in healthy PBMCs) (Figure 14 A). These results indicate that the 
increased frequency of activated MAIT cells at least partly reflects the broader activation 
of the T cell pool, but the extent of the increase was greater for MAIT cells, suggesting 
they may have been more specifically involved. As the T cells have different subsets, we 
examined MAIT-like (CD161-Vα7.2TCR+CD3+) T cells and found that the frequency of 
activated cells was also significantly higher compared to blood of healthy donors (mean 
ranged 4.1% - 12.9% in patient PBMCs cf 1.7% in healthy PBMCs), which was similar to 
what we observed for MAIT cells (Figure 13 C).  
The frequency of activated T cells in BM of patients with NHL, MM or ‘other’ 
blood cancers was significantly higher than in PBMCs of healthy donors (5.2% ± 0.4 in 
NHL, 0.58% ± 0.19 in MM or 2% ± 0.8 in ‘other’ of patient BM cf 0.13% ± 0.02 in 
healthy PBMCs), whereas the BM of patients with CLL had similar levels (Figure 14 A).  
The frequency of activated MAIT-like T cells from BM of patients with NHL or ‘other’ 
blood cancers was significantly higher than in blood of healthy donors (23.6% ± 7.9 or 
14.1% ± 3.4 cf 1.7% ± 0.4) (Figure 13 C) but no difference was found for BM of patients 
with CLL. While the extent of MAIT cells, T cells or MAIT-like T cells activation varied 
between patient groups, it was interesting that MAIT cells and MAIT-like T cells showed 
similar levels of activation that were higher than we found for T cells. These findings may 
indicate that MAIT cells and MAIT-like T cells could be responding in BM of patients 
with blood cancers, but this requires further investigation. 
  
56 
  
Figure 13. The frequency of activated MAIT cells or MAIT-like T cells in patients with 
blood cancer. (A) The frequency of CD25+MAIT cells or (C) MAIT-like T cells in patient 
PBMCs (Bl), bone marrow (BM) derived cells of each patient group with blood cancer or 
PBMCs of healthy individuals (Ctrl) were assayed. Each symbol represents one patient 
sample. 0.001% includes <0.001%. Mann-Whitney test was conducted to determine 
statistical significance (P<0.05* /P<0.01** /P<0.001*** /P<0.0001****). (B, D) 
Matched PBMCs and BM derived cells from patients with CLL were compared for 
frequency of activated MAIT cells or MAIT-like T cells. Each symbol represents one 
patient sample. Wilcoxon test was used to determine statistical significance (P<0.05* 
/P<0.01** /P<0.001*** / P<0.0001****). 
 
Figure 14. The frequency of activated T cells in patients with blood cancer. (A) The 
frequency of CD25+ T cells in patient PBMCs (Bl), bone marrow (BM) derived cells of 
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each patient group with blood cancer or PBMCs of healthy individuals (Ctrl) was 
assayed. Each symbol represents one patient sample. Mann-Whitney test was conducted 
to determine statistical significance (P<0.05*/P<0.01**/P<0.001***/P<0.0001****). 
(B) Matched PBMCs and BM derived cells from patients with CLL were compared for 
frequency of CD25+ T cells. Each symbol represents one patient sample. Wilcoxon test 
was used to determine statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). 
 
II. Comparison of blood and bone marrow within same patients (or patient group) 
with blood cancer 
i. MAIT cells. Next, we found the frequency of activated MAIT cells was similar in BM 
derived cells and PBMCs for most patient groups, including CLL and the ‘other’ blood 
cancers, but patients with NHL had lower MAIT cell activation in PBMCs than in BM 
derived cells (8.1% ± 2 cf 17% ± 7.7) (Figure 13 A). We were able to conduct a donor 
matched comparison of BM derived cells and PBMCs in patients with CLL, and found no 
significant difference in the frequency of activated MAIT cells (Figure 13 B). 
 
ii. Non MAIT T cells. We also found no significant difference in the frequency of 
activated T cells between PBMCs and BM derived cells of different patient groups 
(Figure 14 A), or for patient matched PBMCs and BM derived cells of CLL patients 
(Figure 14 B). Similarly, most patient groups showed no significant difference in 
activation of MAIT-like (CD161-Vα7.2TCR+CD3+) T cells between patient PBMCs and 
BM derived cells including patient matched samples (Figure 13 C, D), with the exception 
of patients with ‘other’ blood cancers, including natural killer cell leukaemia and T cell 
lymphoma, where we observed a higher frequency of activated MAIT-like T cells in 
patient BM than in PBMCs (14.1% ± 3.4 cf 6.4% ± 1.2) (Figure 13 C). These findings 
indicate that the frequency of activated MAIT cells or other broader T cell populations in 
patient PBMCs are mostly similar to patient group matched BM derived cells. Exceptions 
included our observation of a higher frequency of activated MAIT cells in BM of patients 
with NHL and of MAIT-like T cells in BM of patients with ‘other’ blood cancers.  
 
III. Proportion of activated CD8+ and CD8- MAIT cell subsets 
We next asked whether CD25+ expression was similar for CD8+ and CD8- MAIT cell 
subsets in patients with blood cancers. Our results showed no significant difference 
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between the two subsets in PBMCs or BM derived MAIT cells of different patient groups 
suggesting that both subsets are equally impacted (Figure 15). Due to lack of tissue 
samples, BM of patients with MM was not investigated. 
 
Figure 15. The comparison between activated CD8+ and CD8- MAIT cells in blood or 
bone marrow of patients with blood cancers. The frequency of CD25+ CD8+ (+) and 
CD8- (-) MAIT cells was compared in PBMCs or BM derived cells of patients with blood 
cancer. As a control, PBMCs of healthy donors (Ctrl) was also assayed. 0.001% includes 
<0.001%. Wilcoxon test was used to determine statistical significance (P<0.05*/ 
P<0.01**/ P<0.001***/ P<0.0001****). 
 
3.1.14. Summary 
Our findings indicate that the frequency of activated MAIT cells was higher in PBMCs 
and BM derived cells of patients compared to PBMCs of healthy donors. Similar 
differences were observed for MAIT-like cells, suggesting a non specific stimulus, 
however the proportion of activated T cells was clearly lower than MAIT cells or MAIT-
like T cells. Tregs also express CD25 but given that MAIT cells are predominantly CD4- 
population, it is less likely that increase in CD25 expression among MAIT cells don’t 
include Tregs in patient tissue samples. 
Activation of CD8+ and CD8- MAIT cell subsets was similar in PBMCs and BM 
derived cells of patients and PBMCs of healthy donors, suggesting that these subsets are 
equally impacted.  
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3.2. NKT cells 
NKT cells are innate-like T cells that express a Vα24Jα18-Vβ11 semi-invariant T cell 
receptor (TCR) in humans 37. There are many reports suggesting that NKT cells are 
associated with cancer. Some of the most notable findings relate to a significant defect in 
the frequency of NKT cells in patients with cancer, with many studies showing a 
significant reduction in the frequency of NKT cells in mostly blood of patients with 
cancer that has often been correlated with poor prognosis 160,198,210,211. However, an 
increase in the frequency of NKT cells in tumours has also been reported for patients with 
colorectal carcinoma 161. These studies indicate that NKT cells are not similarly impacted 
in all patients with cancer, but can be interpreted as consistent with a role in tumour 
immunity. There are differences between studies that may have contributed to this 
uncertainty, including how the groups defined NKT cells, as some studies used 
monoclonal antibodies specific to Vα24 or Vβ11, and others using CD1d tetramer loaded 
with αGal-Cer. Another variable is that different groups have used FACS analysis or 
immunofluorescence staining to identify NKT cells. A significant issue is that 
conclusions about the role of NKT cells in cancer have been drawn from studies of 
patient groups where only one form of cancer was studied. A more definitive conclusion 
will come from analysis of NKT cells across several cancers where there is a consistent 
approach to analysis of patient peripheral blood mononuclear cells (PBMCs), tumour 
infiltrating lymphocytes (TILs) and bone marrows (BM) derived cells.  In the past, 
PBMCs has been mostly studied due to lack of availability of other tissues, but in our 
project, we have identified NKT cells using the most stringent approach of CD1d tetramer 
loaded with αGal-Cer and used this to examine several types of tissue from patients with 
different forms of cancer.  
 
3.2.1. Identification and quantification of NKT cells 
To investigate the frequency of NKT cells in patients with cancer, CD1d tetramer loaded 
with αGal-Cer and monoclonal antibody specific for CD3 (anti-CD3 mAbs) were used to 
identify and quantify NKT cells in processed blood, bone marrow or tumours from 
patients and healthy donors (blood only) (Figure 16). Expression of other relevant surface 
markers such as CD4, CD8, activation markers, and NK receptors such as CD161 were 
also investigated. Where relevant, conventional T cells were assayed as a point of 
comparison to determine whether observations were specific to NKT cells or reflected 
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characteristics of the overall T cell population. Due to low cell NKT cell frequency, at 
least 1x106 cells were analysed to confidently confirm the presence and quantify NKT 
cells. Where cell numbers in a sample were lower, all possible cells were used for 
analysis and an assessment made as to whether the data should be included. Most cell 
populations of interest were clearly distinct from other cell types in analysis (e.g., Fig 16) 
so it was often possible to accurately assess frequency with relatively few positively-
stained cells. Appropriate gating guidelines were discussed with supervisors to ensure the 
method was consistent and reasonable.   
 
Figure 16. The identification and characterization of NKT cells in patients with solid 
cancer. Patient tissue samples from various cancers were used to identify NKT cells and 
their subsets. Co-staining with CD1d tetramer loaded with αGal-Cer and anti-CD3 was 
used to identify NKT cells in lymphocytes isolated from blood, tumours and bone marrow 
(A). Where necessary, functionally significant subsets such as CD4 and CD8 defined NKT 
cells were also investigated (B). 
 
3.2.2. Patients with solid cancer  
In this section, patient groups with solid tumours, including colorectal (colon) cancer, 
lung cancer and melanoma were assayed for frequency of NKT cells in blood and 
tumours. We also assayed overall T cells to determine whether changes were specific to 
NKT cells or also affected other T cells. 
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I. The frequency of NKT cells in patient PBMCs compared to healthy controls 
i. NKT cells. When PBMCs from separate patient groups were compared to healthy 
individuals, the frequency of NKT cells was varied between the groups (Figure 17 A-B). 
For instance, the frequency of NKT cells in PBMCs of patients with lung cancer or 
‘other’ solid cancers were significantly lower than PBMCs of healthy donors (0.004% ± 
0.002 or 0.013% ± 001 cf 0.05% ± 0.01 in lymphocytes or 0.013% ± 0.006 or 0.02% ± 
0.01 cf 0.11% ± 0.02 in T cells) whereas it was significantly higher in patients with 
colorectal cancer both as a proportion of viable lymphocytes despite showing similar 
frequency or T cells (0.06% ± 0.02 cf 0.05% ± 0.01 in lymphocytes or 0.2% ± 0.13 cf 
0.11% ± 0.02 in T cells) (Figure 17 A-B).  
 
Figure 17. The frequency of NKT cells in patients with solid cancer. The frequency of 
NKT cells in PBMCs (Bl) or TILs (Tu) from patients with solid cancer was measured 
relative to viable lymphocytes (A) or to T cells (B). The frequency was compared between 
PBMCs and TILs in each patient group, and PBMCs of patients and healthy individuals 
(Ctrl). Each symbol represents one patient tissue sample. 0.0001% includes <0.0001% 
when measured among (A) lymphocytes or (B) T cells. Mann-Whitney test was conducted 
to determine statistical difference (P<0.05*/P<0.01**/P<0.001***/ P<0.0001****). The 
frequency in NKT cells was also investigated between patient matched PBMCs and TILs 
from patients with colorectal cancer. The frequency was expressed relative to viable 
lymphocytes (C) or T cells (D). Each symbol represents the frequency of NKT cells found 
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in patient matched tissue samples. Each line represents the change in frequency between 
matched patient samples. (C) 0.00001% includes <0.00001% when measured among 
lymphocytes or (D) 0.001% includes <0.001% when measured among T cells. Wilcoxon 
test was conducted to determine statistical significance (P<0.05* / P<0.01**/ 
P<0.001***/ P<0.0001****). 
 
ii. Non NKT T cells. The frequency of overall T cells as a proportion of viable 
lymphocytes in PBMCs of patients with lung cancer or ‘other’ solid cancers was similar 
to the PBMCs of healthy individuals, despite trending lower (40.1% ± 6.9 or 37.6% ± 7.8 
cf 54.5% ± 2.3), whereas T cell frequency was significantly lower in patients with 
colorectal cancer, compared to healthy donors (36.9% ± 2.8 cf 54.49% ± 2.3) (Figure 3 C). 
These findings indicate that NKT cell deficiency in PBMCs of patients with lung cancer 
or ‘other’ solid cancers could be reflecting a broader deficiency of all T cells, although 
the NKT cell deficiency was more severe. For patients with colorectal cancers, NKT cell 
frequency was impacted differently to broader T cell population, indicating an NKT cell 
specific defect. 
 
II. The frequency of tumour infiltrating NKT cells compared to healthy controls 
i. NKT cells. We next investigated the frequency of NKT cells infiltrating tumours. In 
contrast to the results from patient PBMCs, the frequency of NKT cells as a proportion of 
viable lymphocytes, or of T cells, was significantly lower for all patient groups compared 
to the PBMCs of healthy donors (Figure 17 A-B). Typically, the frequency of NKT cells 
in patient TILs ranged between 0.001% to 0.007% cf 0.05% among lymphocytes or 
0.002-0.01% cf 0.11% among T cells (Figure 17 A-B).  
 
ii. Non NKT T cells. We also identified a deficiency of overall T cells infiltrating tumours 
compared to PBMCs of healthy donors. More specifically, the frequency of overall T 
cells infiltrating tumours of different patient groups was significantly lower than in 
PBMCs of healthy donors (mean ranged between 15.2% to 38.9% in patient PBMCs cf 
54.49% in healthy PBMCs) (Figure 3 C). These findings indicate that NKT cell 
deficiency in patient TILs is reflecting the impact on broader T cell populations. However, 
as for patient PBMCs, we observed a more severe deficiency in NKT cells compared to 
overall T cells.  
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III. Comparing TILs and PBMCs of the same patient group  
i. NKT cells. When we compared the frequency of NKT cells in TILs and PBMCs of the 
same patient group, we found no significant difference (among lymphocytes; 0.06% ±0.02 
in patient PBMCs cf 0.018% ± 0.017 in patient TILs for colorectal cancer; 0.004% ± 
0.002 cf 0.001% ± 0.0007 in lung cancer; 0.01% ± 0.01 cf 0.007% ± 0.007 in ‘other’ 
solid cancers) (Figure 17 A-B). However, it may be useful to conduct further studies as 
the frequency of NKT cells in patient PBMCs consistently trended higher than in TILs for 
colorectal cancer and lung cancer.  
 
ii. Non NKT T cells. As a control, we also compared T cell frequency in patient PBMCs 
and TILs. When compared to PBMCs of healthy donors, the frequency of T cells in 
patient PBMCs or TILs was significantly lower. Interestingly, in the vast majority of 
patient groups, the frequency of overall T cells was similar between TILs and PBMCs (% 
in lymphocytes; 13.5% ± 5.9 in patient PBMCs cf 10.8% ± 2.3 in patient TILs for lung 
cancer; 9.1% ± 2.2 in patient PBMCs cf 12.8% ± 4.4 in ‘other’ solid cancers) (Figure 3 
C). However, the relative frequency of T cells in TILs of patients with colorectal cancer 
was significantly lower than in PBMCs of those patients (36.9% ± 2.3 cf 15.5% ± 2.2) 
(Figure 3 C). Overall, we showed that most patient groups had similar levels of NKT cells 
and T cells in PBMCs and TILs, except for patients with colorectal cancer. However, the 
magnitude of changes was higher for NKT cells, indicating NKT cells may have been 
specifically affected, at least in part. 
 
IV. Patient matched TILs and PBMCs within patients with colorectal cancer 
i. NKT cells. Having compared cells from PBMCs and TILs within different patient 
groups, we next compared patient-matched (colorectal) PBMCs and TILs. Our results 
showed that the frequency of NKT cells in TILs was typically significantly lower than in 
PBMCs of same patients relative to viable lymphocytes (0.003% ± 0.001 cf 0.00018% ± 
0.00014), or to T cells (0.08% ± 0.03 cf 0.002% ± 0.0006) (Figure 17 C-D). While no 
significant difference had been identified for patient group matched comparisons, we 
identified similar trends with significant differences in patient matched tissues suggesting 
that NKT cells are locally impacted with specific deficiency in patient TILs. 
 
ii. Non NKT T cells. Like NKT cells, we identified a deficiency of overall T cells in TILs 
of patients with colorectal cancer compared to patient matched PBMCs (14.6% ± 
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3.2 cf 37.1% ± 3.4) (Figure 3 C). Therefore, both NKT cells and T cells were deficient in 
patient TILs compared to PBMCs. However, we identified a more severe deficiency of 
NKT cells in TILs compared to overall T cells. This may mean that while all T cells are 
affected, NKT cells are impacted more severely in patients with colorectal cancers. 
Patient matched tissues were not available for other patient groups, so we were not able to 
conduct a matched study of patients with lung cancer or ‘other’ solid cancers. 
 
3.2.3. Summary of overall NKT cells 
Collectively, our findings revealed that the frequency of NKT cells in PBMCs varied 
between different patient groups with solid cancer. For example, patients with colorectal 
cancer had a significantly higher frequency of NKT cells compared to healthy donors 
while patients with lung cancer or ‘other’ solid cancers showed a deficiency of NKT cells. 
These findings showed that not every patient group with cancer will have a NKT cell 
deficiency. We also compared the NKT cell frequency to overall T cells to determine if 
both populations are similarly impacted. The frequency of overall T cells trended lower 
for all of different patient groups, but only the colorectal cancer group showed a 
significant deficiency. This indicates that the NKT cell frequency in the PBMCs of 
patients with colorectal cancer, lung cancer or ‘other’ solid cancers do not simply reflect 
the overall T cell pool.  
Comparing PBMCs between patients and healthy donors yielded varying results, 
but the NKT cell frequency in TILs was consistently deficient and similar results were 
also identified for overall T cells in the TILs. Therefore, our results showed that both 
NKT cells and overall T cells are impacted in a similar way. However, the degree of 
deficiency in NKT cells was more severe than for overall T cells, suggesting NKT cell 
specific factors were contributing.   
Interestingly, we saw no significant difference when we compared PBMCs and 
TILs of patient groups, suggesting a systemic effect despite a significantly lower 
frequency of NKT cells for the majority of patient tissues compared to PBMCs of healthy 
donors. 
However, patient matched PBMCs and TILs did reveal a NKT cell deficiency in 
TILs of patients with colorectal cancers. Other groups were not tested in this way due to 
lack of tissues, but it is interesting that the NKT cell frequency in TILs consistently 
trended lower than in PBMCs of patients with lung cancer or ‘other’ solid cancers.  
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3.2.4. NKT cell subsets in patients with solid cancer 
In this section, we examined expression of CD4, CD8, CD25 and CD161 NKT cell 
subsets defined as CD4+CD8- (CD4+) or CD4-CD8- (DN) have distinctive functions 
while CD161 is variably expressed on unconventional T cells, including NKT cells. 
CD25 was used as a marker of activation. Due to lack of patient tissue samples, only 
patients with colorectal cancer was statistically compared while no subset data was 
available from patients with lung cancer. Samples with low overall NKT cell number 
were not considered for this section and this did lead to lower N value when compared to 
previous section investigating overall NKT cell frequency.  
 
I. The frequency of CD4+ and DN NKT cell subsets in patient PBMCs  
i. NKT cell subsets. The frequency of CD4+ or DN NKT cell subsets in PBMCs of 
different patient groups was within the range observed in PBMCs of healthy donors 
(Figure 29 A-B). A lack of tissue samples may have been a limiting factor in our analysis, 
but we showed that patients with colorectal cancer had a statistically similar frequency of 
CD4+ and DN NKT cells in PBMCs as healthy donors (in CD4+ subset; 36.6% ± 14.6 cf 
30.2% ± 22.2; in DN subset; 48.7% ± 11.8 cf 44.4% ± 4.3) (Figure 18 A-B). It was not 
possible to compare all patient groups, but CD4+ and DN NKT cells in PBMCs of 
patients with ‘other’ solid cancers were also within the frequency range observed in 
PBMCs of healthy donors but due to lack of tissue samples, we were not able to test the 
significance of the data (in CD4+ subset 70.7% cf 30.2% ± 22.2; in DN subset; 24% cf 
44.4% ± 4.3) (Figure 18 A-B).  
 
ii. Non NKT T cell subsets. The frequency of CD4+ T cells among overall T cells in 
PBMCs of colorectal cancer or ‘other’ solid cancers was significantly lower than in 
PBMCs of healthy donors (32.1% ± 4.2 or 40.6% ± 4.5 cf 52.7% ± 2.2) whereas PBMCs 
of patients with lung cancer had a lower frequency CD4+ T cells but with no significant 
difference to healthy donors (38% ± 8.8 cf 52.7% ± 2.2) (Figure 19 A). DN T cells were 
at a similar frequency among overall T cells in patient PBMCs or TILs compared to 
PBMCs of healthy donors (mean ranged between 9.1% to 13.5% cf 11.6%) (Figure 19 C). 
One exception was patients with colorectal cancer, where the frequency in PBMCs was 
significantly lower (16.9% ± 3.2 cf 11.6% ± 2) (Figure 19 C). Due to low cell numbers, 
we were unable to investigate the frequency of CD8+ NKT cells in patient PBMCs so we 
didn’t investigate CD8+ T cells in detail, but we identified significantly higher frequency 
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in PBMCs of patients with colorectal cancer or ‘other’ solid cancers while no significant 
difference was found in patients with lung cancer despite trending higher than healthy 
donors (e.g. in colorectal cancer; 47.9% ± 3.8 in patient PBMCs cf 32.8% ± 1.7 in 
healthy PBMCs. For more data, refer to Figure 19 B). Our findings confirmed that 
deficiency in CD4+ T cells was associated with an increase in CD8+ T cells in patient 
PBMCs. 
 
II. The frequency of CD4 and CD8 defined NKT cell subsets in patient TILs  
i. NKT cell subsets. Although low cell numbers meant it was not possible to assay all 
groups, most patient groups had similar proportions of CD4+ and DN NKT cell subsets in 
TILs compared to PBMCs of healthy donors (for example, colorectal cancer; in CD4+ 
subset; 30.2% ± 22.6 cf 36.5% ± 14; in DN subset; 59.7% ± 24.1 cf 48.7% ± 11.8. For 
more data refer to Figure 18 A-B).  
 
ii. Non NKT T cell subsets. As a point of comparison to NKT cell subsets, when we 
assayed CD4+ or DN subsets among T cells in patient TILs, only CD4+ T cells showed 
significant deficiency in patients with colorectal cancer or ‘other’ solid cancers (35.5% ± 
3.9 or 38.2% ± 5.9 cf 52.7% ± 2.2) (Figure 19 A). This deficiency of CD4+ T cells meant 
that CD8+ and DN subsets among T cells may have increased, but despite trending higher 
in patient TILs, no significant difference was found for healthy individuals (CD8+ T cells 
mean ranged between 39.1% to 43.3% cf 32.9%; DN T cells mean ranged between 10.8% 
to 14.5% cf 11.6%) (Figure 19 B-C). These findings indicate that at least in TILs of 
patients with colorectal cancer, the distribution of CD4+ NKT cells did not follow that of 
the broader T cell population while DN NKT cells were similar to healthy donors.  
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Figure 18. The frequency of NKT cell subsets in patients with solid cancer. The 
frequency of CD4+CD8- (CD4+) (A), CD4-CD8- (B), CD161+ (C) or CD25+ (D) NKT 
cell subsets from PBMCs (Bl) and TILs (Tu) of patients with solid cancer was assayed. 
Data was not included from samples where NKT cell numbers were below the threshold 
for accurate assessment of each subset. The frequency was compared between patient 
tissue samples and PBMCs of healthy individuals (Ctrl). Each coloured symbol 
represents the data obtained from one patient tissue sample. 0.1% includes <0.1%. 
Mann-Whitney test was conducted to determine statistical significance (P<0.05*/ 
P<0.01**/ P<0.001***/ P<0.0001****). 
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Figure 19. The frequency of T cell subsets defined by CD4 and CD8 in patients with 
solid cancer. Using patient PBMCs (Bl) and TILs (Tu) pooled into different patient 
groups with solid cancer, the frequency of T cell subsets defined by CD4 and CD8 (A-C) 
were compared for different patient groups and PBMCs of healthy individuals (Ctrl). 
Mann-Whitney test was conducted to determine statistical difference (P<0.05*/ 
P<0.01**/ P<0.001***/ P<0.0001****). 
 
III. A comparison between patient PBMCs and TILs for CD4 and CD8 defined NKT 
cell subsets  
i. NKT cell subsets. We also asked in patients with colorectal cancer whether NKT cell 
subsets have any specific tissue impacted by comparing PBMCs and TILs. However, our 
findings showed no significant difference for CD4+ or DN NKT cell subsets between 
patient tissue samples in patients with colorectal cancer while remaining patient groups 
were not measured due to lack of patient tissue samples (36.5% ± 14.6 cf 30.2% ± 22.6 in 
CD4+ subset; 48.7% ± 11.8 cf 59% ± 24.1 in DN subset) (Figure 25 A-B).  
 
ii. Non NKT T cell subsets. Similarly, no difference was found between patient TILs and 
PBMCs for CD4+ or DN T cells (e.g. in colorectal cancer; 32.1% ± 4 in patient PBMCs 
cf 35.6% ± 4 in patient TILs for CD4+ T cells; 16.9% ± 3.2 cf 14% ± 2.6 for DN T cells. 
  
69 
For more data, refer to Figure 26 A, C). Taken together, NKT cell subsets are likely to be 
impacted equally in the overall deficiency of NKT cells. 
 
IV. The frequency of CD161+ NKT cell subset in patients with solid cancer 
i. NKT cell subset. We next investigated the frequency of CD161+ NKT cells in PBMCs 
pooled into different patient groups and revealed a statistically similar frequency of 
CD161+ NKT cells in patients with colorectal cancer compared to PBMCs of healthy 
donors (80.5% ± 8.2 cf 72.2% ± 2.8), but remaining patient groups didn’t have enough 
patient tissues to definitively compared between patient PBMCs and healthy donors (8% 
or 17.1% cf 72.2% ± 2.8) (Figure 18 C). In patient TILs however, the frequency of 
CD161+ NKT cells in patients with colorectal cancer was deficient (72.2% ± 2.3 cf 37% 
± 13.3) (Figure 18 C).  
 
ii. Non NKT T cell subset. When we compared the frequency of CD161+ T cells as a 
point of comparison to CD161+ NKT cells, most patient PBMCs and TILs showed 
significantly lower frequency of CD161+ T cells compared to PBMCs of healthy donors. 
(e.g. in ‘other’ solid cancer; 1.1% ± 0.2 in patient PBMCs or 8.6% ± 2.7 in patient TILs 
cf 12.7% ± 1.6 in healthy PBMCs. For more data, refer to Figure 3 A). An exception was 
for tumours of patients with colorectal cancer, which was similar to healthy donors. As 
CD161+ NKT cells in TILs of patients with colorectal cancer were deficient, this suggests 
a specific deficiency.  
 
V. A comparison between patient PBMCs and TILs for CD161+ NKT cells 
i. NKT cell subset. When patient PBMCs and TILs were compared directly in colorectal 
cancer, we found that CD161+ NKT cells in patient TILs were significantly lower (80.5% 
± 8.2 in patient PBMCs cf 37% ± 13.3 in patient TILs) (Figure 18 C).  
 
ii. Non NKT T cell subset. In contrast, the frequency of CD161+ T cells in TILs of 
patients with colorectal or ‘other’ TILs was significantly higher than in PBMCs of same 
patient group (17.2% ± 3.6 cf 6.5% ± 1.1 in colon cancer & 8.6% ± 2.7 cf 1.1% ± 0.2 in 
‘other’ solid cancer) (Figure 3 A). This indicates that CD161+ NKT cells have specific 
deficiency in patients with colorectal cancer distinct from CD161+ T cells. 
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VI. The frequency of CD25+ NKT cell subset in patients with solid cancer 
i. Activated NKT cells. Finally, we quantified the frequency of activated (CD25+) NKT 
cells as a proportion of overall NKT cells in patient PBMCs or TILs of different patient 
groups. Results from colorectal cancer patients showed that a similar proportion of NKT 
cells were activated in patient TILs as for PBMCs of healthy donors. In contrast PBMCs 
of patients with colorectal cancer had a lower proportion of activated NKT cells than in 
PBMCs of healthy donors (0.1% cf 1.7% ± 0.6) (Figure 18 D). Due to lack of cell 
numbers, we could not definitively investigate in patients with lung cancer or ‘other’ solid 
cancers.  
 
ii. Activated non NKT T cells. As a point of comparison, we examined T cells and found 
that the activated proportion was mostly low, but significantly higher in patient PBMCs 
or TILs compared to PBMCs of healthy donors (mean ranged between 0.82% to 1.6% in 
patient PBMCs or 2.6% to 4.6% in patient TILs cf 0.13% in healthy PBMCs) (Figure 7 A). 
Since activated NKT cells didn’t show significantly higher proportion of activated 
population than T cells, it is unlikely that they were specifically activated in patient 
PBMCs or TILs.  
 
VII. A comparison between patient PBMCs and TILs for CD25+ NKT cells  
i. Activated NKT cells. Interestingly, no significant difference was found in the frequency 
of activated NKT cells in PBMCs and TILs of patients with colorectal cancer for cells 
despite patient TILs trending higher (0.1% cf 1.87% ± 0.9) (Figure 18 D). Remaining 
patient groups lacked sufficient cell number for definitive analysis of patient grouped 
tissue samples. 
 
ii. Activated non NKT T cells. A similar trend of T cell activation was observed between 
patient PBMCs and TILs in patients with colorectal cancer to NKT cells, but we found 
significantly higher activation of T cells in patient TILs than in patient group matched 
PBMCs (4% ± 0.78 cf 1% ± 0.77) (Figure 7 A).  
 
3.2.5. Summary of NKT cell subsets in patients with solid cancer 
Collectively, our results show that the distribution of NKT cell subsets in patient tissue 
samples was mostly similar to PBMCs of healthy individuals, but CD161+ NKT cells in 
TILs of patients with colorectal cancer and CD25+ NKT cells in PBMCs of patients with 
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colorectal cancer appeared lower than expected, suggesting that the overall deficiency in 
NKT cells may have impacted these subsets. An important caveat was that there were 
difficulties obtaining sufficient NKT cell numbers to quantify different subsets for all 
patient groups so only those where sufficient numbers are shown. 
 
3.2.6. Blood cancers  
In this section, we assayed the frequency of NKT cells using PBMCs or bone marrow 
(BM) derived cells from patients with different forms of blood cancers, including CLL, 
NHL and MM. Where relevant, other T cells subsets including overall T cells were used 
as a point of comparison. 
 
I. The frequency of NKT cells in patient PBMCs compared to healthy donors  
i. NKT cells. The frequency of NKT cells as a proportion of lymphocytes or T cells was 
lower in patient PBMCs than in PBMCs of healthy donors for most patient groups, with 
the exception of patients with ‘other’ blood cancers (defined as non-CLL, non-MM or 
non-NHL) (mean ranged between 0.0002% to 0.009% in patient PBMCs cf 0.05% 
healthy PBMCs) (Figure 20 A). Patients with ‘other’ blood cancers, such as T cell 
lymphoma, had a higher NKT cell frequency among lymphocytes than in PBMCs of 
healthy controls (0.31% ± 0.29 cf 0.05% ± 0.01).  
Similarly, when NKT cell frequency was measured as a proportion of T cells, 
patient groups had significantly lower frequency than healthy donors (mean ranged 
between 0.012% to 0.029% cf 0.11%) (Figure 20 B). The exception was patients with 
‘other’ blood cancers, which had a statistically similar frequency to PBMCs of healthy 
donors (Figure 20 B).  
 
ii. Non NKT T cells. We next assayed the frequency of T cells in PBMCs of patients with 
blood cancers. The overall T cell frequency in PBMCs of patients with blood cancers was 
significantly lower than in PBMCs of healthy individuals (mean ranged between 16.4% 
to 39.3% cf 54.9%) except for patients with NHL, which was similar to healthy donors 
(Figure 13 C).  Taken together, patient groups with blood cancer showed a deficiency of 
NKT cells and T cells, but NKT deficiency appears more severe. It is important to note 
that the increased frequency of malignant B cells associated with diseases such as CLL 
and MM would impact frequency of cells expressed as a proportion of overall 
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lymphocytes, but this was not a factor when NKT cells were expressed as a proportion of 
T cells.   
 
II. The frequency of NKT cells in patient BM compared to healthy donors 
i. NKT cells. We next quantified the frequency of NKT cells from BM derived cells of 
different patient groups. NKT cells frequency was significantly lower in most patient 
groups compared to PBMCs of healthy donors regardless of whether the cells were 
measured as a proportion of lymphocytes (mean ranged between 0.0002% to 0.012% cf 
0.05%) or T cells (mean ranged between 0.001% to 0.02% cf 0.11%) (Figure 27 A-B). 
One exception was that the frequency of NKT cells in BM of patients with CLL measured 
relative to T cells was statistically similar to PBMCs of healthy controls. 
 
ii. Non NKT T cells. The frequency of overall T cells in BM derived cells from different 
patient groups with blood cancer was also significantly lower than in PBMCs of healthy 
donors (mean ranged between 9.7% to 35.9% in patient BM cf 54.9% in healthy PBMCs) 
(Figure 13 C). Taken together with NKT cell data from patient BM derived cells, both 
overall T cell and NKT cell frequency was deficient, indicating that the deficiency of 
NKT cells in patient BM derived cells may reflect an impact on broader T cell population. 
However, the frequency deficiency observed in patient BM derived cells was more 
pronounced for NKT cells as the change in T cell was roughly 1 to 6 fold where as NKT 
cell frequency showed roughly 4 to 250 fold difference. 
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Figure 20. The frequency of NKT cells in PBMCs and BM from patients with blood 
cancer. The frequency of NKT cells in blood (Bl), bone marrow (BM) derived cells of 
patients with blood cancer or PBMCs of healthy donors (Ctrl) was measured as a 
proportion of viable lymphocytes (A) or total T cells (B). Each symbol represents one 
tissue sample. (A) 0.00001% includes <0.00001% when measured among lymphocytes, 
(B) 0.001% includes <0.001% when measured among T cells. Mann-Whitney test was 
used to determine statistical difference (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). The frequency of NKT cells was compared between matched PBMCs 
and BM derived cells from patients with CLL. The frequency was expressed as a 
proportion of lymphocytes (C) or T cells (D). Each symbol represents one patient sample. 
(A) 0.001% includes <0.001% when measured among lymphocytes, (B) 0.01% includes 
<0.01% when measured among T cells. Each line represents the change in the frequency 
between matched patient samples. (C-D) 0.001% includes <0.001%. Wilcoxon test was 
conducted to determine statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). 
 
III. NKT cells in PBMCs and BM within different patient groups with blood cancer 
i. NKT cells. In comparison to PBMCs of healthy donors, patient PBMCs and BM 
derived cells showed a significant NKT cell deficiency. We next asked whether the 
  
74 
frequency of NKT cells assayed from patient PBMCs was different to BM derived cells. 
Past studies have shown that NKT cells are impacted in PBMCs or BM derived cells of 
different patient groups with blood cancer 202,211, but few studies have directly compared 
these tissues. We found no significant difference between NKT cell frequency measured 
as a proportion of lymphocytes or of T cells in PBMCs and BM derived cells within 
different patient groups (Figure 20 A-B). 
 
ii. Non NKT T cells. The overall T cell frequency differed between PBMCs and BM 
derived cells in patient groups, indicating that T cells may be impacted differently to 
NKT cells (Figure 10 C). More specifically, in NHL or MM patient groups, the frequency 
of T cells in BM derived cells was lower compared to PBMCs of that patient group 
(26.2% ± 4.2 cf 46.5% ± 4.7 in NHL or 24.3% ± 3.2 cf 39.3% ± 3.2 in MM), but no 
significant difference was seen in other patient groups (16.4% ± 3 cf 9.8% ± 3 in CLL or 
34.7% ± 4 cf 35.9% ± 5 in ‘other’ blood cancers) (Figure 10 C). In patients with CLL or 
‘other’ blood cancers however, both NKT cells and T cells showed similar frequencies 
across tissues suggesting that this characteristic is not impacted by tumours.  
 
I.V. The frequency of NKT cells in PBMCs and BM of patients with CLL  
We had sufficient CLL samples to directly compare the frequency of NKT cells in patient 
matched PBMCs and BM derived cells for this patient group. We found no significant 
difference between the samples and this was also the case with overall T cells (0.002% ± 
0.0006 in patient PBMCs cf 0.004% ±0.001 in patient BM among lymphocytes or 0.06% 
± 0.02 cf 0.03% ± 0.006 in T cells; 12% ± 4.7 cf 14.6% ± 3.1 among viable lymphocytes 
for T cells) (Figure 20 C-D or Figure 10 D). This supports the view that the frequency of 
NKT cells and T cells in CLL is determined systemically and is not greatly affected by 
tumours. Lower sample and cell numbers meant prevented tissue matched analysis in 
other patient groups. 
 
3.2.7. Summary 
Collectively, the frequency of NKT cells in PBMCs and BM derived cells of different 
blood cancer patient groups was significantly lower than in PBMCs of healthy donors. 
This suggests NKT cells are often deficient in these patients, although this partly reflects 
reduced numbers within the overall T cell compartment.  
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Comparing PBMCs and BM derived cells within patient groups showed most had 
similar NKT cell frequency. Therefore, NKT cell frequency appears to be systemically 
controlled and not greatly impacted by interaction with the tumour cells.  
 
3.2.8. NKT cell subsets in patients with blood cancers 
To understand more about NKT cells in patients with blood cancers, we examined 
expression of CD4, CD8, CD25 and CD161 on NKT cells from PBMCs or BM derived 
cells of patients with blood cancers to determine whether specific NKT cell subsets were 
activated, or otherwise impacted. As a point of comparison, we measured the frequency 
of CD4+ and CD8+ T cells, CD161+ T cells and activated T cells. 
 
I. The frequency of CD4+ or DN NKT cell subsets in patients with blood cancers  
i. NKT cell subsets. Due to low frequency, only CD4+CD8- (CD4+) and CD4-CD8- 
(DN) subsets from patients were studied. Generally, the frequency of the CD4+ subset as 
a proportion of NKT cells in PBMCs of patients was higher than in healthy donors, but 
mostly without statistical significance. We did not identify a clear pattern of subset ratios 
across patients that differed from healthy donors. For instance, the frequency of CD4+ 
NKT cells in PBMCs of patients with ’other’ blood cancers was significantly higher than 
in PBMCs of healthy donors (66.4% ± 6.1 cf 39.6% ± 4.1) (Figure 21 A), whereas 
patients with CLL were statistically similar to healthy donors (58.9% ± 12.5 or 66.4% ± 
6.1 cf 39.6% ± 4.1) (Figure 21 A). 
The frequency of CD4+ NKT cells in BM of patients with CLL was significantly 
higher than in PBMCs of healthy donors (94.6% ± 1.1 cf 39.6% ± 4.1), and a similar trend 
was seen for ‘other’ blood cancers with 74.3% CD4+ (Figure 21 A). The overall 
deficiency of NKT cells in BM of patients with NHL or MM prevented investigation.  
Not surprisingly, the frequency of DN NKT cells generally trended lower in most 
of patient groups but no significant difference was found with exception of PBMCs from 
patients with ‘other’ blood cancers, which had a significantly lower DN NKT cell 
frequency than PBMCs of healthy donors (17.9% ± 5.2 cf 44.3% ± 4.3) while no 
noticeable difference was found in patients with CLL (30.9% ± 12.4 cf 44.3% ± 4.3) 
(Figure 21 B). Patients with MM or NHL were not measured due to lack of patient tissue 
samples. 
The frequency of DN NKT cells among overall NKT cells in patient BM derived 
also trended lower than in PBMCs of healthy controls, but this lacked statistical power 
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due low patient tissue numbers, except for BM of patients with CLL, where NKT cells 
were dominated by the CD4- NKT cell subset (0.1% cf 44.3% ±4.3) (Figure 21 B).  
 
Figure 21. NKT cell subsets in PBMCs and BM derived cells from patients with blood 
cancer. Using PBMCs (Bl) or bone marrow (BM) derived cells from patients with blood 
cancer or PBMCs of healthy donors (Ctrl), the frequency of NKT cell subsets CD4+ (A), 
CD4-CD8- (B), CD161+ (C) or CD25+ (D) was assayed. Each symbol represents one 
sample. 0.1% includes <0.1% (B, D). Mann-Whitney test was conducted to determine 
statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non NKT T cell subsets. Unlike NKT cells, the frequency of CD4+CD8- (CD4+) T 
cells among PBMCs or BM derived T cells was significantly lower for all patient groups 
(mean ranged between 31.7% to 40.4% cf 52.7% in PBMCs and BM derived cells) 
(Figure 29 A). The increased frequency of CD4+ NKT cells seen in patients with blood 
cancers therefore did not appear to reflect the impact on CD4+ T cells. 
The frequency of DN T cells was statistically similar to PBMCs of healthy donors 
for all patient groups (Figure 22 C). This is not unexpected as the change in CD4+ T cells 
likely reflected a shift in CD8+ T cells. 
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Figure 22. The frequency of T cell subsets defined by CD4 and CD8 expression in 
patients with blood cancer. Using patient PBMCs (Bl) and bone marrow (BM) derived 
cells from different patient groups with blood cancer, or PBMCs of healthy individuals 
(Ctrl), the frequency of T cell subsets defined by CD4 and CD8 (A-C) was compared 
between tissues, Mann-Whitney test was conducted to determine statistical difference 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
II. The frequency of CD4+ or DN NKT cell subsets in PBMCs and BM derived cells 
of patients with CLL  
i. NKT cell subsets. We had sufficient samples to independently examine the CD4+ or 
DN NKT cell subsets frequency in PBMCs and BM derived cells of CLL patients. Our 
data showed no significant differences between PBMCs and BM of the patient group with 
CLL (58.9% ± 12.5 cf 94.6% ± 1.1 for CD4 subset; 30.9% ± 12.4 cf 0.1% for DN subset) 
(Figure 21 A-B).  
 
ii. Non NKT T cells. A similar comparison was not possible for other patient groups due 
to a lack of tissue samples for NKT cells. When we analysed CD4+ and DN T cells from 
patient PBMCs and BM derived cells as a point of comparison to NKT cell subsets, we 
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found no significant difference (Figure 22 A, C). Collectively these findings indicate that 
there are no tissue specific impacts for NKT cell subsets in blood cancer.  
 
III. The frequency of CD161+ NKT cells in patients with blood cancers compared to 
healthy controls 
i. NKT cell subset. CD161 is expressed by different groups of T cells including innate-
like T cells. The role of CD161 is not known for NKT cells but it is differentially 
expressed and we were interested to monitor changes in patients with cancer. Where we 
could statistically compare patient tissue samples, the frequency of CD161+ NKT cells in 
PBMCs or BM derived of patients with blood cancers was not significantly different to 
PBMCs of healthy donors (In patient PBMCs; 55.2% ± 11.1 in CLL or 70% ± 9.7 in 
‘other’ blood cancers cf 72.7% ± 2.8; in patient BM; 68.8% ± 7.7 cf 72.7% ± 2.8 in CLL) 
(Figure 21 C).  
 
ii. Non NKT T cell subset. In contrast, the frequency of CD161+ T cells in PBMCs was 
lower in all patient groups (mean ranged between 4% to 9.6% cf 12.7%), whereas patient 
BM was normal when compared to PBMCs of healthy donors (mean ranged between 
7.9% to 18% cf 12.7%) (Figure 10 A).  
 
IV. The frequency of CD161+ NKT cells in patient PBMCs and BM derived cells 
within same patients with blood cancers 
We next established that patient PBMCs and BM derived cells have broadly similar 
frequency of CD161+ NKT cells and of CD161+ T cells across different patient groups 
with blood cancer (CD161+ NKT cells; in patients with CLL; 55.2% ± 11.1 in patient 
PBMCs cf 68.8% ± 7.7 in patient BM) (CD161+ T cells; in patients with CLL; 9.6% ± 2 
in patient PBMCs cf 18.3% ± 6.8 in patient BM; in patients with NHL; 4% ± 1.7 cf 8.4% 
± 4.2; in patients with MM; 9.7% ± 3 cf 7.9% ± 1.9; in patients with ‘other’ blood 
cancers; 6.7% ± 1.7 cf 8.8% ± 1.9) (Figure 21 C & Figure 10 A). The results for CD161+ 
T cells were unexpected because earlier data had shown a deficiency in PBMCs of patient 
groups (Figure 13 A). Nevertheless, our results showed that there was no great difference 
in CD161 expression by NKT cells and T cells in blood and BM of patients with blood 
cancer.  
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V. The frequency of activated NKT cells in patients with blood cancers  
i. Activated NKT cells. We investigated whether NKT cells in patients with blood cancer 
were activated based on expression of CD25. When statistical comparison was possible, 
our results revealed that patient PBMCs and BM derived cells had a similar frequency of 
CD25+ cells as PBMCs of healthy donors, indicating that NKT cells in patient PBMCs or 
BM derived cells were not specifically activated (in patients with CLL; 0.6% ± 0.3 
(PBMCs) or 0.1% (BM) cf 1.8% ± 0.6; in patients with ‘other’ blood cancers; 0.99% ± 
0.4 (PBMCs) cf 1.8% ± 0.6) (Figure 21 D). 
 
ii. Activated non NKT T cells. In contrast to activated NKT cells, the frequency of 
activated T cells in patients with blood cancer was increased in patients compared to 
PBMCs of healthy donors, as described earlier in the analysis of activated MAIT cells 
(Figure 14 A).  
 
VI. The frequency of activated NKT cells and T cells in PBMCs and BM derived 
cells of patients with blood cancers 
We next compared the frequency of activated (CD25+) NKT cells and T cells in PBMCs 
and BM derived cells of patients and found no significant difference (e.g. activated NKT 
cells in patients with CLL; 0.6% ± 0.3 (PBMCs) cf 0.1% (BM) (Figure 21 D) (activated T 
cells in patients with CLL; 0.35% ± 0.05 cf 0.31% ± 0.2; in patients with NHL; 1.1% ± 
0.4 cf 5.2% ± 4.1; in patients with MM; 0.6% ± 0.2 cf 0.58% ± 0.28; in patients with 
‘other’ blood cancers; 1.5% ± 0.5 cf 2% ± 0.8) (Figure 14 A). Therefore, there was no 
indication of increased NKT cell activation in PBMCs or BM derived cells of different 
patient groups.  
  
3.2.9. Summary 
We found a few differences in NKT cell subsets defined by CD4 and CD8 markers, but 
no significant increase in CD25 expression to suggest NKT cells were activated in 
PBMCs or BM derived cells of patients.  
Furthermore, there was no noticeable difference between PBMCs and BM derived 
cells within the different patient groups. We were unable to separately assay all patient 
groups but in CLL, NKT cell subsets and the extent of activation was also similar 
between patient group matched PBMCs and BM derived cells. 
 
  
80 
3.3. γδ T cells in patients with cancer 
γδ T cells are innate-like T cells with the capacity to regulate the function of other 
immune cells. Similar to NKT cells and MAIT cells, γδ T cells release various cytokines 
upon stimulation and can respond to tumour cells in vitro 87. However, the role of γδ T 
cells in cancer immunity is still poorly understood and more studies of their frequency 
and functional capacity in patients with cancer are required.  
γδ T cells have been analysed in blood of some patient groups with cancer, but 
less often from tumours 182,183,212,213. Separate studies have reported altered frequencies of 
γδ T cells in patients with solid cancers, which suggests a role in anti-tumour immunity, 
but changes have been inconsistent. For example, breast cancer patients reportedly exhibit 
a higher frequency of γδ T cells in blood 206 compared with healthy counterparts, but 
melanoma patients had a lower frequency 180.  The significance of these changes is not 
clear, but they suggest γδ T cells may be involved in anti-tumour responses or are 
impacted by it. In order to extend and clarify the importance of these reports, we have 
characterized γδ T cells from patients with different forms of cancer, including 
haematological malignancies (Figure 23). Patient variabilities were taken into 
consideration using appropriate gating strategy to ensure that background staining was 
not impacting the interpretation of facs plots. 
In our project, PBMCs and BM derived cells from patients with CLL, NHL or 
MM, and PBMCs and tumour infiltrating lymphocytes (TILs) from patients with 
colorectal, lung or breast cancers were assayed.  
 
 
Figure 23. Identification and quantification of γδ T cells in solid and blood cancers. γδ 
T cells were identified based on co-expression of γδ TCR and CD3. 
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3.3.1. Solid Cancer 
I. γδ T cell frequency in PBMCs of patients with solid cancer 
i. γδ T cells. In patient PBMCs, MAIT cells and NKT cells were deficient in most patient 
groups compared to PBMCs of healthy individuals, but the frequency of γδ T cells among 
lymphocytes or T cells was consistently normal across patient groups (mean ranged 
between 3% to 4.8% in patient PBMCs cf 3.8% in healthy PBMCs among lymphocytes; 
ranged between 9.1% to 13.8% cf 7% among T cells) (Figure 24 A-B).  
 
ii. Non γδ T cells. PBMCs of patients with colorectal cancer was significantly lower for T 
cells (36.9% ± 2.8 cf 54.49% ± 2.3) (Figure 3 C). Patients with lung cancer or ‘other’ 
solid cancers showed no statistically significant change, but trended lower (40.1% ± 6.9 
or 37.6% ± 7.8 cf 54.5% ± 2.3) (Figure 3 C). 
 
II. The frequency of γδ T cells infiltrating tumours 
i. γδ T cells. Having established that the frequency of γδ T cells in patient PBMCs was 
similar to that of healthy controls, we next assayed the frequency of γδ T cells in patient 
TILs. The γδ T cell frequency in TILs was also similar to that of PBMCs of healthy 
donors relative to lymphocytes or T cells (mean 1.4% to 2.6% in patient PBMCs cf 1.8% 
in healthy PBMCs among lymphocytes; 5.6% to 12.8% cf 7% among T cells) (Figure 24 
A-B). An exception was patients with ‘other’ solid cancers, which had a significantly 
lower frequency among lymphocytes than PBMCs of healthy donors (1.4% ± 0.5 cf 3.8% 
± 0.4) (Figure 24 A).  
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Figure 24. The frequency of γδ T cells in PBMCs and TILs of patients with solid 
cancer. The frequency of γδ T cells relative to lymphocytes (A) or T cells (B) was 
investigated in PBMCs (Bl), TILs (Tu) of patient groups, or in PBMCs from healthy 
donors (Ctrl) were assayed. Each symbol represents one independent sample. Mann-
Whitney test was conducted to determine statistical significance (P<0.05*/ P<0.01** / 
P<0.001*** / P<0.0001****). Matched PBMCs and TILs from colorectal cancer 
patients were assayed for γδ T cells. The frequency was expressed relative to lymphocytes 
(C) or to T cells (D). Wilcoxon test was used to determine statistical significance. 
(P<0.05* /P<0.01**/P<0.001***/P<0.0001****) 
 
ii. Non γδ T cells. In contrast to γδ T cells, tumour infiltrating T cells were consistently 
deficient in all patient groups compared to PBMCs of healthy donors when measured 
among lymphocytes (mean ranged 15. 2% to 38.9% in patient TILs cf 54.49% healthy 
donors) (Figure 3 C). Therefore, T cells appear to more significantly impacted than γδ T 
cells in patient TILs, although this was not seen for all groups. Collectively, the frequency 
of γδ T cells in patient blood and tumours was similar to that in the blood of healthy 
donors in most patient groups.  
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III. γδ T cells in TILs and PBMCs of same patient group 
i. γδ T cells. We next compared PBMCs and TILs within each patient group but no 
significant differences were seen (in lymphocytes; 3.98% ± 2.2 in patient PBMCs cf 2.6% 
± 1.2 in patient TILs for lung cancer; 3% ± 0.8 cf 1.4% ± 0.5 in ‘other’ solid cancers), 
except for patients with colorectal cancer, where the frequency of γδ T cells among 
lymphocytes was significantly lower in tumours than in blood (1.88% ± 0.5 cf 4.88% ± 
1.2) (Figure 24 A). This difference was not seen when measured as a proportion of viable 
T cells (13.8% ± 3 patient PBMCs cf 12.8% ± 3 in patient TILs for colorectal cancer; 
9.8% ± 5.3 cf 5.8% ± 2.5 in lung cancer; 9.1% ± 1.7 cf 5.6% ± 1.7 in ‘other’ solid 
cancers) (Figure 24 B). As the collective lymphocyte pool is quite heterogeneous, the 
earlier difference may have been impacted by changes in non-T cells and we conclude 
that the frequency of γδ T cells relative to other T cells is similar in PBMCs and TILs for 
most patient groups. 
                 
ii. Non γδ T cells. The T cell frequency among viable lymphocytes was similar in TILs 
and PBMCs for lung cancer and the ‘other’ solid cancer group (in lymphocytes; 13.5% ± 
5.9 in patient PBMCs cf 10.8% ±2.3 in patient TILs for lung cancer; 9.1% ± 2.2 cf 12.8% 
± 4.4), but was significantly lower in TILs of patients with colorectal cancer (15.5% ± 2.2 
cf 36.9% ± 2.3) (Figure 3 C). This deficiency of γδ T cells in tumours mirrored the defect 
in overall T cells and therefore is probably not specific to γδ T cells. 
 
IV. Matched TILs and PBMCs of patients with colorectal cancer 
 i. γδ T cells. Surprisingly, the significant difference between PBMCs and TILs of 
patients with colorectal cancer in the frequency of γδ T cells among lymphocytes or T 
cells, was not evident in patient matched data (5.7% ± 2 in patient PBMCs cf 2.1% ± 0.6 
in patient TILs among lymphocytes; 16.8% ± 5.1 cf 15.4% ± 3.5 among T cells) (Figure 
24 C-D) although the low statistical power resulting from sample size may have been a 
factor and larger studies may be necessary.  
 
 ii. Non γδ T cells. In contrast, the T cell frequency was significantly lower in TILs than 
PBMCs (37.1% ± 3.4 cf 14.6%  ± 3.2 in T cells) (Figure 3 D). An important caveat is the 
low n-value for this data, but our results suggests that γδ T cell differences between 
PBMCs and TILs of patient groups are not always reflected in patient matched data and 
may reflect the impact of changes in other T cell populations.  
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3.3.2. Summary on γδ T cells 
Unlike other innate-like T cells such as NKT or MAIT cells, most patient groups with 
solid cancers had no overall deficiency of γδ T cells in PBMCs or TILs compared to 
PBMCs of healthy individuals. The γδ T cell frequency in PBMCs and TILs was mostly 
similar, indicating that γδ T cells may be less impacted by than NKT cells or MAIT cells, 
where we identified significant changes in frequency. 
 
3.3.3. γδ T cells expressing CD94 
Although the overall frequency of γδ T cells appeared relatively normal in patients, it 
remained possible that specific subsets were affected. To examine this, we assayed the 
frequency of CD94+ γδ T cells in PBMCs or TILs of different patient groups. CD94 is 
associated with down regulation of immune responses 89,214,215, and we examined whether 
the frequency of CD94+ γδ T cells was impacted in patients with solid cancer. We 
assayed CD94+ T cells as a point of comparison to CD94+ γδ T cells.  
 
I. The frequency of CD94+ γδ T cells in patients with solid cancer 
i. γδ T cell subset. When we compared patient PBMCs or TILs from different patient 
groups to the PBMCs of healthy individuals, we found no significant differences in 
CD94+ γδ T cells among γδ T cells (mean ranged 15.5% - 27.4% in patient PBMCs and 
14.1% - 18.9% in patient TILs cf 17.9%) (Figure 25 A-C). 
 
ii. Non γδ T cell subset. Consistent with γδ T cells, CD94+ T cells among T cells in 
patient PBMCs or TILs consistently showed no significant difference between patient 
tissue samples and healthy donors (mean ranged between 4.2% to 4.4% in patient PBMCs 
or 9% to 10.6% in patient TILs cf 4.2%) (Figure 26 A). However, in TILs of patients with 
colorectal cancer, the frequency of CD94+ T cells was significantly lower than in PBMCs 
of healthy donors (4.2% ± 0.5 cf 9% ± 1.1) (Figure 26 A). These findings suggest that 
expression of CD94 by γδ T cells in patient PBMCs or TILs is not greatly impacted. 
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Figure 25. The frequency of γδ T cells expressing CD94 in solid cancer. (A) The 
frequency of CD94+ γδ T cells among γδ T cells in PBMCs (Bl), TILs (Tu) from solid 
cancer patients or PBMCs from healthy donors (Ctrl) was investigated. Mann-Whitney 
test was conducted to determine statistical significance (P<0.05*/P<0.01**/P<0.001*** 
/P<0.0001****). (B) Matched PBMCs and TILs from colorectal cancer patients were 
investigated for the frequency of CD94+ γδ T cells among γδ T cells. Wilcoxon test was 
used to determine statistical significance (P<0.05*/P<0.01**/P<0.001*** 
/P<0.0001****). 
 
Figure 26. The frequency of CD94+ T cells in solid cancer. (A) The frequency of 
CD94+ T cells among T cells in PBMCs (Bl), TILs (Tu) from patients with solid cancer 
or PBMCs from healthy donors (Ctrl) was investigated. Mann-Whitney test was 
conducted to determine statistical significance (P<0.05*/P<0.01**/ 
P<0.001***/P<0.0001****). (B) Matched blood and tumours from colorectal cancer 
patients were investigated for the frequency of CD94+ T cells among T cells. Wilcoxon 
test was used to determine statistical significance (P<0.05*/P<0.01**/ 
P<0.001***/P<0.0001****). 
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II. Comparing TILs and PBMCs within patient groups with solid cancers 
i. γδ T cell subset. We found no significant difference in the frequency of CD94+ γδ T 
cells between TILs and PBMCs of individual patient groups (e.g. 27.4% ± 5.6 in patient 
PBMCs cf 18.9% ± 3.8 in patient TILs for colorectal cancer and refer to Figure 25 A). 
We also, compared tissue matched PBMCs and TILs from patients with colorectal cancer 
but again, no noticeable difference was observed (10.2% ± 5.4 cf 4.1% ± 1.6) (Figure 25 
B). 
 
ii. Non γδ T cell subset. Like CD94+ γδ T cells, CD94+ T cells also showed no 
significant differences between patient group matched TILs and PBMCs across different 
patient groups (e.g. 9.5% ± 2.7 in PBMCs cf 9% ± 1.1 in TILs for colorectal cancer; for 
other patient groups, refer to Figure 26 A). This was in line with other results from 
CD94+ T cells comparing between patient matched PBMCs and TILs in colorectal cancer, 
which also showed no significant difference (9.8% ± 2.9 cf 8.8% ± 1.1) (Figure 26 B). 
The findings suggest there is no specific impact on CD94+ γδ T cell frequency in patients 
with solid cancer.  
 
3.3.4. Summary on CD94+ γδ T cells 
Collectively, the frequency of CD94+ γδ T cells infiltrating tumours or blood of patients 
with solid cancer was not significantly different to PBMCs of healthy donors, indicating 
that CD94 expression by γδ T cells was not specifically impacted in those patients. We 
also showed that CD94+ γδ T cell frequency was similar in patient PBMCs and TILs. 
Similar findings were made for CD94+ T cells.  
 
3.3.5. Activation of γδ T cells in patients with cancer 
In earlier sections, we observed higher proportions of activated (CD25+) T cells and 
MAIT cells in patient PBMCs or TILs than in PBMCs of healthy controls. In this section, 
we measured the frequency of activated γδ T cells. 
 
I. The frequency of activated γδ T cells in PBMCs of patients with solid cancer 
Generally, the frequency of CD25+ T cells among γδ T cells in PBMCs of patient groups 
was similar to that seen in PBMCs of healthy donors (mean ranged between 0.5% to 
1.2% in patient PBMCs cf 0.51% in healthy PBMCs) (Figure 27 A), whereas the 
frequency of activated T cells was significantly higher in different patient groups (mean 
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ranged between 0.82% to 1.6% cf 0.13%) (Figure 7 A). This suggests that broader T cell 
populations are more activated in patient blood than γδ T cells. 
 
Figure 27. The frequency of activated γδ T cells in solid cancer. (A) The frequency of 
CD25+ γδ T cells in PBMCs (Bl), TILs (Tu) or PBMCs from healthy donors (Ctrl) was 
investigated. Each symbol represents one sample. 0.001% includes <0.001% (A). Mann-
Whitney test was conducted to determine statistical significance (P<0.05*/ P<0.01** 
/P<0.001*** /P<0.0001****). (B) The frequency of activated γδ T cells in matched 
PBMCs and TILs from patients with colorectal cancer was also measured. Each symbol 
represents one sample. Wilcoxon test was carried to determine statistical significance 
(P<0.05* /P<0.01** /P<0.001*** /P<0.0001****).  
 
II. The frequency of activated γδ T cells infiltrating patient tumour 
i. Activated γδ T cells. In contrast to patient PBMCs, the frequency of CD25+ γδ T cells 
was significantly higher in tumours than in PBMCs of healthy donors for most patient 
groups, including patients with colorectal cancer or ‘other’ solid cancers (9.9% ± 5.4 or 
3.4% ± 2.1 in patient TILs cf 0.5% ± 0.09 in healthy donors) (Figure 34 A).  One 
exception was patients with lung cancer where the frequency was not significantly 
different, although it trended higher than in PBMCs of healthy donors (1.77% ± 0.6 cf 
0.51% ± 0.01) (Figure 27 A).  
 
ii. Activated non γδ T cells. As previously shown, the frequency of activated (CD25+) T 
cells in patient tumours was also significantly higher for all patient groups (Figure 7 A). 
Therefore, the increased frequency of activated γδ T cells in tumours may partly reflect 
the impact on the broader T cell populations, however, as seen for activated MAIT cells, 
the proportion of activated γδ T cells was far higher than for T cells and may therefore 
indicate a specific response. 
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III. Comparing TILs and PBMCs within patient groups with solid cancer 
i. Activated γδ T cells. In patients with colorectal cancer, the proportion of activated γδ T 
cells in patient TILs was significantly higher than in PBMCs (9.9% ± 5.4 cf 0.57% ± 0.2) 
(Figure 27 A). However, no significant difference was found in patients with lung cancer 
or ‘other’ solid cancers (1.4% ± 0.55 cf 1.7% ± 0.58 in lung cancer; 1.2% ± 0.43 cf 3.4% 
± 2.1 in ‘other’ solid cancers) (Figure 27 A). This suggest that γδ T cells may be 
specifically responding to tumours in patients with colorectal cancer, but not in patients 
with lung cancer or ‘other’ solid cancers. Consistent with this, the frequency of activated 
(CD25+) γδ T cells in TILs of patients with colorectal cancer was significantly higher 
than in patient matched PBMCs (10.6% ± 7.1 cf 0.59% ± 0.31) (Figure 27 B). 
 
ii. Activated non γδ T cells. The frequency of activated (CD25+) T cells in TILs of 
patients with colorectal cancers was significantly higher than in patient group matched 
PBMCs (4% ± 0.78 in patient TILs cf 1% ± 0.77 in patient PBMCs), while no significant 
difference was found in patients with lung cancer or ‘other’ solid cancers (0.8% ± 0.2 cf 
2.6% ± 0.9 in lung cancer; 1.6% ± 0.4 cf 4.6% ± 2 in ‘other’ solid cancers) (Figure 7 A). 
Not surprisingly, similar results were evident in patient matched TILs and PBMCs from 
patients with colorectal cancer (4.4% ± 1.3 cf 0.2% ± 0.11) (Figure 7 B). However, there 
was a greater increase in activated γδ T cells in TILs than in PBMCs, and the increase in 
γδ T cell activation in TILs of patients with colorectal cancer was higher than for T cells. 
Since, there was an increase in activated γδ T cells and T cells, our results could 
indicate that activated γδ T cells are reflecting the broader T cell population in some 
patient groups. However, in patients with colorectal cancer, the difference in CD25 
expression between patient TILs and PBMCs was greater γδ T cells for than activated T 
cells. This may suggest that γδ T cells might have a specific response to the tumours in 
addition to reflecting the increased in frequency of activated T cells. 
 
3.3.6. Summary on activated γδ T cells 
The frequency of CD25+ γδ T cells was similar in PBMCs of patients and healthy donors, 
suggesting no systemic response to the cancer. However, a higher frequency of CD25+ γδ 
T cells infiltrating patient tumours suggests a possible response within the tumour 
microenvironment and there was a significantly higher frequency of activated γδ T cells 
in TILs across different patient groups. The frequency of activated γδ T cells in patient 
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matched TILs was also significantly higher than in patient matched PBMCs in the 
colorectal cancer group.   
We also showed that tumour specific changes in patients with colorectal cancer 
was likely to be influenced by the impact on the overall T cell population as a 
significantly higher frequency of activated T cells was also found in TILs. However, the 
extent of activation was greater for γδ T cells in TILs. Taken together, our results suggest 
γδ T cells may be specifically responding to TILs in patients with cancer because they 
show increased activation in TILs that was greater than for T cells. 
 
3.3.7. γδ T cells in patients with blood cancer 
In this section, we have investigated the frequency of γδ T cells in patients with blood 
cancers by assaying PBMCs and bone marrow (BM) derived cells from different patient 
groups including CLL, NHL and MM. T cells were analysed as a control. 
 
I. The frequency of γδ T cells in patient groups with blood cancer 
i. γδ T cells. In patient PBMCs, the frequency of γδ T cells relative to lymphocytes or T 
cells was similar to that in PBMCs of healthy donors (mean ranged between 1.9% to 
4.8% in patient PBMCs cf 3.5% in healthy PBMCs among lymphocytes or 4.2% - 13.6% 
cf 6.8% among T cells) (Figure 35 A). One exception was patients with CLL, where there 
was a significantly lower frequency of γδ T cells among lymphocytes in PBMCs 
compared to healthy donors (1.4% ± 0.3 cf 3.8% ± 0.4) (Figure 28 A).  
The frequency of γδ T cells in patient BM derived cells was also similar to 
PBMCs of healthy donors (mean 0.59% - 4.5% in patient BM cf 3.5% in healthy PBMCs 
among lymphocytes or 3.7% - 15.6% cf 6.8% among T cells) (Figure 28 A). The only 
exception was BM of patients with CLL, which had significantly lower γδ T cell 
frequency relative to lymphocytes than PBMCs of healthy donors (0.59% ± 0.21 cf 3.8% 
± 0.4) (Figure 28 A). These findings suggest that most patient groups with blood cancers 
have a normal γδ T cell frequency in PBMCs and BM derived cells.  
 
ii. Non γδ T cells. In contrast to γδ T cells, the frequency of T cells among lymphocytes 
in PBMCs was significantly deficient in most patient groups compared to PBMCs of 
healthy donors (mean ranged between 16.4% to 39.9% in patient PBMCs cf 54.5% in 
healthy PBMCs), apart from patients with NHL, which had a statistically similar 
frequency to healthy donors (45.5% ± 4.7 cf 54.5% ± 2.3) (Figure 10 C). These data 
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indicate that the frequency of γδ T cells in patients with blood cancer is impacted 
differently to T cells.  
In patient BM, different patient groups consistently had significantly lower 
frequencies of T cells among lymphocytes when compared to PBMCs of healthy donors 
(ranged between 9.8% to 35.9% cf 54.5%) (Figure 10 C).  Our findings suggest that the 
frequency of γδ T cells is relatively normal in patient PBMCs and BM derived cells 
despite an apparent deficiency of overall T cells.  
 
Figure 28. The frequency of γδ T cells in patients with blood cancer. The frequency of 
γδ T cells in lymphocytes (A) or T cells (B) was investigated using PBMCs (Bl), bone 
marrow (BM) derived cells from patients with blood cancer and PBMCs from healthy 
donors (Ctrl). Each symbol represents one sample. Mann-Whitney test was conducted to 
determine statistical significance (P<0.05*/P<0.01**/P<0.001***/P<0.0001****). 
Patient matched PBMCs and BM derived cells from CLL patients were assayed for 
frequency of γδ T cells in lymphocytes (C) or T cells (D). Wilcoxon test was used to 
determine statistical significance (P<0.05* / P<0.01**/P<0.001***/P<0.0001****). 
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II. Comparison of γδ T cell frequency in PBMCs and BM derived cells of patient 
groups with blood cancers 
i. γδ T cells. PBMCs and BM derived cells of individuals from most patient groups had a 
similar γδ T cell frequency to PBMCs of healthy donors. A comparison between patient 
PBMCs and BM derived cells also showed no significant difference across different 
patient groups (e.g. in CLL; 1.4% ± 0.3 in PBMCs cf 0.6% ± 0.2 in BM; for other patient 
groups, refer to Figure 28 A). Hence, there was no specific impact on γδ T cell frequency 
in PBMCs or BM derived cells in patients with blood cancers. 
 
ii. Non γδ T cells. In contrast to γδ T cells, there were some differences in T cell 
frequency between tissues in patient groups. For instance, the PBMCs of patients with 
NHL or MM had significantly higher T cell frequency than BM (45.5% ± 4.7 cf 26.2% ± 
4.2 in NHL or 39.3% ± 3.2 cf 24.3% ± 3.2 in MM) (Figure 10 C), while CLL or ‘other’ 
blood cancer patient groups had statistically similar T cell frequencies in blood and BM 
(16.4% ± 3 cf 9.8% ± 3 in CLL; 34.7% ± 4.2 cf 35.9% ± 5.5 in ‘other’ blood cancers) 
(Figure 10 C). Therefore, the frequency of T cells appeared to be more affected than γδ T 
cells in PBMCs and BM derived cells of patients.  
 
III. The frequency of γδ T cells in patient matched PBMCs and BM derived cells of 
patients with CLL 
In patients with CLL, we had sufficient samples to compare patient matched PBMCs and 
BM derived cells, but again there was no significant difference in the frequency of γδ T 
cells or T cells (Figure 28 B & Figure 10 D). 
 
3.3.8. Summary on γδ T cells in patients with blood cancer 
Collectively, the frequency of γδ T cells in PBMCs or BM derived cells of most patient 
groups with blood cancers was similar to PBMCs of healthy donors and therefore was not 
indicative of a response by γδ T cells to cancer. We found no significant difference 
between PBMCs and BM derived cells of patients.  
Interestingly, our analysis of patients with CLL revealed that the frequency of γδ 
T cells and T cells were similarly impacted among viable lymphocytes while the 
frequency of γδ T cells among T cells was normal. This suggests that the proportion of γδ 
T cells among T cells remained same but was relatively reduced as a proportion of 
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lymphocytes. This could be due to the presence of other lymphocytes including malignant 
cells in patient blood or BM or the statistical power limitations of our cohort size.  
 
3.3.9. CD94+ γδ T cells in patients with blood cancer 
The frequency of γδ T cells in patient PBMCs or BM derived cells was normal, but we 
could not exclude subset specific changes. Increased expression of CD94 on T cells is 
associated with immune suppression 214.  Here, we investigated CD94 expression by γδ T 
cells to determine if the proportion of CD94+ γδ T cells was altered in patients with blood 
cancers.  
 
I. The frequency of CD94+ γδ T cells in patient tissue samples and healthy donors 
i. γδ T cell subset. The proportion of CD94+ γδ T cells in patient PBMCs was mostly 
similar to that of healthy donors (mean ranged 15.3% -20.5% in patient PBMCs cf 18.5% 
healthy PBMCs) (Figure 29 A). Only in PBMCs of patients with NHL was CD94 
expression significantly lower than in healthy donors (9.2% ± 3.2 cf 18.5% ± 2.3) (Figure 
29 A). This result suggests that most patient groups with blood cancers have a normal 
proportion of CD94+ γδ T cells. 
In patient BM, the frequency of CD94+ γδ T cells was also similar to PBMCs of 
healthy donors suggesting that CD94 expression by γδ T cells in patient BM is not 
impacted by cancer (mean ranged 14.6% - 16.6% in patient BM cf 18.5% in healthy 
PBMCs) (Figure 29 A). Due to lack of patient tissue samples, BM of patients with MM 
could not be analysed.  
 
Figure 29. The frequency of CD94+ γδ T cells in patients with blood cancer. (A) The 
frequency of CD94+ γδ T cells in PBMCs (Bl), bone marrow (BM) derived cells from 
blood cancer patients or PBMCs from healthy donors (Ctrl) was assayed. Each symbol 
represents one tissue sample. Mann-Whitney test was conducted to determine statistical 
significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). (B) Patient matched 
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PBMCs and BM derived cells from CLL patients were assayed for frequency of CD94+ 
γδ T cells. Wilcoxon test was used to determine statistical significance (P<0.05* 
/P<0.01** /P<0.001*** /P<0.0001****). 
 
ii. Non γδ T cell subset. Interestingly, the PBMCs of every patient group had a 
significantly higher CD94+ T cell frequency among T cells than for blood of healthy 
donors (mean ranged between 6.3% to 12.5% in patient PBMCs cf 4.2% in healthy 
PBMCs) (Figure 30 A). These findings indicate that CD94 expression on γδ T cells in 
patient blood may be impacted differently by blood cancer to CD94+ T cells. 
The frequency of CD94+ T cells among T cells in patient BM was statistically 
similar to PBMCs of healthy donors for most patient groups (mean ranged between 7.7% 
to 15.6% in patient BM cf 4.2% in healthy PBMCs) (Figure 30 A). The only exception 
was a significantly higher frequency in BM of patients with NHL (5.8% ± 1.5 cf 4.2% ± 
0.57) (Figure 30 A). Taken together, our data showed that CD94+ γδ T cells in BM of 
different patient groups are comparable to blood of healthy donors even when the 
frequency of CD94+ T cells in blood is increased. 
 
Figure 30. The frequency of CD94+ T cells in blood cancer. (A) The frequency of 
CD94+ T cells in PBMCs (Bl) or bone marrow (BM) derived cells in different patient 
groups with blood cancer was investigated and compared to PBMCs from healthy donors 
relative to T cells. Each symbol represents one tissue sample. Mann-Whitney test was 
conducted to determine statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). (B) The frequency of CD94+ T cells in patient matched PBMCs and BM 
derived cells in patients with CLL was measured among viable T cells. Wilcoxon test was 
used to determine statistical significance (P<0.05*/ 
P<0.01**/P<0.001***/P<0.0001****). 
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II. The frequency of CD94+ γδ T cells in PBMCs and BM derived cells of patient 
groups with blood cancers 
i. γδ T cell subset. The frequency of CD94+ γδ T cells in patient PBMCs and BM was 
similar to PBMCs of healthy donors. We next compared PBMCs and BM derived cells 
within each patient group and found no significant differences (20.5% ±2.5 in PBMCs cf 
14.6% ± 7.9 in BM for CLL, 9.2% ± 3.2 cf 6.2% ± 1.6 for NHL, 15.3% ± 6.4 cf 17.6% ± 
3.1 cf 16.6% ± 3.2 for ‘other’ blood cancers) (Figure 29 A). No differences were also 
seen between patient matched PBMCs and BM derived cells in patients with CLL (0.58% 
± 0.29 cf 0.36% ± 0.16) (Figure 29 B). Due to low numbers of samples, we were unable 
to assay BM of patients with MM.     
 
ii. Non γδ T cell subset. Patient group matched PBMCs and BM had a similar frequency 
of CD94+ T cells (12.5% ± 2.5 in PBMCs cf 15.5% ± 6.5 in BM for CLL, 10.5% ± 5.5 cf 
5.8% ± 1.5 in NHL, 6.6% ± 1.9 cf 7.7% ± 2.9 in MM, 6.3% ± 1.6 cf 9.6% ± 2.4 in ‘other’ 
blood cancers) (Figure 30 A). This was also seen for patient matched PBMCs and BM in 
CLL (22.1% ± 10.4 cf 14.6% ± 7.8) (Figure 30 B). Overall, there were no significant 
changes in CD94 expression by γδ T cells in patients with blood cancer. 
 
3.3.10. Summary on CD94+ γδ T cells in patients with blood cancer 
Our results showed that the frequency of CD94+ γδ T cells in patient PBMCs in different 
patient groups was consistently similar to PBMCs of healthy donors. Interestingly, 
CD94+ T cells in patient PBMCs consistently showed significantly higher frequency than 
healthy PBMCs perhaps suggesting that CD94+ T cells may be impacted differently to 
CD94+ γδ T cell in patient PBMCs. In contrast to patient PBMCs, BM derived cells in 
most patient groups had a similar CD94 expression by γδ T cells or T cells. 
We also compared between patient group matched or patient matched BM and 
PBMCs but there was no significant difference indicating that there was no tissue specific 
differences in CD94 expression by γδ T cells and T cells in patients with blood cancers.  
 
3.3.11. The activation of γδ T cells in patients with blood cancers 
To determine if γδ T cells are activated in patients with blood cancer, we assayed CD25 
expression by PBMCs and bone marrow (BM) derived cells of different patient groups. 
We also assayed T cells to determine if the activation status of γδ T cells correlated with 
changes to the broader T cell pool. 
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I. The frequency of activated γδ T cells in patient groups with blood cancers 
i. Activated γδ T cells. γδ T cells in patient PBMCs and BM mostly had similar CD25 
expression as γδ T cells in healthy PBMCs. (Figure 38 A). The one exception was 
PBMCs of patients with ‘other’ blood cancers, which had significantly higher γδ T cell 
activation (4.2% ± 2.9 cf 0.52% ± 0.09) (Figure 31 A).  
 
Figure 31. The frequency of γδ T cells expressing CD25 in blood cancer. (A) The 
frequency of CD25+ γδ T cells in PBMCs (Bl) and bone marrow (BM) from patients with 
blood cancer and PBMCs of healthy donors are shown. Each symbol represents one 
sample. 0.01% includes <0.01% (A). Mann-Whitney test was conducted to determine 
statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). (B) The 
frequency of CD25+ γδ T cells in matched PBMCs and BM derived cells of patients with 
CLL was assayed. Each symbol represents one sample. Wilcoxon test determined 
statistical significance (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Activated non γδ T cells. We next measured the frequency of CD25+ T cells as a point 
of comparison to activated γδ T cells. There was a small but significant increase in the 
frequency of activated T cells in PBMCs of different patient groups compared to healthy 
donors (mean ranged between 0.62% to 1.1% in patient PBMCs cf 0.13% in healthy 
PBMCs) (Figure 14 A).  Similarly, there was a higher frequency of CD25+ T cells in 
patient BM of patients with NHL, MM and ‘other’ blood cancers compared to PBMCs of 
healthy donors (5.2% ± 0.4 in NHL, 0.58% ± 0.19 in MM or 2% ± 0.8 in ‘other’ of patient 
BM cf 0.13% ± 0.02 in healthy PBMCs), although the BM of patients with CLL had 
statistically similar levels (Figure 14 A).   
Overall, γδ T cells in PBMCs and BM of patients with CLL, NHL or MM are not 
activated. 
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II. The frequency of activated γδ T cells in PBMCs and BM derived cells of patient 
groups with blood cancers 
i. Activated γδ T cells. CD25 expression was similar for PBMCs and BM derived γδ T 
cells of different patient groups (e.g. in patients with CLL; 0.95% ± 0.41 cf 0.43% ± 0.23; 
for remaining patient groups refer to Figure 38 A). There were sufficient samples for 
patient matched comparison of PBMCs and BM derived γδ T cells for patients with CLL, 
but CD25 expression was similar (0.58% ± 0.29 cf 0.36% ± 0.16) (Figure 31 B). 
 
ii. Activated non γδ T cells. We also saw no difference in expression of CD25 between 
patient group matched PBMCs and BM (e.g. in patients with CLL; 0.35% ± 0.05 cf 0.31% 
± 0.19; for remaining patient groups, refer Figure 19 A), or for patient matched PBMCs 
and BM samples from patients with CLL (0.32% ± 0.11 cf 0.12% ± 0.03) (Figure 14 B). 
Taken together, γδ T cells do not appear to be specifically activated in patients with blood 
cancer. 
 
3.3.12. Summary on activated γδ T cells in patients with blood cancer 
Collectively, our analysis of patients with blood cancer revealed similar CD25 expression 
by γδ T cells in PBMCs and BM derived cells and PBMCs of healthy donors. In fact, only 
PBMCs of patients with ‘other’ blood cancers showed any significant increase and 
although relatively low, the magnitude of the increase was larger than for activated T 
cells in same patient group suggesting potential anti-tumour reactivity.  
We saw no difference in CD25 expression by patient PBMCs and BM derived γδ 
T cells, which also suggests the cells are not responding directly to the tumours in patients 
with blood cancer.  
 
3.4. Chapter 3 discussion 
Studies of patients with cancer have shown changes in the frequency of innate-like T cells 
that suggest these cells may be important in anti-tumour immunity. Unfortunately, many 
of the studies have caveats that mean the role of these cells remains poorly defined. For 
example, the majority of studies compared patient blood to blood of healthy donors, but 
tissues such as tumours and bone marrow were not often studied despite them being 
where anti-tumour responses might be most apparent 159,160,182,198. Furthermore, most of 
the past investigations reported on one kind of innate-like T cell, so the correlation 
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between these cells and other innate-like T cells or conventional T cells is not well 
defined in patients with cancer 68,160,182 and there is little understanding of whether 
changes in the frequency of one kind of innate-like T cell is similar to other T cell subsets. 
Past studies have used different methods to isolate and identify cells and many have had 
to rely on low group sizes due to difficulties in accessing patient tissue samples, or 
include patients with varied treatments 182,198. These factors contribute to difficulties 
interpreting these studies and defining the importance of innate-like T cells. 
In Chapter 3, we asked whether the frequency of innate-like T cells, including 
MAIT cells, NKT cells and γδ T cells, was significantly different in patients with cancer 
compared to healthy people, and if there were differences between blood and tumours of 
patients with cancer. In order to investigate this question, innate-like T cells and their 
subsets were identified and quantified. The frequency of conventional T cells and their 
subsets was also measured to consider whether changes to innate-like T cells were 
specific, or were part of broader changes to the overall T cell pool.  
In the latter part of this chapter, the frequency of innate-like T cells within 
matched tissue samples was compared to determine whether changes occurred 
systemically. Our objective was to establish whether innate-like T cells have frequency 
defects in patients with cancer and to determine which innate-like T cells are most 
affected. This information could then be considered in later Chapters where functional 
capacity was tested. 
 
I. MAIT cells. To investigate whether MAIT cells contributed to anti-tumour immunity, 
we studied the association between MAIT cell frequency and cancer in patients and 
healthy donors. Previous studies had reported a deficiency of MAIT cells in PBMCs of 
patients with colorectal cancer, but there was normal frequency in patients with lung 
cancer 68,69,197. These findings suggest that a MAIT cell deficiency is sometimes 
associated with cancer, but analysis of a wider range of patient groups and of tissue 
samples other than PBMCs is required to better understand that finding. MAIT cells 
produce cytokines that could potentially regulate anti-tumour responses so changes to 
MAIT cell frequency or function could directly or indirectly affect anti-tumour immunity.  
Our analysis of MAIT cells from different patient groups often identified a 
deficiency in PBMCs, BM and TILs, compared to PBMCs of healthy donors, suggesting 
a systemic deficiency (Table 1 & 2). Deficiencies were sometimes seen in conventional T 
cells also, but the magnitude of the MAIT cell deficiency was usually more severe. This 
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is consistent with a specific deficiency of MAIT cells in patients with cancer, although 
the cause of the deficiency is not clear. Interestingly, previous studies showed a higher 
frequency of MAIT cells in patient TILs when compared to patient PBMCs or non-
affected tissues 68,69. This suggests MAIT cell migration to the tumour, or perhaps 
activation within the tumour itself.  However, analysis of Ki67 expression in one study 
showed that MAIT cells in TILs from patients with colorectal cancer were not 
proliferating 68 and our study showed a similar deficiency in all patient tissue samples, 
which suggests it is unlikely that the MAIT cell deficiency is the result of migration 
between tissues, although reduced proliferation could potentially contribute to deficiency 
68,69.  
 
Table 1. Overview of results comparing the frequency of MAIT cells in patients with 
solid cancer compared to blood of healthy donors. Results are shown from Ch. 3 
comparing the frequency of MAIT cells and their subsets in patient blood and tumours, 
and blood of healthy donors. For comparison, results from T cells are also shown. Green 
indicates significantly higher frequency than healthy donors, red significantly lower 
frequency and blue indicates statistically similar outcomes. 
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Table 2. Overview of results comparing the frequency of MAIT cells in patients with 
blood cancer compared to blood of healthy donors. Results are shown from Ch. 3 
comparing the frequency of MAIT cells and their subsets in patient blood or bone marrow 
compared to blood of healthy donors. As a point of comparison, results from T cell 
populations are also shown. Filling with green indicates significantly higher frequency 
than healthy donors, red represents lower frequency and blue represents statistically 
similar outcomes. 
 
An earlier study showed that cancer cells could induce apoptosis of T cells in vitro 216. It 
is therefore possible that cancer cells induced apoptosis that resulted in a MAIT cell 
deficiency in patients with cancer. Past studies have also shown similar levels of PD-1 
between MAIT cells and other T cells. Increased PD-1 expression can trigger apoptosis of 
CD8+ T cells 217,  but the fact that similar PD-1 expression was found between MAIT 
cells and other T cells 68 indicates  the deficiency is unlikely to have been triggered by 
PD-1. We did not directly examine Annexin V staining for apoptosis, however there was 
no evidence of overt apoptosis and no studies have found MAIT cells in patients with 
cancer to be more apoptotic than T cells or those from healthy donors, which would be 
necessary to explain our observations. One possibility is that patients with cancer had a 
lower frequency of MAIT cells before onset of the disease. A longitudinal study of MAIT 
cell frequency could establish whether MAIT cell deficiency is a predisposing risk for 
cancer, although the practicalities of this approach are problematic.   
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We investigated MAIT cell subsets to determine if overall deficiencies affected all MAIT 
cells or only particular subsets. MAIT cell subsets may have distinct functions (like NKT 
cells) and changes affecting the balance between subsets could impact their collective 
anti-tumour capacity. A past study reported that MAIT cells subset expressing retinoic 
acid-related orphan receptor γt (RORγt) expressed IFNγ or IL-17 in mice suggesting 
MAIT cells subsets are functionally distinct 54, but it is not established that the 
functionally distinct subset could be identified based on CD8 expression in patients with 
cancer. We found that the ratio between CD8+ and CD8- subsets among MAIT cells was 
similar for patient groups and healthy donors, with CD8+ cells consistently higher in 
frequency than the CD8- subset. Consistent with this trend, no significant difference was 
found each MAIT cell subset was compared between patient tissue samples and healthy 
donors (Table 1 & 2). We have also shown that the frequency of MAIT cells and their 
subsets was similar between blood and tumours of patients with solid cancers and blood 
and bone marrow of patients with blood cancers (Table 3 & 4), implying that interactions 
with the tumours were probably not impacting their frequency. 
Our results support the concept that MAIT cell deficiency is associated with 
cancer and are consistent with MAIT cells being important in patients with cancer. MAIT 
cells are usually associated with anti-microbial responses, but several recent studies have 
suggested they may also be important in other disease settings, including viruses and 
cancer 59,61,68,218. We also found a significantly higher proportion of activated MAIT cells 
in patient tissues compared to blood of healthy donors. Interestingly, the proportion of 
activated MAIT cells was higher than for T cells, perhaps indicating a MAIT cell specific 
response (Table 1-2). We also showed that activated MAIT cells and their subsets are 
elevated in patient TILs compared to PBMCs (Table 3). Patients with haematological 
cancers also showed a similar level of activated MAIT cells in PBMCs and BM. Our 
findings suggest that MAIT cells are capable of being activated in the presence of cancer 
cells and there are often a higher proportion of activated MAIT cells than other T cell 
populations. Therefore, it will be important to investigate the function and competency of 
MAIT cells in patients with cancer.  
Based on our observation, MAIT cell activation could be subset specific as CD8+ 
MAIT cells were more activated than CD8- MAIT cells in patients with colorectal cancer 
(Table 1).  It will therefore be important to compare the anti-tumour activities of CD8+ 
and CD8- MAIT cell subsets, such as cytokine profiles.  While the reason for this skewed 
CD8+ subset activation of MAIT cells in patients with cancer is not clear, differing 
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responses to factors that can activate MAIT cells, including cytokines (e.g. IL-18), cancer 
cells and bacteria could play a role. Interestingly, Escherichia (E). coli and Helicobacter 
(H). pylori have been reported in patients with cancer and MAIT cells are activated by 
them 63,219–221.  
 
Table 3. Overview of results comparing the frequency of MAIT cells between patient 
groups and patient matched blood and tumours. Here, we have summarized results 
comparing the frequency of MAIT cells using patient matched (PM) or patient grouped 
but non-patient matched (NP) blood and tumours. Orange indicates TILs had 
significantly higher frequency, purple represents significantly higher PBMCs, blue 
represents statistically similar frequency. As a point of comparison, results from other T 
cell populations are also shown. 
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Table 4. Overview of results comparing the frequency of MAIT cells between patient 
group or patient matched blood and bone marrows. Here, we have summarized our 
results comparing the frequency of MAIT cells in patient matched (PM) or patient 
grouped but non-patient matched (NP) blood and bone marrow samples. Orange 
indicates significantly higher frequency in TILs, purple indicates significantly higher in 
PBMCs, blue represents statistically similar frequency. As a point of comparison, results 
from other T cell populations are also shown. 
 
II. NKT cells. Previous studies have generated conflicting results regarding the frequency 
of NKT cells in tissue samples from patients with cancer 161,211. For example, there are 
reports of reduced NKT cell frequency in tumours of patients with hepatocarcinoma 159 
and in blood of patients with colorectal carcinoma, breast cancer, head and neck cancer, 
renal cell carcinoma and melanoma 160. In contrast, are examples of increased NKT cell 
frequency in primary tumours of patients with colorectal carcinoma and intrahepatic 
tumours 157,161. These findings came mostly from studies of one form of cancer, and 
ideally, cells from blood and tumours across different patient groups would be 
investigated in one study to better understand how NKT cells frequency is impacted in 
patients with cancer. Our study addresses this issue and is designed to show how the NKT 
cell frequency in blood, BM or tumours in different patient groups are impacted across 
patient groups and whether NKT cells have a role in anti-tumour immunity. 
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Like MAIT cells, the frequency of NKT cells in patient tissue samples was 
significantly lower than in PBMCs of healthy donors for most patient groups (Table 5-6). 
Our data support some earlier findings that NKT cells are deficient in patients with cancer 
and raise the possibility that this may affect anti-tumour immunity 160,211.  We also 
showed that the deficiency was greater among NKT cells than the overall T cell pool 
suggesting a NKT cell specific deficiency. The importance of NKT cells for inducing 
anti-tumour response is evident from a series of studies showing reduced tumour 
immunity in NKT cell deficient mice, so it will be important to determine if cancer 
patients had lower frequencies of NKT cells before disease onset 99. While this type of 
study cannot easily be conducted in humans, a longitudinal study may help to provide 
better understanding of whether NKT cell deficiencies predispose to cancer, or are caused 
by it. We also identified tissue specific defects in patients with solid cancer suggesting 
that the frequency of NKT cells can change when they interact with tumour cells (Table 
7-8). 
 
Table 5. Overview of results comparing the frequency of NKT cells in patients with 
solid cancer compared to blood of healthy donors. Here, we have summarized our 
results comparing the frequency of NKT cells and their subsets in patient blood or 
tumours and blood of healthy donors. As a point of comparison, results from T cells are 
also shown. Green indicates frequency was significantly higher in healthy donors, red 
indicates significantly lower frequency and blue represents statistically similar outcomes. 
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Table 6. Overview of results comparing the frequency of NKT cells in patients with 
blood cancer compared to blood of healthy donors. The table summarizes data 
comparing the frequency of NKT cells and their subsets in patient blood and bone 
marrow compared to blood of healthy donors. As a point of comparison, results from T 
cells are also shown. Green indicates significantly higher frequency for healthy donors, 
red represents significantly lower frequency and blue represents statistically similar 
outcomes. 
 
Table 7. Overview of results comparing the frequency of NKT cells between patient 
group and patient matched blood and tumours. Here, we have summarized results 
comparing the frequency of NKT cells in patient matched (PM) and patient grouped but 
non-patient matched (NP) blood and tumours. Orange represents significantly higher 
frequency for TILs, purple represents significantly higher in PBMCs, blue represents 
statistically similar frequencies. As a point of comparison, results from other T cells are 
also shown. 
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Table 8. Overview of results comparing the frequency of NKT cells between patient 
group or patient matched blood and bone marrows. Here, we have summarized results 
comparing the frequency of NKT cells in patient matched (PM) and patient grouped but 
non-patient matched (NP) blood and bone marrow. Orange indicates significantly higher 
frequency in TILs, purple indicates significantly higher PBMCs, blue indicates 
statistically similar frequency. As a point of comparison, results from T cells are also 
shown. 
 
Another possible reason for the NKT cell deficiency is that activation of NKT cells down 
regulates expression of the NKT cell TCR, which is used for identification 222. Therefore, 
reduced detection of NKT cells could potentially coincide with activation and lead to 
underestimating of the actual frequency found in patients with cancer. In addition, 
activated NKT cells are reported to express PD1 (programmed death 1) and engage with 
PD-ligand on cancer cells to cause anergy, which could lead to apoptosis of the cells 
222,223. We do not see evidence of extensive activation of NKT cells, or of NKT specific 
apoptosis, but these possibilities should be directly investigated in future studies of NKT 
cells in these groups.  
Patient-matched colorectal cancer samples revealed a specific NKT cell 
deficiency in TILs compared to PBMCs (Table 7). This conflicts with an earlier study 
showing patients with liver cancer had increased NKT cell frequency in tumours 
compared to cells derived from patient blood 157. The reason for difference is not clear, 
although healthy liver has a higher frequency of NKT cells 36 and liver tumours may 
therefore be more readily infiltrated by NKT cells compared to colorectal tumours. 
Interestingly, no significant difference was seen between PBMCs and BM in patients with 
CLL (Table 8). As the deficiency is not more severe within the tumour microenvironment, 
it may be that the deficiency was pre-existing. It is therefore important to determine the 
functional impact of reduced NKT cell frequency in patients with cancer. 
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NKT cells have functionally distinct subsets and the CD4- subset is most capable 
of supporting anti-tumour responses 45. Therefore, it was important to assess the 
proportions of NKT cell subsets as well as the overall levels. In contrast to an earlier 
study that found a significantly higher frequency of CD4+ NKT cells in liver tumours 157, 
we found no significant difference in the proportion of NKT cell subsets in tissue samples 
across many patient groups compared to PBMCs of healthy donors (Table 5-6). While we 
didn’t have any liver tumour to investigate in this project to compare to the previous 
report, it will be interesting to investigate whether patient tumours and non-affected 
tissues taken from same patient show differences in the proportion of NKT cell subsets.  
Interestingly, NKT cells in patients with blood or solid cancers showed no 
noticeable difference in activation compared to PBMCs of healthy donors (Table 5-6). 
This may indicate that NKT cells are not responding to cancer cells in patients. While 
there was an activated NKT cells in patient samples, their relatively low frequency 
indicates that most NKT cells were not activated and likely not involved in anti-tumour 
responses. 
Taken together, we showed that the frequency of overall NKT cells is deficient in 
patients with cancer. There was a systemic deficiency of the broader T cell population too, 
but NKT cells showed a more severe deficiency. Interestingly, the proportion of NKT cell 
subsets and of activated cells among overall NKT cells in patient tissue samples was 
similar to those found in PBMCs of healthy donors, suggesting little overall response or 
change in subset distribution in the presence of cancer cells. 
 
III. γδ T cells. There are mixed reports about the frequency of γδ T cells in patients with 
cancer. For instance, one study of blood from patients with solid cancers, including 
colorectal, lung, breast, liver and thyroid cancer, showed no significant difference in 
frequency of γδ T cells compared to PBMCs of healthy donors 197. Another study on 
advanced stage cancer patients also showed no statistical difference between patient 
PBMCs and PBMCs of healthy donors 182. These findings suggest that the frequency of 
γδ T cells was not impacted in patients with different forms of cancers and may have little 
impact on anti-tumour immunity. A different study however reported deficiencies in γδ T 
cells could increase the chance of recurring cancer in patients with hepatocellular 
carcinoma 183 and a separate study of patients with melanoma reported that γδ T cells had 
a reduced anti-tumour capacity due to reduced overall population and a lower proportion 
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of  γδ T cells producing cytokines such as IFNγ 180. These reports indicate the need to 
investigate different patient groups and tissues in one study to determine the impact of γδ 
T cells in patients with blood or solid cancers.  
In our study, we found no noticeable difference in the overall frequency of γδ T 
cells among viable lymphocytes or T cells in patient tissue samples when compared to 
PBMCs of healthy donors (Table 9-10). Collectively, our results suggest little impact of 
cancer on γδ T cell frequency, although a previous study showed that γδ T cells play 
important role in optimizing anti-tumour response triggered by αGal-Cer stimulated NKT 
cells 70.  
 
Table 9. Overview of results comparing the frequency of γδ T cells in patients with solid 
cancer compared to blood of healthy donors. Here, we have summarized our results 
comparing the frequency of γδ T cells and their subsets in patient blood or tumours 
compared to blood of healthy donors. Green indicates a significantly higher frequency in 
healthy donors, red indicates a lower frequency and blue indicates a statistically similar 
outcome. As a point of comparison, T cells were also investigated. 
 
Table 10. Overview of results comparing the frequency of γδ T cells in patients with 
blood cancer compared to blood of healthy donors. Here, we have summarized our 
results comparing the frequency of γδ T cells and their subsets in patient blood and bone 
marrow compared to blood of healthy donors. Green indicates a significantly higher 
frequency in healthy donors, red indicates significantly lower frequency and blue 
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indicates statistically similar outcomes. As a point of comparison, T cells were also 
investigated. 
 
We next investigated γδ T cells expressing CD94 in patients with blood or solid cancers 
(Table 9-10). CD94 interacts with the NKGA2 subunit to suppress functional activity of 
NK cells 224,225.  Consistent with what was seen overall, we found no significant 
difference in the frequency of CD94+ γδ T cells in patients with solid cancers compared 
to healthy donors. Interestingly, PBMCs of patients with blood cancer consistently 
showed significantly higher CD94+ T cell frequency compared to healthy donors, perhaps 
indicating that broader CD94+ T cells are impacted differently to CD94+ γδ T cells in 
patient PBMCs (Table 10). While we only investigated the CD94+ subset in this project, 
the possibility of other subset specific responses by γδ T cells can’t be excluded. For 
example, a report on rectal cancer showed that the δ1 subset of γδ T cells was increased 
while the δ2 subset was decreased, even though the overall frequency showed no 
significant difference 213. This subset analysis was beyond the scope of this project, but in 
future studies, these subsets could be separately investigated. 
Most patients with solid cancers had a significantly higher frequency of activated 
γδ T cells in patient TILs compared to PBMCs of healthy donors, but the extent of the 
increase was relatively low and similar in other T cell populations and may therefore 
reflect broad non-specific factors (Table 9). The frequency of activated γδ T cells in 
patient PBMCs and BM was also similar to healthy donors, with the exception of PBMCs 
from patients with ‘other’ blood cancers, which was higher. However, this group 
represented a collection of samples from several distinct patient groups, so studies of 
individual groups would be required to confirm this finding.  
Our comparison of patient matched TILs and PBMCs showed a significantly 
higher proportion of activated γδ T cells in patient TILs than PBMCs, suggesting 
increased activation of γδ T cells in the tumour microenvironment (Table 11). In contrast, 
no difference was found between PBMCs and BM of patients with blood cancer (Table 
12). Therefore, while γδ T cells may have some functional response in TILs of patients 
with solid cancers that results in increased expression of CD25, this does not appear to be 
the case in patients with blood cancer. 
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Table 11. Overview of analysis of the frequency of γδ T cells comparing patient groups 
and patient matched blood and tumours. Here, we have summarized our results 
comparing the frequency of γδ T cells in patient matched (PM) or patient grouped but 
non-patient matched (NP) blood and tumours. Orange indicates significantly higher 
frequency in TILs, purple indicates significantly higher PBMCs, blue indicates 
statistically similar frequency. As a point of comparison, results from other T cells are 
shown. 
 
Table 12. Overview of results comparing the frequency of γδ T cells in patient groups 
and patient matched blood and bone marrow. Summarized results are shown comparing 
the frequency of γδ T cells from patient matched (PM) and patient grouped but non-
patient matched (NP) blood and marrows. Orange indicates significantly higher 
frequency in TILs, purple indicates higher frequency in PBMCs, blue indicates 
statistically similar frequency. As a point of comparison, results from other T cells are 
also shown. 
 
We were not able to conduct any form of longitudinal study to ask if the γδ T cell 
frequency is maintained regardless of the clinical staging of patients with cancer and 
based on a past study, it appears that γδ T cell frequency may stay unchanged during 
disease progression, as blood of patients with advanced cancer had a similar frequency as 
the overall (healthy) population 182. 
Taken together, our investigation of innate-like T cells in patients with cancer 
showed a varying impact on the frequency of NKT, MAIT and γδ T cells, with 
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deficiencies of NKT and MAIT cells, but not γδ T cells. The causes are not known and it 
remains to be established whether the NKT and MAIT cell defects were present before 
the cancer developed, or were caused by the cancer itself, but it is clear that not all innate-
like T cells are impacted in the same fashion. This could also indicate that they have 
distinct anti-tumour activities, although we didn’t directly address that issue and cannot 
exclude the possibility that the changes were unrelated to the cancer. Previous studies also 
reported aging dependent deficiency of innate-like T cells in healthy donors, or changes 
to the proportion of respective subsets 53,226. Thus, age matched healthy controls should 
be also considered in the future studies. Indeed, we considered aging as a potential factor 
that could influence the frequency of innate-like T cells in patients with cancer. However, 
our study didn’t show any significant correlation when the frequency of innate-like T 
cells and their subsets were measured based on aging (data not shown). Therefore, it may 
be controversial that aging could impact the frequency of innate-like T cells in patients 
with cancer. 
Investigating the frequency of innate–like T cells in patients with cancer provides 
important information about which innate-like T cells are impacted, but it doesn’t reveal 
potential functional defects of innate-like T cells. Therefore, in the next chapter, we 
shifted our focus to investigate to functional capacity of innate-like T cells to better 
understand their potential role in patients with cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
111 
Chapter 4: Functional capacity of activated innate-like T cells 
In Chapter 3, we showed that innate-like T cells were deficient in patients with cancer, 
suggesting that the deficiency could be linked to reduced anti-tumour capacity. Innate-
like T cells from healthy donors produce cytokines that can potentially promote or 
suppress anti-cancer responses 53,227,228. However, their function in patients with cancer 
has not been well studied, especially in tumour infiltrating lymphocytes (TILs). Among 
innate-like T cells, NKT cells have the most well documented potential to affect anti-
cancer responses 39. Most human studies were undertaken using cells from blood, with 
only a few examining tumours or bone marrow (BM) 160,162,229. Some reported NKT cell 
functional defects in patients with cancer, including reduced cytokine production or 
capacity to expand upon stimulation. For instance, NKT cells in patient blood had a 
reduced capacity to produce IFNγ when stimulated with PHA and showed a reduced 
proliferative response to stimulation with αGal-Cer 160,163. So far, most studies have only 
examined one innate-like T cell lineage or patient group so the extent of the defects is not 
well defined.  
In this chapter, we have analysed the functional capacity of innate-like T cells 
from PBMCs and TILs of patients with solid cancer, or PBMCs and BM of patients with 
blood cancer. MAIT cells, NKT cells and γδ T cells were sorted and stimulated using 
PMA and ionomycin for 6 h in vitro before staining for surface markers and intracellular 
cytokines. This method of stimulation was used to induce a maximal response because 
cell numbers were often quite low as these cells are rare and deficient in the patients we 
analysed. 
 
4.1.1. Functional capacity of MAIT cells in cancer patients 
When stimulated, MAIT cells can produce many cytokines including IFNγ, TNF and IL-
17 68,194. In colorectal cancer, tumour infiltrating MAIT cells and circulating MAIT cells 
reportedly have a reduced capacity to produce IFNγ compared to cells from healthy 
donors 68,69. However, a different study showed IFNγ expression was preserved in 
circulating MAIT cells from PBMCs of patients with colorectal cancer and from patients 
with lung cancer, breast cancer and liver cancer 197. Given these seemingly contradictory 
findings, we examined cytokine production by MAIT cells from patients with different 
forms of cancer to determine their capacity to contribute to anti-tumour responses and 
whether they are defective in patients with cancer. 
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A key finding from Chapter 3 was the increased proportion of activated (CD25+) 
MAIT cells in patients with cancer, despite an overall deficiency. Where numbers 
allowed, we assayed the cytokine responses of MAIT cells isolated from PBMCs, TILs 
and/or bone marrow (BM) of patients with solid or blood cancers.  
We tested the responses of MAIT cells (CD161+Vα7.2TCR+CD3+) and their 
CD8+/-subsets (Figure 32 A-F), and compared them to responses of cells from healthy 
donors, and of other T cells including CD161-Vα7.2TCR+ CD3+ T (MAIT-like T) cells 
or CD161+ T cells. The goal was to determine if MAIT cells from patients were 
responding similarly to cells from healthy donors and whether responses differ between 
tumour and blood derived MAIT cells.  
 
 
Figure 32. Identification and quantification of intracellular cytokines expressed by 
MAIT cells from cancer patients. Vα7.2TCR+CD3+ T cells (A) were sorted from frozen 
PBMCs, TILs or BMs from patients with cancer and stimulated for 6h with PMA / 
ionomycin with GolgiPlug. MAIT cells (B) and their subsets (C) were stained for IFNγ, 
TNF and IL-4 cytokines (D-F). The frequency of unstimulated, cytokine positive MAIT 
cells was also measured (G-I). 
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4.1.2. Intracellular cytokine expression by MAIT cells from patients with solid 
cancer 
MAIT cells within sorted Vα7.2TCR+CD3+ T cells from patients with colorectal cancer, 
lung cancer or ‘other’ solid cancer groups were tested for cytokine expression before and 
after 6h stimulation with PMA and ionomycin with GolgiPlug. 
We first asked whether unstimulated MAIT cells isolated from PBMCs or TILs 
expressed intracellular cytokines because of an increase in CD25 expression in these 
patient groups. The frequency of unstimulated MAIT cells was similar for patient PBMCs 
and TILs and PBMCs of healthy donors and no significant cytokine expression was 
detected (Figure 32 G-I). This suggests that MAIT cells were not producing cytokines 
when isolated from patient samples, including from tumours.  
 
I. The cytokine response of MAIT cells from PBMCs of patients with solid cancers  
i. MAIT cells. The frequency of IFNγ+ or TNF+ MAIT cells from PBMCs of patients 
with solid cancer after stimulation was comparable to cells from PBMCs of healthy 
donors (mean 21.7% - 35.7% in patient PBMCs cf 29% for healthy PBMCs for IFNγ; 
27.6% to 46.3% in patient PBMCs cf 33.5% in healthy PBMCs for TNF) (Figure 33 A, C). 
This demonstrates that the cells were functional in terms of cytokine production. Indeed, 
the raw data showed a higher frequency of IFNγ+ and TNF+ MAIT cells in patients so we 
cannot rule out that a larger sample size may reveal a significant difference. Low cell 
numbers and/or sample number meant we lacked the statistical power to definitively 
compare the frequency of IL-4+ MAIT cells, but patients with lung cancer or ‘other’ solid 
cancer showed no noticeable difference to PBMCs of healthy donors (mean 0.33% - 0.8% 
cf 1.2%; IL-4+ MAIT-like T cells; 1% - 1.4% cf 1% in IL-4) (Figure 33 E). IL-4+ MAIT 
cells in PBMCs of colorectal cancer were similar to healthy PBMCs (Figure 33 E). 
 
 
 
 
 
  
114 
 
Figure 33. Cytokine responses of MAIT cells and MAIT-like T cells from patients with 
solid cancer. MAIT cells or MAIT-like (CD161- Vα7.2TCR+CD3+) T cells among sorted 
Vα7.2TCR+CD3+ T cells from patient PBMCs (Bl), tumours (Tu) or PBMCs of healthy 
individuals (Ctrl) were stimulated using PMA and ionomycin for 6 h with GolgiPlug and 
assayed for expression of IFNγ (A-B), TNF (C-D) and IL-4 (E-F). 0.1% includes <0.1% 
for IFNγ (A-B) and TNF (C-D) while 0.01% includes <0.01% for IL-4 (E-F). Each 
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symbol represents one sample. Statistical significance was assessed by Mann–Whitney 
analysis (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cells. We observed no significant difference in the frequency of IFNγ+, 
TNF+ or IL-4+ CD161-Vα7.2TCR+CD3+ (MAIT-like T) cells for patient and healthy 
PBMC samples (e.g. IFNγ 23.5% - 34.7% in patient PBMCs cf 24.8% in healthy PBMCs; 
for more data refer to Figure 33 B, D, F). This suggests MAIT cells were functionally 
competent in these patients and that the IFNγ, TNF and IL-4 profiles were mostly similar 
to healthy donors. 
Many innate-like T cells express CD161 and we were interested in the cytokine 
responses of CD161+ T cells from patients and healthy donors. The frequency of IFNγ+ 
or TNF+ CD161+ T cells from patient PBMCs was similar to healthy donors (mean 
28.5% - 62.7% in patient PBMCs cf 43.7% in healthy PBMCs for IFNγ; 36.6% - 36.8% in 
patient PBMCs cf 49.2% in healthy PBMCs for TNF) (Figure 34 A-B). Exceptions were 
IFNγ+ CD161+ T cells in PBMCs of patients with ‘other’ solid cancers, which was 
significantly lower than for PBMCs of healthy donors (22.6% ± 3.8 cf 43.72 % ± 5.7), 
and the frequency of TNF+ CD161+ T cells from PBMCs of patients with colorectal 
cancer, which was significantly higher (78.4% ± 3.2 cf 49.3% ± 6.6) (Figure 34 A-B). 
Interestingly, the raw data of IFNγ expression by CD161+ T cells was much higher in 
patients with colorectal cancer than in healthy donors but lacked significance, thus studies 
with more statistical power may be useful. The frequency of IL-4+ CD161+ T cells was 
also higher in patient PBMCs, but still relatively low in most patient groups (1.1% - 9.7% 
in patient PBMCs cf 0.1% in healthy PBMCs) (Figure 34 C). Collectively, these findings 
indicate that MAIT cells from PBMCs of patients with cancer can mount a similar 
cytokine response to PBMCs from healthy donors and show little indication of abnormal 
function. 
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Figure 34. Cytokine responses of CD161+ T cells in blood and tumours from patients 
with solid cancer. CD161+CD3+ T cells among sorted T cells from PBMCs (Bl) or TILs 
(Tu) of patients with solid cancer and PBMCs of healthy individuals (Ctrl) in vitro were 
assayed for IFNγ (A), TNF (B) or IL-4 (C) after stimulation with PMA and ionomycin 
with GolgiPlug for 6 h. 0.1% includes <0.1%. Each symbol represents one sample. 
Statistical significance was determined by Mann–Whitney analysis (P<0.05*/ P<0.01**/ 
P<0.001***/ P<0.0001****). 
 
II. The cytokine response of MAIT cells from TILs of patients with solid cancers and 
PBMCs of healthy donors 
i. MAIT cells. MAIT cells from patient TILs of nearly all patient groups showed similar 
intracellular IFNγ, IL-4 and TNF responses to cells from PBMCs of healthy donors 
(mean; 21.9% - 33% in patient TILs cf 29% in healthy PBMCs for IFNγ; 26.6% - 51.8% 
in patient TILs cf 33.5% in healthy PBMCs for TNF; 1% - 2.2% in patient TILs cf 0.81% 
in healthy PBMCs for IL-4) (Figure 33 A, C, E). One exception was that patients with 
lung cancer had a reduced frequency of IFNγ+ MAIT cells in patient TILs compared to 
healthy donors (8.2% ± 2.3 cf 29% ± 4.7) (Figure 33 A). There was no statistically 
significant difference in the proportion of IL-4+ MAIT cells from TILs of patients with 
colorectal cancers compared to PBMCs of healthy donors, but disparities in the raw data 
suggests this may warrant further investigation. Taken together, stimulated MAIT cells in 
patient TILs appear to have a comparable capacity to produce cytokines as PBMCs of 
healthy donors. 
 
ii. Non MAIT T cells. Similar results were seen for CD161-Vα7.2TCR+CD3+ T (MAIT-
like T) cells (IFNγ+ mean; 18.1% - 27.7% in patient TILs cf 24.9% in healthy PBMCs; 
TNF+ mean 21.9% - 36.2% cf 32.3% or IL-4+ mean 0.6% - 0.9% cf 1%) (Figures 33 B, 
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D, F) and CD161+ T cells (18.1% to 27.3% cf 24.8% in IFNγ or 21% to 36% cf 32.2% in 
TNF) (Figure 34 A-B). IL-4+ CD161+ T cells trended higher in patient TILs than healthy 
PBMCs but low n values may have impacted the results. Collectively, we demonstrated 
that MAIT cells in patient TILs were functionally responsive to stimulation and had 
similar responses to MAIT cells from healthy donors. 
 
III. Comparison between patient group matched TILs and PBMCs   
i. MAIT cells. We next compared the cytokine responses of stimulated MAIT cells from 
patient group matched TILs and PBMCs. We found no significant difference between 
tissues in patient groups, although the statistical power was relatively low due to sample 
sizes and unexpected variability within groups. We did identify differences in the mean 
cytokine responses that could be important if they were maintained with increased 
statistical power. Our data therefore warrants more investigations because there were 
usually more MAIT cells from patient PBMCs producing cytokines than from TILs (e.g. 
IFNγ+ MAIT cells; 35.8% ± 8 in patient PBMCs cf 21.9% ± 9.5 in TILs for colorectal 
cancer, 21.7% ± 14.7 cf 8.2% ± 2.3 for lung cancer or 33% ± 7.9 cf 45.5% ± 16.4 for 
‘other’ solid cancers; non-significant difference for TNF+ or IL-4+ MAIT cells; refer to 
Figure 33 A, C, E).  
 
ii. Non MAIT T cells. There was also no difference in the responses of patient group 
matched PBMCs and TILs for MAIT-like T cells (e.g. IFNγ+ MAIT-like T cells; 34.7% ± 
7.8 cf 27.7% ± 10.6% in colorectal cancer, TNF+ MAIT-like T cells; 43.3% ± 8.9 cf 
36.2% ± 10.9 in colorectal cancer, IL-4+ MAIT-like T cells; 1% ± 0.4 cf 0.67% ± 0.4 in 
lung cancer; for additional data refer to Figure 33 B, D, F).  
The frequency of IFNγ+ and TNF+ CD161+ T cells were similar for blood and 
tumour cells of the same patient group (e.g. in lung cancer; 28.5% ± 8.4 IFNγ+ CD161+ 
T cells in PBMCs cf 31.7% ± 9.4 in TILs; 36.7% ± 10.6 TNF+ CD161+ T cells in PBMCs 
cf 38.1% ± 8.5 in TILs; for additional data refer to Figure 41 A-B). One exception was 
the lower frequency of IFNγ+ or TNF+ CD161+ T cells in TILs compared to PBMCs of 
patients with colorectal cancer (62.7% ± 6.3 IFNγ+ CD161+ T cells in PBMCs cf 36% ± 
5.5 in TILs; 78.4% ± 3.2 TNF+ CD161+ T cells in PBMCs cf 64.3% ± 6 in TILs) (Figure 
34 A-B). PBMCs of patients with ‘other’ solid cancers had a significantly higher 
frequency of IL-4+ CD161+ T cells than patient group matched TILs (1.1% ± 0.4 cf 
0.23% ± 0.13) but the levels were low and other patient groups showed no difference or 
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were not tested (1.1% ± 0.4 cf 0.23% ± 0.13 in ‘other’ solid cancers; 9.7% ± 3.9 cf 9.9% 
in colorectal cancer) (Figure 34 C). 
Taken together, the capacity of MAIT cells to express IFNγ, TNF or IL-4 was 
similar between patient group matched PBMCs and TILs.  
 
4.1.3. Summary 
Our data showed that the IFNγ, TNF and IL-4 responses of MAIT cells, CD161-
Vα7.2TCR+CD3+ T (MAIT-like T) cells and CD161+ T cells were mostly similar in 
PBMCs and TILs of patients with solid cancer and PBMCs of healthy donors. Hence, 
MAIT cells from these patient groups do not appear to have a defect in cytokine 
production and their response to stimulation does not appear to have been changed by 
exposure to cancer. Blood and tumour samples had similar cytokine responses in most 
patient groups, although there were sometimes large, non-significant differences in the 
raw data that suggest further studies may be worthwhile. For example, we found that 
21.7% of MAIT cells in PBMCs were IFNγ+, compared to 8.2% among TILs of patients 
with lung cancer, but the difference was not significant. 
 
4.1.4. Cytokine production by MAIT cell subsets from patients with solid cancers 
In a previous study, there was lower expression of IFNγ for CD8+ MAIT cells in TILs of 
patients with colorectal cancer compared to non-affected tissue samples, while another 
study showed reduced IFNγ expression in MAIT cells from patient PBMCs when 
compared to cells from PBMCs of healthy donors 68,69. These findings suggest 
functionally abnormal MAIT cells are sometimes present that could negatively impact the 
anti-tumour capacity in patients with colorectal cancer. CD8- MAIT cells were not 
investigated in those studies and it is not known if the defect affects other patient groups 
with solid cancer. Therefore, we assayed CD8+ and CD8- MAIT cell subsets cells from 
PBMCs and TILs of patients with solid cancer for IFNγ, TNF or IL-4 responses to 
PMA/ionomycin.  
 
I. Cytokine response of patient blood derived MAIT cell subsets in vitro  
We first compared the frequency of cytokine positive CD8+ and CD8- MAIT cells in 
PBMCs of patient groups with solid cancers. The difference between the subsets was not 
statistically significant, although the CD8+ subset mostly trended higher for IFNγ (e.g. 
48.3% ± 7.8 in CD8+ cf 27.6% ± 6.1 in CD8- for colorectal cancer), TNF (e.g. 52.2% ± 
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12.3 cf 23.1% ± 13.3 for lung cancer) and IL-4 (0.4% ± 0.3 cf 0.76% ± 0.3 for lung 
cancer) (Figure 35 A-C). We also found no significant difference in the frequency of 
cytokine positive MAIT cell subsets in PBMCs of healthy donors but again, the CD8+ 
subset consistently showed a higher proportion of cytokine expression over CD8- subset 
(IFNγ expression; 30.5% ± 4.5 in CD8+ subset cf 20% ± 4.5 in CD8- subset; TNF; 34.7% 
± 5.2 in CD8+ subset cf 28.3% ± 5.2 in CD8- subset or IL-4; 1.2% ± 0.5 in CD8+ subset 
cf 0.27% ± 0.13 CD8- subset) (Figure 35 A-C). We did not have the statistical power to 
definitively compare IL-4 expression by CD8+ and CD8- MAIT cell subsets in patients 
with colorectal cancer due to low sample size (Figure 35 A). Overall, we saw no 
significant difference between CD8+ and CD8- MAIT cell subsets from PBMCs of 
patients or healthy donors but it would be interesting to determine whether the trend of 
higher expression of cytokines by CD8+ MAIT cells is confirmed with larger group sizes.  
 
 Figure 35. Cytokine responses of MAIT cell subsets from patients with solid cancers. 
CD8+ and CD8- MAIT cell subsets from sorted Vα7.2TCR+CD3+ T cells from PBMCs 
or TILs of patients with solid cancer or PBMCs of healthy donors (Ctrl) were assayed for 
expression of IFNγ (A), TNF (B) or IL-4 (C) after stimulation with PMA and ionomycin 
with Golgiplug for 6h. Each symbol represents one patient sample. 0.1% includes <0.1%. 
Statistical significance was assessed by Mann–Whitney analysis (P<0.05*/ P<0.01**/ 
P<0.001***/ P<0.0001****).  
 
 
  
120 
II. Cytokine response of stimulated MAIT cell subsets from patient and healthy 
PBMCs   
i. MAIT cell subsets. MAIT cell subsets of patients with solid cancers such as colorectal 
cancer or lung cancer were stimulated in vitro and assayed for cytokine expression. We 
found no significant difference between CD8+ and CD8- MAIT cell subsets of most 
patient groups and healthy donors (IFNγ+ CD8+ MAIT cells mean range 40.6% - 48.8% 
in patient PBMCs cf 30.5% in healthy PBMCs; and IFNγ+ CD8- MAIT cells mean 
between 16.1% - 27.6% in patient PBMCs cf 20% in healthy PBMCs. Comparisons were 
also similar for TNF and IL-4 see Figure 36 A, C, E, G, I, K). Two exceptions were 
CD8+ and CD8- MAIT cells from PBMCs of patients with colorectal cancer, which had 
significantly higher expression of TNF than cells from PBMCs of healthy donors (55.4% 
± 8.2 cf 34.7% ± 5.2 in CD8+ MAIT cells or 49% ± 8.1 cf 28.3% ± 5.2 in CD8- MAIT 
cells) (Figure 36 E, G). Low cell numbers meant MAIT cell subsets from PBMCs of 
patients with colorectal cancer were not assayed for IL-4, but other patient groups had 
similar frequency of IL-4+ MAIT cell subsets. 
Most patient groups showed no significant difference between the frequency of 
IFNγ+, TNF+ or IL-4+ CD8+ MAIT cells in patient PBMCs and healthy controls, 
although the raw MAIT cell responses were often higher for patients than PBMCs of 
healthy donors. It would be interesting to examine a larger patient cohort, but our findings 
indicate that CD8+ and CD8- MAIT cell subsets have a statistically similar functional 
capacity to produce IFNγ, TNF and IL-4 as MAIT cells from healthy donors.  
 
ii. Non MAIT T cell subsets.  Consistent with CD8+ and CD8- MAIT cell subsets, the 
frequency of cytokine positive CD161-Vα7.2TCR+CD3+ (MAIT-like) T cell subsets 
defined by CD8 was similar for cells from PBMCs of different patient groups and healthy 
donors after in vitro stimulation using PMA and ionomycin (Figure 36). Exceptions were 
PBMCs of patients with colorectal cancer, which showed a significantly higher frequency 
of IFNγ+ and TNF+ CD8+ MAIT-like T cells compared to PBMCs of healthy donors 
(Figure 36 B, F). Like CD8+ MAIT cells, the frequency of IFNγ+, TNF+ and IL-4+ 
CD8+ MAIT-like T cells in patient PBMCs consistently trended higher than healthy 
PBMCs without reaching statistical significance. Collectively, the cytokine responses of 
MAIT cell subsets and MAIT-like T cell subsets from patient PBMCs are similar to 
healthy donors.  
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Figure 36. Cytokine responses of CD8+ and CD8- MAIT cells and MAIT-like T cell 
subsets from patients with solid cancer. CD8+ and CD8- MAIT cell or MAIT-like 
(CD161-Vα7.2TCR+CD3+) T cell subsets from PBMCs (Bl) or TILs (Tu) from patients 
with solid cancer or healthy individuals (Ctrl) were assayed for expression of IFNγ (A–D) 
or TNF (E–H) or IL-4 (I-L) after stimulation with PMA and ionomycin with GolgiPlug for 
6 h. 0.1% includes <0.1%. Each symbol represents one sample. Statistical significance 
was determined by Mann–Whitney analysis (P<0.05*/ P<0.01**/ P<0.001***/ 
P<0.0001****). 
 
III. Comparing cytokine responses of stimulated MAIT cell subsets from patient 
TILs  
Using patient TILs, we found that CD8+ and CD8- MAIT cell subsets from patient TILs 
have a similar cytokine response (e.g. in colorectal cancer; 32.6% ± 9.6 in CD8+ subset 
cf 20.6% ± 7.2 in CD8- subset for IFNγ; 33.6% ± 9.8 cf 35.3% ± 10 for TNF; 3.9% ± 3.3 
cf 3.7% ± 1.5 for IL-4; refer to Figure 36 A-C for patients with lung cancer and ‘other’ 
solid cancers). This pattern was similar to CD8+ and CD8- MAIT cells in PBMCs of 
healthy donors (IFNγ; 30.5% ± 4.5 in CD8+ subset cf 20% ± 4.5 in CD8- subset; TNF; 
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34.7% ± 5 cf 28.3% ± 5.2; IL-4; 1.2% ± 0.5 cf 0.27% ± 0.13) (Figure 36 A-C). There 
were instances of different frequencies (e.g. lung cancer), but these were not statistically 
measured due to lack of tissue samples (Figure 36 A-C). However, CD8+ MAIT cells had 
a consistently higher proportion of IFNγ positive cells in patient TILs and in PBMCs of 
healthy donors. Therefore, it would be useful to increase the power of this study to 
determine whether CD8+ subsets are significantly more potent in producing cytokines 
compared to CD8- subsets.  
Collectively, our data showed that MAIT cell subsets from TILs have a similar 
capacity to produce IFNγ, TNF and IL-4 as subsets from PBMCs of healthy donors 
(Figure 36 A-C).  
 
IV. Cytokine responses of MAIT cell subsets from patient TILs and healthy donors 
i. MAIT cell subsets. The proportions of CD8+ or CD8- MAIT cells producing IFNγ, 
TNF or IL-4 after in vitro stimulation was similar for patient TILs and cells from PBMCs 
of healthy donors (e.g. IFNγ+ CD8+ MAIT cells ranged between 32.6% to 48.9% in TILs 
cf 30.5% in healthy PBMCs; TNF+ CD8+ MAIT cells ranged between 50.3% to 55.4% cf 
34.6%; IL-4+ CD8+ MAIT cells ranged between 1.7% to 3.8% cf 1.2%. Refer to Figure 
36 for CD8- MAIT cells). We lacked statistical power for analysis of CD8+ MAIT cells in 
patients with lung cancer, but there was a significantly lower frequency of IFNγ+ CD8- 
MAIT cells in TILs of patients with lung cancer compared to PBMCs of healthy donors 
(4.8% ± 2.3 cf 20.5% ± 4.5) (Figure 36 C). We also noted that the frequency of IL-4+ 
CD8- MAIT cells in TILs of patients with colorectal cancer was significantly higher than 
in PBMCs of healthy donors (1.97% ± 1.8 cf 0.27% ± 0.13) (Figure 36 K). We believe 
larger studies may be warranted to investigate if cytokine expression is higher in cells 
from patients with cancer as we again noted that more cells from TILs produced 
cytokines, although the differences were not always statistically significant. Our findings 
indicate that MAIT cells subsets are not grossly defective for producing IFNγ, TNF or IL-
4 in patient TILs.  
 
ii. Non MAIT T cells. The frequency of CD8+ or CD8- CD161-Vα7.2TCR+CD3+ 
(MAIT-like) T cell subsets stimulated in cell culture with PMA and ionomycin showed 
no significant difference in cytokine responses between patient TILs and PBMCs of 
healthy donors in most patient groups (Figure 36). One exception was TNF+ CD8+ 
MAIT-like T cells in TILs of patients with ‘other’ solid cancers, which was significantly 
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lower than in PBMCs of healthy donors (24.5% ± 6.4 cf 30.6% ± 3.6) (Figure 36 F), but 
this was relatively minor. Our findings indicate that MAIT-like T cells from most patient 
TILs had similar cytokine responses as cells from healthy PBMCs. 
 
V. Comparison of cytokine responses from patient group matched TILs and PBMCs  
i. MAIT cell subsets. Consistent with the comparison between patient TILs and PBMCs 
of healthy donors, no significant difference was identified between cytokine responses of 
MAIT cell subsets from TILs and PBMCs of patients (e.g. 40.6% ± 8.9 IFNγ+ CD8+ 
MAIT cells in patient PBMCs cf 48.9% ± 17.2 TILs for ‘other’ solid cancers; 42.4% ± 8.4 
TNF+ CD8+ MAIT cells in patient PBMCs cf 50.4% ± 18.6 in patient TILs; 0.1% in IL-
4+ CD8+ MAIT cells from patient PBMCs cf 1.7% ±1.3 patient TILs; refer to Figure 36 
for additional data). We did not have the required statistical power to fully analyse 
patients with colorectal cancer or lung cancer, but while no significant differences were 
identified, it was clear that cytokine responses were detected. Subsets of MAIT cells in 
PBMCs of patients with colorectal cancer consistently showed a higher proportion of 
cytokine positive population compared to cells from TILs of the patient group and this 
may require further investigation. Taken together, our data suggests that MAIT cell 
subsets from TILs and blood of patient groups had similar IFNγ, TNF or IL-4 responses 
to PMA and ionomycin.  
 
ii. Non MAIT T cell subsets. We found similar expression of cytokines by CD161-
Vα7.2TCR+CD3+ (MAIT-like T) cell subsets from TILs and patient group matched 
PBMCs after stimulation with PMA and ionomycin (Figure 36). We did not have the 
statistical power to compare the frequency of IL-4+ MAIT-like T cell subsets in patients 
with colorectal cancer (Figure 36 K). Again, we noted non significant differences 
between groups that may warrant further investigation, including CD8+ MAIT-like T 
cells where IFNγ+ expression from patient PBMCs was higher than TILs (46% ± 7 cf 
31% ± 8) (Figure 36 B). Collectively, we showed that cytokine responses of MAIT cells 
and other T cell lineages from patient groups are similar regardless of whether they were 
isolated from patient blood or tumours.  
 
4.1.5. Summary 
We found no significant defects or differences in cytokine responses of MAIT cells 
subsets in patient PBMCs and TILs after stimulation. Although mostly lacking statistical 
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significance, the response of the CD8+ subset trended consistently higher than CD8- cells 
particularly for expression of IFNγ, suggesting that further studies may be useful, 
including of a wider range of cytokines than we assessed.  
We observed similar capacity of MAIT cells (and broader T cell populations) 
from patient TILs and PBMCs within patient groups to generate IFNγ, TNF and IL-4 so 
there does not appear to be an overt functional defect, or tissue specific differences in the 
cytokine responses of MAIT cells in patients with solid cancer. One interesting 
observation was that PBMCs of patients with colorectal cancer trended to have a higher 
(but not statistically significant) frequency of CD8+ MAIT cells expressing IFNγ or TNF 
than patient group matched TILs, which may warrant further investigation.  
 
4.1.6. Cytokine response by MAIT cells in patients with blood cancer 
To our knowledge, the functional capacity of MAIT cells from patients with blood cancer 
has not been investigated. In this section, we again analysed MAIT 
(CD161+Vα7.2TCR+CD3+) cells from sorted Vα7.2TCR+CD3+ T cells from PBMCs or 
cells from bone marrow (BM) for cytokine expression after PMA and ionomycin 
stimulation. Cytokine expression of MAIT cells was compared to CD161+ T cells and 
CD161-Vα7.2TCR+CD3+ T (MAIT-like T) cells. We also tested whether MAIT cells 
from patients were releasing cytokines as there was an increased frequency of CD25+ 
MAIT cells in patients compared to healthy individuals. However, we found very little 
cytokine expression by unstimulated MAIT cells and no significant difference between 
patients and healthy donors.  
 
I. Cytokine response of patient blood derived MAIT cells  
i. MAIT cells. MAIT cells from patients with NHL or ‘other’ blood cancers had a similar 
cytokine response to healthy donors (26.7% ± 5.5 in NHL or 29.4% ± 5 in ‘other’ blood 
cancers of patient PBMCs cf 29 % ±4.7 of healthy PBMCs for IFNγ+; 20.7% ± 8.3 in 
NHL or 26.2% ± 3.9 in ‘other’ blood cancers for patient PBMCs cf 29% ± 4.7 for TNF+ 
MAIT cells) (Figure 37 A-C). Exceptions included PBMCs of patients with MM, which 
had significantly lower IFNγ+ or TNF+ MAIT cell frequency than PBMCs of healthy 
donors (11.5% ± 2.6 cf 29% ± 4.7% for IFNγ and 14.8% ± 2.5 cf 33.5% ± 5.4 for TNF) 
(Figure 37 A, C). These findings indicate that stimulated MAIT cells in patient PBMCs 
could produce IFNγ and TNF at a similar level as healthy donors. IL-4 expression was 
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low for all groups, so although there were some differences between groups (Figure 37 E), 
it is unlikely these were functionally important. 
 
Figure 37. The frequency of cytokine producing MAIT cells or MAIT-like T cells from 
patients with blood. MAIT cells or MAIT-like (CD161-Vα7.2TCR+CD3+) T cells were 
stimulated with PMA and ionomycin for 6h with GolgiPlug in cultures of 
Vα7.2TCR+CD3+ T cells sorted from PBMCs (Bl) and BM of patients with blood cancer 
and blood of healthy donors (Ctrl). Harvested cells were then assessed for expression of 
IFNγ (A-B), TNF (C-D) or IL-4 (E-F). 0.1% includes <0.1% for IFNγ (A-B) or TNF (C-
D) while 0.01% includes <0.01% for IL-4 (E-F) expression. Each symbol represents one 
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patient sample. Statistical significance was determined by Mann–Whitney analysis 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cells. We found no significant difference in cytokine production by 
CD161-Vα7.2TCR+CD3+ T (MAIT-like T) cells between patient groups (Figure 37). Of 
note, the IL-4 response was the same for MAIT-like T cells in PBMCs of patients and 
healthy donors, suggesting the small but significant difference for MAIT cells was 
specific. 
The response of CD161+ T cells from patient PBMCs sometimes differed from 
healthy donors. For instance, in PBMCs of patients with MM or ‘other’ blood cancers, the 
frequency of IFNγ+ or TNF+ CD161+ T cells after stimulation was significantly lower 
than for PBMCs of healthy donors (IFNγ+ CD161+ T cells, 20.4% ± 3.3 in PBMCs of 
MM or 25.7% ± 3.6 in PBMCs of ‘other’ blood cancers cf 49.2% ± 6.6 for healthy 
PBMCs; TNF+CD161+ T cells, 22.6% ± 3.1 or 28.1% ± 3.3 cf 49.2% ± 6.6). Raw results 
from PBMCs of patients with NHL were variable, but statistically similar to PBMCs of 
healthy donors (Figure 38 A-B). These results reveal that MAIT cells in patient PBMCs 
are similar to PBMCs of healthy donors in their capacity to produce IFNγ and TNF, even 
when there were differences with other T cell populations.  
 
Figure 38. The frequency of IFNγ, TNF or IL-4 producing CD161+ T cells from 
PBMCs and BM of patients with blood cancer. The frequency of IFNγ (A), TNF (B) or 
IL-4 producing CD161+ T cells among sorted T cells (C) in PBMCs (Bl) or BM of 
patients with blood cancer and blood of healthy individuals (Ctrl) was compared after 6h 
stimulation with PMA and ionomycin with GolgiPlug. 0.1% includes <0.1%. Each 
symbol represents one patient sample. Mann-Whitney test was conducted to determine the 
statistical difference (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
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II. Cytokine response of BM derived MAIT cells after in vitro stimulation 
i. MAIT cells. Similar to PBMCs, there was no significant difference between the 
frequency of cytokine positive MAIT cells in BM of patient groups and PBMCs of 
healthy donors (17.9% to 26.2% IFNγ+ MAIT cells in patient BM cf 29% for healthy 
PBMCs; 17.2% to 22.4% cf 33.5% for TNF; and 0.01% to 0.84% cf 1.1 for IL-4+ MAIT 
cells) (Figure 37 A, C, E). These results showed that stimulated MAIT cells in patient BM 
are capable of producing IFNγ, TNF and IL-4. 
 
ii. Non MAIT T cells. CD161-Vα7.2TCR+CD3+ (MAIT-like) T cells and CD161+ T 
cells also had a similar cytokine responses to PBMCs of healthy donors (Figure 37 and 
38). There were instances where groups differed, but these were often relatively minor 
and did not alter the interpretation of data from MAIT cells. 
 There were several examples where the frequency of IFNγ+ and TNF+ cells was 
lower in BM of patients than for healthy donors but the significance of this is uncertain 
and didn’t alter the central finding that stimulated MAIT cells in BM of all patient groups 
could produce IFNγ, TNF and IL-4 in response to stimulation at a similar frequency as for 
PBMCs of healthy donors (Figure 38). It may be interesting to investigate the potential 
importance of these non-MAIT cells given they were more variable in their cytokine 
responses than MAIT cells.  
 
III. Patient PBMCs and BM derived cells within same patient group  
i. MAIT cells. Having established that MAIT cells from patient PBMCs and BM were 
similar to healthy controls in their capacity to produce cytokines, we directly compared 
PBMCs and BM within same patient groups. Not surprisingly, we confirmed that there 
was no significant difference in cytokine responses of PBMCs and BM derived cells from 
the same blood cancer patient group (Figure 37). These findings confirmed that MAIT 
cells in patient PBMCs and BM have similar cytokine responses to healthy PBMCs.  
 
ii. Non MAIT T cells. Most patient groups showed similar cytokine responses by other T 
cell lineages as healthy donors, including CD161-Vα7.2TCR+CD3+ (MAIT-like T) cells 
and CD161+ T cells. Exceptions included significantly higher proportions of IL-4+ and 
IFNγ+ MAIT-like T cells in PBMCs of patients with ‘other’ blood cancers compared to 
patient group matched BM (1.69% ± 0.7 cf 0.01%  for IL-4; 31.9% ± 3.8 cf 19.6% ± 2.5 
for IFNγ expression) (Figure 37 and 38). Taken together, MAIT cells of patient groups 
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appear to have similar cytokine responses regardless of whether they were isolated from 
blood or bone marrow, and similar findings were seen mostly for non MAIT T cells. 
 
4.1.7. Summary 
In this section, we showed that MAIT cells from patient PBMCs or BM have a similar 
functional capacity to produce IFNγ and TNF as cells from PBMCs of healthy donors. 
This applied to all patient groups with blood cancer, although the frequency of MAIT 
cells revealed significantly lower proportion of IL-4+ (in patients with MM or NHL in 
patient PBMCs) and IFNγ or TNF cells (in patients with MM) than seen in healthy donors. 
Surprisingly, responses from non MAIT T cells from patient groups were more varied 
than those of MAIT cells, although it is unclear if this is a specific deficiency. 
 
4.1.8. Cytokine production by MAIT cell subsets in blood cancers 
We next compared IFNγ, TNF and IL-4 responses of CD8+ and CD8- subsets of 
CD161+Vα7.2TCR+CD3+ T (MAIT) cells from PBMCs and bone marrow (BM) of 
patients with blood cancers. Subsets were compared to each other and to subsets from 
healthy donors.  
 
I. Cytokine response of in vitro stimulated MAIT cell subsets in patient PBMCs  
IFNγ producing CD8+ MAIT cells in patient PBMCs showed significantly higher 
frequency than CD8- subset in patients with MM or ‘other’ blood cancers (e.g. 19.6% ± 5 
in CD8+ subset cf 8.3% ± 2.8 in CD8- subset for MM), while PBMCs of patients with 
NHL had statistically similar responses from MAIT cell subsets (Figure 39 A). This was 
interesting because the cytokine responses of CD8+ and CD8- MAIT cell subsets from 
healthy donors showed no significant. We found a greater frequency of CD8+ MAIT cells 
from patients with ‘other’ blood cancers expressing TNF than CD8- MAIT cells (33.6% ± 
4.5 cf 11.6% ± 2.8), while NHL or MM patient groups had comparable TNF expression 
from the CD8+ and CD8- subsets when stimulated (40.1% ± 9.6 in CD8+ subset cf 
28.4% ± 6.7 in CD8- subset for NHL; 21.5% ± 4.7 cf 11.6% ± 2.8 for MM) (Figure 39 B). 
IL-4 expression was similar for both MAIT cell subsets in patients with MM or ‘other’ 
blood cancers, although technical limitations (e.g., low cell numbers or frequency in 
samples) prevented analysis of some other groups (Figure 39 C). As we observed in 
patients with solid cancers, CD8+ MAIT cells from PBMCs in certain patient groups 
appear to have increased IFNγ and TNF responses, but the subsets were equally capable 
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of producing IL-4. This differed from what was seen in healthy donors so further 
investigation is required to determine the basis for this observation.    
                       
Figure 39. The frequency of cytokine producing MAIT cell subsets from patients with 
blood cancers. CD8+ and CD8- MAIT cell subsets from PBMCs (blood) and bone 
marrow of patients with blood cancer, and blood of healthy donors (Ctrl), were assessed 
for expression of IFNγ (A), TNF (B) and IL-4 (C) after stimulation using PMA and 
ionomycin for 6h with GolgiPlug. 0.1% includes <0.1%. Each symbol represents one 
patient sample. Mann-Whitney test was conducted to test statistical significance 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
II. Comparing cytokine responses of stimulated MAIT cell subsets from PBMCs of 
patients and healthy donors 
i. MAIT cell subsets. We identified no significant difference in the frequency of cytokine 
expressing CD8+ MAIT cells from PBMCs of patients and healthy donors (Figure 47). 
These findings indicate that CD8+ MAIT cells from patient PBMCs have a comparable 
capacity to produce cytokines as MAIT cells from healthy donors.  
In contrast, the frequency of cytokine expressing CD8- MAIT cells was different 
between patients and healthy donors. For example, while there was no significant 
difference in the frequency of IFNγ+ or TNF+ CD8- MAIT cells between PBMCs of 
patients with NHL and healthy donors (19% ± 6.7 cf 20% ± 4.5 for IFNγ; 28.4% ± 6.7 cf 
28.3% ± 5.2 for TNF) (Figure 40 C, G, K), CD8- MAIT cells from patients with MM 
showed a significantly reduced frequency of IFNγ+ or TNF+ CD8- MAIT cells and 
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reflected the deficiency observed for IFNγ+ or TNF+ MAIT cells (8.3% ± 2.8 cf 20% ± 
4.5 for IFNγ expression; 11.6% ± 2.8 cf 28.3% ± 5.2 for TNF expression; 0.7% ± 0.6 cf 
0.27% ± 0.13 for IL-4 expression) (Figure 40 C, G, K). Given that no significant 
difference was found for CD8+ MAIT cells, functional capacity of IFNγ+ or TNF+ CD8- 
MAIT cells could be specifically impacted in PBMCs of patients with MM. The 
frequency of IFNγ+ or IL-4+ CD8- MAIT cells from PBMCs of patients with ‘other’ 
blood cancers was comparable to PBMCs of healthy donors, but there were fewer TNF+ 
responding cells (17% ± 5.6 cf 20% ± 4.5 for IFNγ; 20.7% ± 6.3 cf 28.3% ± 5.2 for TNF; 
1.6% ± 0.9 cf 0.27% ± 0.13 for IL-4) (Figure 40 C, G, K). Our findings suggest that 
stimulated CD8- MAIT cells in patient PBMCs are variably impacted with reduced 
capacity to produce IFNγ or TNF while CD8+ MAIT cells response was similar across 
different patient groups and healthy donors. A lack of patient tissue samples with 
sufficient MAIT cells prevented detailed comparisons of IL-4 expression of MAIT cell 
subsets and require more patient tissue samples for better indication of functional capacity 
as certain patient groups showed very little IL-4 production compared to healthy donors. 
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Figure 40. The frequency of CD8+ and CD8- MAIT cells and MAIT-like T cell subsets 
producing IFNγ, TNF or IL-4 in patients with blood cancer. CD8+ and CD8- MAIT 
cells or MAIT-like (CD161-Vα7.2TCR+CD3+) T cell subsets from PBMCs (Bl) and bone 
marrow (BM) from patients with blood cancer were assayed for expression of IFNγ (A–
D), TNF (E–H) or IL-4 (I-L) after stimulation using PMA and ionomycin for 6h with 
GolgiPlug. Results were compared to healthy donors. Each symbol represents one patient 
sample. 0.1% includes <0.1%. Statistical significance was determined by Mann–Whitney 
analysis (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non MAIT T cell subsets. Like CD8+ MAIT cells in patient PBMCs, the frequency of 
activated CD8+ CD161-Vα7.2TCR+CD3+ T (MAIT-like T) cells producing IFNγ, TNF 
or IL-4 was statistically similar between PBMCs of patients and healthy donors (Figure 
40). One exception was patients with ‘other’ blood cancers, where there were a higher 
proportion of IFNγ+ cells compared to PBMCs of healthy donors (38% ± 4.1 cf 28.6% ± 
2.9) (Figure 40 B). These findings indicate that CD8+ MAIT cells and CD8+ MAIT-like 
T cells have similar cytokine responses in patients and healthy donors. 
For CD8- MAIT-like T cells, NHL and ‘other’ blood cancer patient groups 
showed no significant differences for IFNγ, TNF and IL-4 responses to healthy donors, 
but some responses were lower for PBMCs of patients with MM, much like CD8- MAIT 
cells (9.1% ± 1.8 cf 24.3% ± 5.8 for IFNγ; 16.1% ± 3.2 cf 27.7% ±41 in TNF) (Figure 40).  
 
III.  Patient BM derived MAIT cell subsets stimulated in vitro  
In patient PBMCs, we found that CD8+ MAIT cells in some patient groups producing 
more IFNγ or TNF than CD8- MAIT cells. In patient bone marrow (BM) there was no 
difference (Figure 46). An exception was BM from patients with ‘other’ blood cancers, 
where CD8+ MAIT cells had higher IFNγ expression (Figure 39 A).  
 
IV. Cytokine response of MAIT cell subsets from patient BM and healthy PBMCs  
i. MAIT cell subsets. A similar proportion of CD8+ MAIT cells from patient BM and 
healthy PBMCs expressed cytokines after stimulation with PMA and ionomycin (IFNγ; 
mean ranged between 16.2% and 35.7% in patient BM cf 27.4% in healthy PBMCs; TNF; 
18.3% - 36.5% cf 31.5%; IL-4; 0.1% - 1.7% cf 1.2%.) (Figure 40 A, E, I). Results from 
CD8- MAIT cells were less predictable, with the IFNγ response of CD8- MAIT cells 
similar in BM of patients with MM and PBMCs from healthy donors (20.3% ± 5.7 cf 20% 
  
132 
± 4.5), but BM from patients with ‘other’ blood cancers having a lower frequency of 
IFNγ+ cells than PBMCs of healthy donors (5.3% ± 1.2 cf 20% ± 4.5) (Figure 40 C). For 
TNF, CD8- MAIT cells in patients with MM or ‘other’ blood cancers had a lower 
response than PBMCs of healthy donors (18.2% ± 5.7 or 6.5% ± 0.88 cf 28.3% ± 5.3) 
(Figure 40). The results suggest that cytokine expression by CD8+ MAIT cells is similar 
in patients and healthy donors, but the CD8- subset may be deficient in patients for 
production of IFNγ or TNF. Both subsets showed very little IL-4 production. 
 
ii. Non MAIT T cell subsets. Most MAIT-like T cell subsets in BM of different patient 
groups showed similar cytokine responses to PBMCs of healthy donors (Figure 40). One 
exception was a lower frequency of TNF+CD8- MAIT-like T cells from BM of patients 
with MM than in PBMCs of healthy donors (12.8% ± 3.7 cf 27.7% ± 4.2) (Figure 40 H). 
Taken together MAIT-like T cell subsets in BM of patients with blood cancers are mostly 
not impacted for their cytokine production compared to MAIT cell subsets. 
 
V. Comparing MAIT cells from PBMCs and BM derived cells of same patient group  
i. MAIT cell subsets. We found no significant difference in cytokine expression for CD8+ 
and CD8- activated MAIT cell subsets from BM and PBMCs of most patient groups (e.g. 
CD8+ MAIT cells in patients with NHL; 36.9% ± 9.6 in patient PBMCs cf 35.7% ± 16.4 
in patient BM for IFNγ; 40.1% ± 9.6 cf 36.5% ± 15.8 TNF; 0.1% cf 0.1% for IL-4. See 
Figure 40 for full comparisons including CD8- MAIT cells).  
 
ii. Non MAIT T cell subsets.  There were similar cytokine responses from CD8+ and 
CD8- MAIT-like T cells from PBMCs and BM of patient groups (Figure 40). The only 
exception was a significantly higher frequency of TNF+ cells for CD8+ MAIT-like T 
cells in PBMCs of patients with MM compared to patient group matched BM (38% ± 3.7 
cf 20.9% ± 5.2) (Figure 40). 
Overall, most patient groups showed similar cytokine responses by CD8+ and 
CD8- subsets of MAIT cells and MAIT-like T cell populations in blood and BM.  
 
4.1.9. Summary 
We compared IFNγ and TNF responses of CD8+ and CD8- MAIT cells from PBMCs and 
BM of different patient groups after stimulation and found that CD8+ MAIT cells have a 
higher proportion of IFNγ and TNF expressing cells than the CD8- subset in PBMCs. 
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This is worthy of further investigation as these cytokines are associated with anti-tumour 
activity. No difference was found for IL-4 production among stimulated MAIT cell 
subsets. 
We showed that stimulated CD8+ MAIT cell subsets from PBMCs or BM of 
patients mostly had similar cytokine responses to PBMCs of healthy donors, indicating 
that this function is preserved. However, comparisons of CD8- MAIT cells were more 
variable but often seemed to reflect the activities of broader T cell populations such as 
CD8- MAIT-like T cells. MAIT cells from PBMCs and BM derived cells of the same 
patient group had similar IFNγ, TNF and IL-4 responses, suggesting these are not 
affected by interactions with the tumour microenvironment. 
 
4.1.10.  Cytokines released by stimulated MAIT cells 
We focused our flow cytometry analysis of MAIT cell cytokine responses on IFNγ, TNF 
and IL-4 because of their importance in anti-tumour immunity. It was not possible to 
routinely assess other cytokines due to the low cell numbers and the limited number of 
channels available in flow cytometry cocktails, but we selectively assayed culture 
supernatants for these and other cytokines in samples where it was possible to sort 
sufficient MAIT cells. The objective was to identify a broader range of secreted cytokines 
and to determine whether the cytokine expression we detected in cells by flow cytometry 
translated to levels of secreted cytokines that would likely impact the function of other 
cells. To measure cytokines, we collected supernatant from cell cultures of sorted MAIT 
(CD161+Vα7.2TCR+CD3+ T) cells stimulated with PMA and ionomycin for 12 hours. 
We measured the concentration of IFNγ, TNF, IL-17, IL-13 or IL-4 in cultures of cells 
from patient PBMCs or TILs using a cytometric bead array and compared this to 
responses by cells from PBMCs of healthy donors (Figure 41). Due to large differences in 
the number of sorted MAIT cells from different patient samples, it was not possible to 
directly compare the concentration of cytokines release by MAIT cells between different 
samples including patient PBMCs or TILs. Instead, we identified and compared the types 
of cytokines released by MAIT cells and their relative concentrations within each sample.  
TNF and IFNγ was produced in highest concentration by stimulated MAIT cells 
across all patient groups (Figure 41) and IL-17, IL-13 and IL-4 was produced in small, 
but detectable amounts, although the relative levels for these varied. In cultures of MAIT 
cells from patient PBMCs, IL-4 was present at higher concentration than IL-13, but IL-17 
was largely undetectable. This was similar to MAIT cells from PBMCs of healthy donors. 
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MAIT cells from patient TILs also showed low expression of IL-4 and IL-13, but IL-17 
was barely detectable. One (of 3) TIL samples had far higher levels of IL-13 and IL-4 
than other samples, which may suggest that MAIT cells in patient TILs could have a 
different functional capacity due to the tumour cells even though intracellular cytokine 
expression measured with low n number appeared to not show high expression for these 
cytokines (data not shown for intracellular expression of IL-13). This may perhaps 
suggest that prolonged activation of MAIT cells may have altered their functional 
capacity. Nevertheless, further studies with larger sample numbers are required to more 
fully understand their potential functional roles and their impact on surrounding immune 
cells or cancer cells. When combined with flow cytometry data, it was clear that MAIT 
cells were high producers of IFN and TNF, with low but variable expression of IL-4 and 
IL-13, with marginal IL-17.  
  
Figure 41. Cytokines released by sorted MAIT cells after stimulation. MAIT cells were 
sorted from blood of healthy donors, or blood and tumours from patients with colorectal 
cancer and stimulated with PMA and ionomycin for 12 h. Supernatants were analysed for 
cytokines using a cytometric bead array kit (BD Biosciences). The maximum available 
number of cells sorted from patient samples were used so results are not directly 
comparable for concentration. Each different colour represents an independent sample, 
but the same colour in different tissue samples is not the same patient tissue sample 
source. Concentration of supernatants were calculated based on positive controls for 
each cytokine according to the instructions from BD Biosciences using FCAP Array 
software (BD Biosciences). 0.1 pg/ml includes <0.1 pg/ml. 
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4.1.11. Summary 
Due to low cell number, we were not able to do duplicates or triplicates as the numbers of 
sorted cells ranged from 300 to 4000. However, we showed that MAIT cells in patients 
with solid cancer release IFNγ or TNF after stimulation and low concentrations of IL-4, 
IL-13 or IL-17, although IL-17 may require a more specific form of stimulation for more 
stringent analysis of functional capacity. Analysis of supernatants closely matched flow 
cytometry data from MAIT cells for patient tissue samples and healthy donors. 
 
4.2. Functional capacity of NKT cells in cancer patients 
NKT cell abnormalities previously reported in patients with cancer include reduced 
frequency and capacity to produce IFNγ upon stimulation 160,163,211. However, most 
findings have only considered PBMC-derived cells and not tumour infiltrating 
lymphocytes (TILs) or bone marrow (BM), where the role or functioning of NKT cells 
might be affected by direct contact with tumour cells. Despite promising results from 
animal models, therapeutic trials that manipulate NKT cells as an immune-based therapy 
against cancer have mostly yielded poor results 168,172,230,231, perhaps partly due to a lack 
of understanding about how NKT cells usually function in patients with cancer. Therefore, 
in our study, we analysed NKT cells from PBMCs and TILs of patients with cancer to 
investigate their capacity to produce cytokines. We compared NKT cells to other immune 
cells from patients and healthy donors to determine the functional competency of these 
cells.  
In Chapter 3, we identified a deficiency in the frequency of NKT cells in patients 
with cancer. We were now interested in how NKT cells function in patients with cancer, 
particularly in tumours, as this had not been studied in many patient groups. The very low 
frequency of NKT cells in many of these patient groups meant we could not conduct 
functional analysis in all groups or for all patients. We stimulated NKT cells with PMA 
and ionomycin and compared the cytokine production of NKT cells from PBMCs of 
patients and healthy donors, and between PBMCs and TILs of patients.  
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Figure 42. Representative flow cytometry plots of functional capacities of NKT cells 
from cancer patients. (A) NKT cells were isolated from PBMCs and TILs from patients 
with cancer and PBMCs of healthy donors were stimulated for 6 h with PMA and 
ionomycin in the presence of GolgiPlug then analysed for expression of IFNγ, TNF and 
IL-4 (D-F). NKT cell subsets defined by CD4 and CD8 or CD161 were also studied (B-C). 
The frequency of cytokine positive NKT cells were also measured (G-I). Low cell number 
restricted sorting of NKT cells in large number and florescense minus one (FMO) was not 
feasible. 
 
4.2.1. Cytokine response by NKT cells from patients with solid cancers 
Sorted NKT cells from PBMCs or TILs of patients with solid cancer and PBMCs from 
healthy donors were stimulated with PMA and ionomycin in the presence of GolgiPlug 
for 6 h before analysing for intracellular cytokine expression. The NKT cell deficiency 
we reported in Chapter 3 meant only low numbers of cells from PBMCs or TILs were 
available for functional analysis so collective data is presented as a ‘solid’ cancer group 
rather than having separate patient groups for different forms of cancer and there were 
insufficient cells to investigate NKT cells from patients with blood cancers. We assayed 
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cytokine production by T cells in case changes within the NKT cell pool were reflecting 
wider trends that affected all T cells. 
We first asked whether sorted NKT cells from patient PBMCs were spontaneously 
producing cytokines without in vitro stimulation. We reasoned that NKT cells could be 
actively participating in an anti-tumour immune response, however, our results showed 
almost no intracellular cytokine expression in NKT cells from either group (Figure 42 G-
I). This suggests that NKT cells are not responding to cancer cells in patient tissue 
samples. It is possible that cytokine production was not detectable after many hours ex 
vivo, but we believe the earlier hypothesis is more likely given the frequency of CD25+ 
(activated) NKT cells in patient PBMCs or TILs was not significantly higher than in 
PBMCs of healthy donors. 
 
I. The cytokine response of NKT cells from PBMCs of patients with solid cancers  
i. NKT cells. NKT cells from PBMCs of patients with solid cancer had a significantly 
higher frequency of IFNγ+ or TNF+ activated NKT cells than PBMCs of healthy donors 
(51.6% ± 6.7 cf 15.3% ± 4.7 in IFNγ or 73% ± 6.9 cf 22.2% ± 7.5 in TNF) (Figure 43 A-
C).   
This suggests that the functional capacity of activated NKT cells in PBMCs of 
patients with solid cancer is intact (i.e. not deficient as in some other reports 160,163) and 
perhaps more potent (at least for production of TNF and IFNγ) compared to PBMCs of 
healthy donors. In contrast, there was no significant difference between PBMCs of 
patients and healthy donors in expression of IL-4 by activated NKT cells in patient 
PBMCs. Interestingly, however, the IL-4 production appeared to be trending higher in 
patients PBMCs, suggesting that further investigation with larger sample numbers may be 
useful (1.6% ± 1 cf 0.31% ± 0.15) (Figure 43 C). 
 
Figure 43. The frequency of NKT cells producing IFNγ, TNF or IL-4 in solid cancer. 
The frequency of cells producing IFNγ (A), TNF (B) or IL-4 (C) was measured for NKT 
cells sorted from PBMCs of healthy individuals and from PBMCs and TIL samples of 
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patients with solid cancer cells. Cells were stimulated using PMA and ionomycin for 6h 
with GolgiPlug. Each dot represents one sample. 0.1% includes <0.1%. Statistical 
significance was determined by Mann–Whitney analysis (P<0.05*/ P<0.01**/ 
P<0.001***/ P<0.0001****). 
 
ii. Non NKT T cells. T cells from PBMCs or TILs of patients and PBMCs of healthy 
donors also showed no intracellular cytokine expression without stimulation (data not 
shown). Blood-derived T cells of patients with colorectal cancer unexpectedly expressed 
higher IFNγ, TNF and IL-4 than T cells from healthy donors when stimulated with PMA 
and ionomycin (44% ± 5.7 cf 16% ± 2.7 for IFNγ expression, 55.7% ± 5.7 cf 31.3% ± 6 
for TNF expression; 5.9% ± 3.2 cf 0.69% ± 0.25 for IL-4 expression) (Figure 44 A-C). 
Other patient groups did not show significant differences, although the mean values were 
generally higher than healthy controls. This was especially the case for IFNγ expression, 
perhaps indicating the need for further studies with increased group sizes (IFNγ+ T cells; 
range 27.9% - 28.1% cf 16%; TNF+ T cells; ranged 31.1% - 36.7% cf 27.2%; IL-4+ T 
cells ranged between 0.6% - 0.54% cf 0.7%) (Figure 44 A-C).  
 
Figure 44. The frequency of IFNγ, TNF and IL-4 expressing T cells isolated from 
blood and tumours of patients with solid cancer. The frequency of IFNγ (A), TNF (B) or 
IL-4 (C) producing T cells was measured after cells were sorted from PBMCs (Bl) or 
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TILs (Tu) of patients with solid cancer and PBMCs of healthy individuals (Ctrl) and 
stimulated using PMA and ionomycin for 6h with GolgiPlug. Each symbol represents one 
sample. 0.1% includes <0.1% for IFNγ (A) or TNF (B) while 0.01% includes <0.01% for 
IL-4 (C) expression. Mann-Whitney test was conducted to determine statistical 
significance (P<0.05* / P<0.01**/ P<0.001***/ P<0.0001****).  
 
II. The cytokine response of activated NKT cells from patient TILs  
i. NKT cells. Due to low frequency of NKT cells in TILs, we could only assay NKT cell 
cytokine responses from two tumour samples. This prevented statistically significant 
results, although strong responses were observed (Figure 43 A-C). The cytokine response 
from stimulated tumour NKT cells was similar to that of blood derived cells and both 
were significantly higher than NKT cells from PBMCs of healthy donors. Overall, these 
results indicate that cytokine production by NKT cells is intact within the tumour 
microenvironment, although more studies are required to compare the responses of cells 
from patients and healthy donors. 
 
ii. Non NKT T cells. T cells from patient TILs and PBMCs of healthy donors had similar 
responses. The only exception was the proportion of IFNγ+/TNF+ T cells in TILs of 
patients with colorectal cancer, which was significantly higher than in PBMCs of healthy 
donors (28.5% ± 4.7 cf 16% ± 2.7 in IFNγ and 55.7% ± 5.7 cf 27.1% ± 2.5 for TNF) 
(Figure 44 A-B), although it should be highlighted that the results trended higher in 
patient groups such as lung and ‘other’ solid cancers without reaching significance (IFNγ 
21.5% - 26% cf 16%; TNF 31.1% - 31.9% cf 27.2 (Figure 44 A-C).  
 
III. Cytokine responses of TILs and PBMCs of patients 
i. NKT cells. Low sample numbers and cell frequency did not provide the statistical 
power to directly compare cytokine production by NKT cells from patient PBMCs and 
TILs, but IFNγ, TNF or IL-4 production appeared similar for cells from these tissues 
(IFNγ; 51.6% ± 6.7 in PBMCs cf 62.5% ± 13.7 in PBMCs; TNF expression; 68.1% ± 6.3 
in PBMCs cf 81% ± 6.8 in TILs; IL-4 expression; 1.59% ± 1 in PBMCs cf 11% ± 8.8 in 
TILs) (Figure 43 A-C). Interestingly, IL-4 expression trended higher in TILs than in 
patient PBMCs (Figure 43 C).  
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ii. Non NKT T cells. We found no significant difference in T cell responses between 
patient group matched TILs and PBMCs. One exception was patient group matched 
colorectal cancer tissue samples, which had a significantly higher frequency of IFNγ+/ 
TNF+ T cells in PBMCs compared to TILs (44% ± 5.8 cf 28.5% ± 4.8 for IFNγ 
expression; 55.7% ± 5.7 cf 39.6% ± 6.5 for TNF expression) (Figure 44 A-C). Taken 
together, our findings indicate that capacity for activated NKT cells to express IFNγ, TNF 
or IL-4 appears intact and were mostly normal in TILs and PBMCs of patients with 
cancer. 
 
4.2.2. Summary 
In contrast to some earlier reports of functional defects, NKT cells from patient PBMCs 
were capable of IFNγ and TNF expression in response to stimulation that was similar to 
those form healthy donors.  
We had insufficient samples to definitively compare cytokine production from 
NKT cells in TILs, but we demonstrated that NKT cells in patient TILs could mount 
cytokine responses and appeared to have similar IFNγ, TNF and IL-4 expression after 
stimulation as those of NKT cells from healthy donors.  
Stimulated T cells from PBMCs or TILs of patients with colorectal cancer had 
significantly higher expression of IFNγ or TNF but normal in patients with lung cancer 
and ‘other’ solid cancers, indicating that cytokine responses by NKT cells in these 
patients may have reflected a broader impact on the T cell pool. IL-4 expression by 
activated T cells from PBMCs or TILs was similar to that of cells from healthy donors, 
although it trended higher like NKT cells.  
 
4.2.3. Cytokine response of CD161+ NKT cells from patients with solid cancers 
Innate immune cells and some T cells often express CD161, including NKT cells. In this 
section, the functional capacity of CD161+ NKT cells from patients with solid cancers to 
produce cytokines in response to stimulation was investigated. 
 
I. The frequency of cytokine positive CD161+ NKT cells from PBMCs of patients 
with solid cancers after stimulation 
i. NKT cell subset. There was no significant difference in the frequency of cytokine 
positive CD161+ NKT cells after stimulation between PBMCs from patients with solid 
cancer and healthy individuals (53.2% ± 7.9 cf 27.9% ± 7.3 for IFNγ expression; 62.1% ± 
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6.8 cf 38.7% ± 9.8 for TNF expression; 3.6% ± 2.4 cf 0.58% ± 0.37 for IL-4 expression) 
(Figure 45 A-C). These preliminary data provide some evidence that there may be an 
increased response by CD161+ NKT cells from patients, although further studies are 
required to test this. 
 
ii. Non NKT T cell subset. CD161+ T cells in PBMCs of patient group had a similar IFNγ 
response to CD161+ T cells from healthy PBMCs. An exception was CD161+ T cells 
from patients with ‘other’ blood cancers, which had a significantly lower proportion of 
IFNγ+ CD161+ T cells (22.6% ± 3.8 cf 43.72% ± 5.7) (Figure 34 A). Virtually all patient 
groups had similar levels of TNF+ CD161+ T cells after stimulation, although it was 
higher in cells from patients with colorectal cancer (78.4% ± 3.2 cf 49.3% ± 6.6) (Figure 
34 B). It will be useful to investigate whether CD161+ T cells from patient PBMCs have 
an increased capacity to produce IL-4 because the frequency of IL-4+ CD161+ T cells 
was consistently higher for patient PBMCs than PBMCs of healthy donors (mean ranged 
between 1.1% to 9.7% cf 0.1%) (Figure 34 C).  
 
II. Comparing cytokine responses of NKT cells from patient TILs and PBMCs of 
healthy donors 
i. NKT cell subset. Due to low numbers of suitable patient tumours, no statistically 
significant comparisons could be carried out for CD161+ NKT cells between patient TILs 
and PBMCs in healthy donors, but we were able to confirm cytokine production by those 
cells and noted intriguing, non-significant increases in IFNγ+, TNF+ or IL-4+ CD161+ 
NKT cells isolated from patient TILs compared to PBMCs of healthy donors (58.8% ± 
13.2 cf 27.9% ± 7.3 for IFNγ expression; 69.6% ± 2.5 cf 38.7% ± 9.8 for TNF expression; 
22.3% ± 15.3 cf 0.5% ± 0.37 for IL-4 expression) (Figure 45 A-C).  
 
ii. Non NKT T cell subsets. The cytokine responses of CD161+ T cells were similar for 
patient TILs and PBMCs from healthy donors for all patient groups (Figure 34 A-B). IL-4 
results were more variable. Our findings suggest that CD161+ NKT cells and CD161+ T 
cells from patient TILs are competent in their capacity to produce IFNγ and TNF.  
 
III. A comparison between patient TILs and PBMCs  
i. NKT cell subset. The raw frequency of cytokine positive CD161+ NKT cells was 
higher for patient TILs than patient PBMCs, suggesting tissue specific changes to 
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function but further study is required as low numbers of patient tumour samples 
prevented an assessment of statistical significance (Figure 45 A-B).  
 
Figure 45. Cytokine production by CD161+ NKT cells from patients with solid tumours. 
CD161+ NKT cells from PBMCs and TILs of patients and PBMCs of healthy individuals 
(Ctrl) were stimulated with PMA and ionomycin for 6 h with GolgiPlug then assayed for 
expression of IFNγ (A), TNF (B) and IL-4. Each symbol represents one sample. 0.1% 
includes <0.1%. Statistical significance determined by Mann–Whitney analysis (P<0.05* 
/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non NKT cell subset. The proportions of cytokine positive CD161+ T cells was 
statistically similar for patient PBMCs and TILs for expression of IFNγ, TNF and IL-4 
after stimulation (Figure 34 A-C).  
 
4.2.4. Summary 
The expression of IFNγ, TNF and IL-4 by activated CD161+ NKT cells from PBMCs of 
patients with solid cancer was statistically similar to that of CD161+ NKT cells from 
PBMCs of healthy donors.  We could only conduct a low powered study of cells from 
patient TILs but confirmed they could produce cytokines in what appeared to be similar 
responses as cells from healthy donors. This suggests that proximity to the tumour cells is 
not affecting local cytokine production, although it was interesting that CD161+ NKT 
cells from patient PBMCs and TILs mostly trended higher for cytokine production than 
PBMCs of healthy donors. This was not statistically significant but suggests further study 
may be worthwhile to increase the statistical power. 
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4.2.5. The cytokine response to stimulation of CD4+ and DN NKT cell subsets from 
patients with solid cancers  
 
NKT cell subsets include CD4+CD8- (CD4+) and CD4-CD8- (DN) cells, which are 
functionally distinct. In this section, the capacity of these cells to produce IFNγ or TNF in 
responses to stimulation was measured using sorted NKT cells from patients with solid 
cancers. Due to low frequency, CD8+ NKT cells were not separately studied. CD4+, DN 
or CD8+ T cells were assayed for comparison. 
 
I. PBMCs from patients with solid cancer and healthy donors  
i. NKT cell subsets. The frequency of CD4+ NKT cells from PBMCs of patients with 
solid cancer that were producing IFNγ or TNF after stimulation was statistically similar to 
NKT cells from healthy donors, even though large differences in mean values were 
observed (52.4% ± 7.7 cf 27.4% ± 7.2 for IFNγ expression; 56.2% ± 4.6 cf 32.2% ±9.6 for 
TNF expression) (Figure 46 A, C). Despite the variability in the data (perhaps 
contributing to a lack of significance), we can conclude that CD4+ NKT cells are 
functionally competent for production of IFNγ and TNF, but more patient samples are 
required to test for differences in the extent of the response. Surprisingly, the frequency of 
DN NKT cells that were IFNγ+ or TNF+ after stimulation was significantly higher in 
PBMCs of patients than in healthy donors (48.6% ± 9.2 cf 21% ± 4.4 for IFNγ or 71.2% ± 
6.7 cf 31.3% ± 8.8 for TNF) (Figure 46 B, D). DN NKT cells are regarded as promoting 
anti-tumour responses so an increased response could be beneficial and is worthy of 
further investigation. 
 
ii. Non NKT T cell subsets. There was no significant difference in the proportion of 
CD4+ or DN (non-NKT) T cells producing IFNγ or TNF between PBMCs of patients and 
healthy donors. An exception was T cells from PBMCs of patients with colorectal cancer, 
which had significantly higher expression of IFNγ or TNF (in CD4+ subset; 29.8% ± 5.5 
cf 12.6% ± 2 for IFNγ expression; 49.6% ± 6.4 cf 23.1% ± 2.4 for TNF expression; in DN 
subset; 36.7% ± 5.5 cf 14.7% ± 1.9 for IFNγ expression; 48.2% ± 6.2 cf 25.7% ± 2.8 for 
TNF expression) (Figure 47 A-F). These findings suggest that the increased cytokine 
production by CD4-CD8- NKT cells from patient PBMCs could be related to events in 
the overall T cells compartment, but further studies are required. 
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Figure 46. The frequency of CD4+ and CD4-CD8- NKT cell subsets producing IFNγ 
and TNF in solid cancer after activation. Stimulated NKT cell subsets from PBMCs and 
TILs of patients with solid cancer, and PBMCs of healthy individuals (Ctrl) were assayed 
for IFNγ (A-B) and TNF (C-D). Sorted subsets were stimulated using PMA and ionomycin 
for 6 h with GolgiPlug. Each symbol represents one sample. Statistical significance was 
determined by Mann–Whitney analysis (P<0.05* / P<0.01**/ P<0.001***/ 
P<0.0001****). 
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Figure 47. The frequency of cytokine positive T cell subsets defined by CD4 and CD8 
from patients with solid cancer. T cell subsets were identified among sorted T cells from 
patient PBMCs (Bl) and TILs (Tu) or PBMCs from healthy donors (Ctrl) and assayed for 
IFNγ (A, C, E) and TNF (B, D, F) after stimulation with PMA and ionomycin for 6 h with 
GolgiPlug. Each symbol represents one sample. Mann-Whitney test was conducted to 
determine statistical significance (P<0.05* / P<0.01**/ P<0.001***/ P<0.0001****). 
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II. Cytokine responses of NKT cell subsets from patient TILs and PBMCs of healthy 
donors  
i. NKT cell subsets. We were unable to definitively compare NKT cell subsets of patient 
TILs to healthy donors, but did establish that CD4+ and DN NKT cells from patient TILs 
could produce IFNγ and TNF at levels that appear similar or higher to those of healthy 
donors (Figure 46 A-D). 
 
ii. Non NKT T cell subsets. The cytokine responses were also similar for T cell subsets 
from patient TILs and PBMCs of healthy donors (Figure 47). Therefore, we have 
established that IFNγ and TNF responses of NKT cell subsets and corresponding T cell 
subsets following in vitro stimulation was not fully defective in these patient groups.  
 
III. Comparing cytokine responses between patient TILs and PBMCs  
i NKT cell subsets. There were insufficient tumour samples to definitively compare 
cytokine responses of NKT cell subsets from patient TILs and PBMCs of patients with 
solid cancer, but we again confirmed cytokine expression after stimulation by both groups 
(Figure 46 A-D). Once again, this confirms the potential of NKT cells from TILs to 
mount a cytokine response, however, we also observed that TNF+ DN NKT cell subsets 
in patient TILs trended higher than from patient PBMCs (82.4% ± 3.3 cf 48.6% ± 9.2) 
(Figure 46 B). Therefore, a further investigation may be required to determine if the 
magnitude of the response differs between NKT cells from patient PMBCs and TILs.  
 
ii Non NKT T cell subsets. The frequency of cytokine positive CD4+ or DN T cells was 
similar between patient PBMCs and TILs of most patient groups (Figure 47 A-F). 
However, there were exceptions, including the significantly higher frequency of IFNγ+ 
and TNF+ CD8+ T cells in PBMCs of patients with colorectal cancer compared to patient 
group matched TILs (IFNγ; 61.6% ± 6.3 cf 42.2% ± 6 TNF expression; 70.4% ± 5.6 cf 
40.4% ± 6.4) (Figure 47). We cannot exclude the possibility that cytokine responses by 
NKT cell subsets differed between patient tissue samples, but this does not appear to be a 
characteristic of broader T cell populations. 
 
4.2.6. Summary 
Previous studies have established that CD4+ and DN NKT cells from healthy donors 
produce IFNγ or TNF 45,157 and our data confirms that NKT cell subsets in patient 
  
147 
PBMCs and tumours have maintained this capacity and in some instances, may even have 
elevated expression of cytokines compared to healthy donors. While we could not 
definitively quantify the cytokine response of NKT cells from patient TILs due to lack of 
patient tissue samples, we noted that NKT cells in TILs often trended higher than patient 
PBMCs derived NKT cells. More studies would be needed to fully characterize the 
functional capacity of NKT cells in different patient groups, but our findings clarify 
conflicting studies about whether NKT cells in patients with cancer are functionally 
defective in patients with cancer. 
   
4.2.7. Analysis of cytokines in supernatants of stimulated NKT cells 
Having demonstrated that NKT cells from the blood and tumours of patients with cancer 
have the capacity to produce cytokines, we next sorted NKT cells and stimulated them 
with PMA and ionomycin for 12 h in cell culture and assayed supernatants to better 
define the cytokines released by NKT cells from patients with cancer (Figure 55). The 
low numbers of NKT cells prevented analysis of many patient groups and definitive per 
cell comparisons, but we confirmed production of cytokines and were able to compare the 
profile of cytokines released by activated NKT cells sorted from PBMCs and TILs of 
patients to PBMCs of healthy donors. In general, NKT cells from all samples, including 
healthy PBMCs, produced similar cytokine patterns. TNF and IFNγ were highly produced 
by stimulated NKT cells while IL-17, IL-13 and IL-4 were produced in lower 
concentrations that varied based on which sample was examined. For instance, in cells 
from PBMCs of healthy donors or TILs of patients, more IL-17 was produced more than 
IL-13 or IL-4. However, in patient PBMCs, IL-17, IL-13 and IL-4 showed similar 
concentration, suggesting that patient PBMCs may have a different cytokine pattern to 
NKT cells from healthy PBMCs or patient TILs. Our investigation was limited by low 
NKT cell numbers, due to the low frequency of NKT cells and because patients with 
cancer were deficient for these cells. It would be interesting to further investigate whether 
NKT cells from patient tissue samples are functioning differently in tumour 
microenvironments or to PBMCs of healthy donors.  
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Figure 48. Cytokine analysis of supernatants from stimulated NKT cells of patients 
with solid cancer. NKT cells were sorted from blood of healthy donors or blood and 
tumours from patients with melanoma (blood), lung cancer (blood) or breast (tumour) 
and stimulated with PMA and ionomycin. Note that different cell numbers were present in 
cultures so concentrations should not be directly compared between groups. Supernatants 
were collected after 12 h and analysed for cytokines using cytometric bead array kit (BD 
Biosciences) (pg/ml). Individual donors are identified with a different colour. The 
concentration of supernatants were calculated based on standards for each cytokine 
according to the instructions from BD Biosciences using FCAP Array software (BD 
Biosciences) 
. 
4.2.8. Summary 
The number of sorted NKT cells available for supernatant assays was 300-3000 cells and 
this restricted the statistical power of our analysis. However, we showed that NKT cells 
from patients with solid cancer unequivocally expressed IFNγ and TNF after stimulation 
along with low concentrations of IL-4, IL-13 and IL-17. The CBA analysis of cytokines 
in supernatant closely matched intracellular expression of cytokines in NKT cells from 
patient tissue samples and healthy donors.  
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4.3. Functional capacity of γδ T cells in cancer patients 
Previous clinical studies have indicated that γδ T cells from patients with cancer show 
reduced cytokine production and cytotoxic responses against cancer cells 232,233. This 
could be modulated by blocking different surface markers such as CD2, NKG2D (natural 
killer group 2 member D), DNAM-1 (DNAX accessory molecule -1) and ICAM-1 
(intracellular adhesion molecule -1), which was reported to reduce IFNγ productivity by 
stimulated γδ T cell 185. Clinical trials suggest that IFNγ production by γδ T cells could be 
restored by expanding γδ T cells in vitro before injecting them back into patients 73. Thus, 
administering stimulated γδ T cells can be well tolerated by patients with cancer and the 
clinical responses against cancer cells were promising, but therapeutic effectiveness 
varied 73,75,233. A limiting factor of these and other clinical trials involving γδ T cells is 
that the functional capacity of γδ T cells in patients with cancer is still not well defined. In 
other diseases and healthy individuals, subsets of γδ T cells produce cytokines such as IL-
17, IL-4, IFNγ and TNF upon stimulation 185,232,234,235. Many of these studies investigated 
blood but function of γδ T cells in tissues such as tumours and BM in patients with cancer 
is not well characterized 192,236,237. In Chapter 3, we established that γδ T cell frequency in 
patients with cancer was similar to that of healthy individuals, although in tumours, we 
observed a significantly higher frequency of activated (CD25+) γδ T cells, which could 
indicate functional involvement. In this section, we investigated the functional capacity of 
γδ T cells from patient blood and tumour samples to determine their ability to produce 
cytokines. 
In order to investigate cytokine responses, γδ T cells were sorted from patient 
tissue samples and stimulated with PMA and ionomycin for 6 h for intracellular 
expression and 12 h to quantify released cytokines in culture supernatants later in this 
section (Figure 49 A-C). Cytokine expression was then compared with healthy donors.  
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Figure 49. Representative plots of cytokine production by γδ T cells from cancer 
patients after stimulation. γδ T cells (A) were isolated from PBMCs and TILs from 
patients with cancer and stimulated for 6 h with PMA and ionomycin with GolgiPlug 
before measuring intracellular cytokine expression (B-C) by flow cytometry. Gated 
populations show cells expressing γδ TCR and CD3 (A), IFNγ (B) and TNF (C) 
respectively. The frequency of unstimulated, cytokine positive γδ T cells were also 
measured (E-F). 
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4.3.1. IFNγ and TNF responses of γδ T cells in patients with solid cancer 
In Chapter 3, we showed there were more activated (CD25+) γδ T cells in patient TILs 
than in PBMCs of healthy donors. We speculated that some γδ T cells from patient 
PBMCs or TILs may therefore express cytokines without additional in vitro stimulation, 
but cytokine staining did not support this (e.g., Figure 49 E-F). We therefore tested the 
ability of γδ T cells to respond to stimulation. 
 
I. The cytokine response of γδ T cells from PBMCs of patients with solid cancers 
i. γδ T cells. We found no significant difference between PBMCs of patients and healthy 
donors in the frequency of cytokine producing γδ T cells after stimulation with PMA and 
ionomycin for 6h with GolgiPlug. Our findings indicate that γδ T cells retain the ability to 
produce IFNγ and TNF in patients with solid cancers, although there is some basis for 
further studies with higher sample numbers as patient PBMCs mostly trended higher than 
cells from healthy donors (IFNγ; 26.8% ± 9.2 for patient PBMCs cf 13.6% ± 3.1 for 
healthy donor PBMCs; TNF; 39.1% ± 11.2 for patient cf 19.6% ± 4 for healthy PBMCs) 
(Figure 50 A-B). and that  
 
ii. Non γδ T cells. The cytokine response of CD3+ T cells after stimulation was the same 
for cells from PBMCs of patients and healthy donors, although the frequency of IFNγ+ T 
cells in PBMCs of patients trended higher, similar to what we observed for γδ T cells 
(IFNγ+ T cells; mean ranged between 27.9% to 28.1% for patient PBMCs cf 16% for 
healthy PBMC) (Figure 47 A-B). One exception was PBMCs of patients with colorectal 
cancer, which had significantly higher frequency of IFNγ+ or TNF+ T cells than for 
PBMCs of healthy donors (44% ± 5.7 cf 16% ± 2.7 in IFNγ, 55.7% ± 5.7 cf 31.3% ± 6 in 
TNF) (Figure 47 A-B). Taken together, the functional response of T cells was similar for 
patients with solid cancers and healthy donors, as was also seen for γδ T cells. 
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Figure 50. The frequency of γδ T cells from patients with colorectal cancer producing 
IFNγ and TNF after stimulation. The frequency of γδ T cells expressing IFNγ (A) or TNF 
(B) after stimulation was assayed using PBMCs or TILs of patients with solid cancer, or 
PBMCs from healthy individuals. Each symbol represents one sample. Statistical 
significance was determined by Mann–Whitney analysis (P<0.05* / P<0.01**/ 
P<0.001***/ P<0.0001****). 
 
II. The cytokine response of γδ T cells in TILs compared to PBMCs of healthy 
donors 
i. γδ T cells. The frequency of γδ T cells expressing intracellular IFNγ and TNF after 
stimulation with PMA and ionomycin for 6h with GolgiPlug was comparable for patient 
TILs and PBMCs of healthy donors (Figure 50 A-B). These findings indicate that 
functional capacity of γδ T cells to produce IFNγ and TNF in TILs of patients with solid 
cancer was preserved. 
 
ii. Non γδ T cells. As described earlier (Figure 44 A-B), the frequency of IFNγ+ and 
TNF+ T cells in TILs of patients was mostly similar, but an exception of the colorectal 
cancer group where expression was significantly higher for T cells from patients. (Figure 
44 A-B). Taken together, we showed that γδ T cells in patient TILs have comparable 
IFNγ and TNF responses to healthy PBMCs after stimulation with PMA and ionomycin. 
Furthermore, we showed that differences in the functional capacity of γδ T cells mostly 
reflected those seen in T cell populations, suggesting the cause was not specific.  
 
III.  Cytokine response of γδ T cells from TILs and PBMCs of patients 
i. γδ T cells. Having established that stimulated γδ T cells from patient PBMCs or TILs 
had similar IFNγ or TNF responses as PBMCs of healthy donors, we next directly 
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compared γδ T cells from patient PBMCs and TILs. We saw no significant difference 
between these groups for IFNγ or TNF responses upon stimulation. (IFNγ; 26.8% ± 9.2 
for patient PBMCs cf 12.6% ± 7 for patient TILs; TNF expression; 39.1% ± 11.2 for 
patient PBMCs cf 18.4% ± 7 for patient TILs) (Figure 57 A-B). PBMCs mostly trended 
higher than TILs, so we cannot exclude the possibility that a larger sample number may 
identify some significant differences.   
 
ii. Non γδ T cells. The frequency of stimulated T cells expressing IFNγ or TNF was the 
same for PBMCs and TILs in most patient groups, except for patients with colorectal 
cancer, where a significantly lower frequency of TILs were expressed cytokines (Figure 
51 A-B).   
 
4.3.2. Summary on IFNγ or TNF expression by activated γδ T cells from patients 
with solid cancers 
Collectively, our findings showed that γδ T cells (and T cells) from PBMCs or TILs of 
patients with solid cancer had similar IFNγ or TNF responses to PBMCs of healthy 
donors. Therefore, the functional capacity of γδ T cells to produce IFNγ or TNF does not 
appear to be defective in patients with solid cancer. There was no significant difference in 
the cytokine responses of γδ T cells from patient PBMCs and TILs after stimulation, 
although patient PBMCs trended higher than TILs. Interestingly this trend was seen 
across many patient groups, although was also seen for non- γδ T cell populations.  
 
4.3.3. Cytokines released by γδ T cells in cancer patients and healthy individuals 
In the previous section, γδ T cells from PBMCs or TILs of patients with solid cancer 
showed similar IFNγ+ or TNF+ cytokine responses to healthy donors. Here, we assayed 
supernatants from cultures of sorted γδ T cells to assess a broader range of cytokines over 
a longer culture time. γδ T cells were sorted from healthy individuals and patients with 
solid cancer and stimulated with PMA and ionomycin for 12 h. Due to large differences 
in the number of γδ T cells available from patient tissue samples and healthy PBMCs, we 
decided not to have identical cell numbers in different cultures in order to maximise the 
number of samples we could test. Instead, we focused on comparing the cytokine profiles 
of γδ T cells from patient tissue samples and PBMCs of healthy donors.  
IFNγ and TNF were the most highly produced cytokines for patient tissue samples 
and healthy donors, while low levels of IL-4, IL-17 and IL-13 were also detected (Figure 
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58). Patient TILs appeared to produce less TNF than IFNγ, which was distinct from 
PBMCs of patients and healthy donors, perhaps indicating a change caused by the tumour.  
Taken together, we showed that stimulated γδ T cells release cytokines into their 
surrounding microenvironment that mostly matched the flow cytometry data presented 
earlier in this chapter.  
 
 
Figure 51. Cytokines released by stimulated γδ T cells. γδ T cells were sorted from 
PBMCs or TILs from solid cancer patients, or from PBMCs of healthy donor, then 
stimulated in cell culture with PMA and ionomycin. Note that different cell numbers were 
present in cultures so concentrations cannot be directly compared between groups. For 
each patient tissue sample, a cytokine profile of γδ T cells was investigated and different 
colours were used to identify patient tissue samples (note that same colours in different 
tissue samples may not be from the same patient tissue sample source). Supernatant was 
collected after 12 h and analysed for cytokines (pg/ml). Each symbol represents one 
sample. Statistical significance was determined by Mann–Whitney analysis (P<0.05* / 
P<0.01**/ P<0.001***/ P<0.0001****). 
 
4.3.4. Summary 
In this section, we showed that γδ T cells from patient tissue samples and healthy donors 
had a similar cytokine response after stimulation for 12 h suggesting that their functional 
capacity is intact in patients with cancer. Follow up studies with greater statistical power 
may be useful to further investigate differences between groups. 
 
4.4. Discussion of Chapter 4 
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Several studies have identified defects in the functioning of innate-like T cells in patients 
with cancer, including a reduced capacity to produce cytokines in response to stimulation. 
IFNγ has been commonly impacted, which is significant because it is associated with 
inducing anti-cancer responses by various kinds of immune cells 68,160,238. Therefore, it 
was important for us to investigate the functional capacity of innate-like T cells in our 
wider study of patients with cancer because of their potential importance in regulating 
anti-cancer immunity and as potential targets for new therapies. Few studies have 
examined the function of MAIT cells in patients with cancer 68,69,197 and the functional 
capacity of other innate-like T cells has mostly been restricted to patient blood and have 
often only 73,143,160,239 assayed one kind of innate-like T cell 68,73,160. Here, we provide 
important information for understanding the functional capacity of innate-like T cells in 
patients across a range of different forms of cancer while examining three innate-like T 
cell populations concurrently. We focused on cytokine expression given its importance in 
the function of these cell types. 
 
I. MAIT Cells. Two previous studies assessed the cytokine profile of MAIT cells from 
PBMCs and TILs of patients with colorectal cancer and showed that PBMCs 69 or TILs 68 
have significantly reduced expression of IFNγ compared to healthy PBMCs or unaffected 
colon tissue samples. The findings suggest that MAIT cells may have reduced capacity to 
affect the anti-tumour response, although their involvement is poorly defined. In contrast, 
a separate study reported no significant difference in IFNγ+, TNF+ or IL-17+ MAIT cells 
between PBMCs of healthy donors and mucosal-associated cancer patients after 
stimulation, although patient TILs were not investigated 197. Few other reports have been 
conducted on MAIT cells from patient groups with other forms of cancer.  
In our study, we showed that stimulated MAIT cells from PBMCs and TILs of 
patient groups with colorectal cancer, lung cancer or ‘other’ solid cancers had similar 
IFNγ, TNF and IL-4 responses to each other and to MAIT cells from healthy donors, 
indicating their function was normal in these groups and apparently unaffected by the 
tumour microenvironment (Table 13-14). Separate analysis of individual patient groups 
with solid or blood cancers confirmed MAIT cell cytokine production in blood was 
similar to that in bone marrow or tumours of these patients and therefore no specific 
impact of the tumour microenvironment on MAIT cells was identified (Table 15-16). The 
intracellular cytokine profile was similar to a past study of intrahepatic MAIT cells 
stimulated in a MR-1 dependent manner, which showed little expression of IL-4, IL-17 or 
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IL-13 61. While the mode of stimulation was different, our data indicates that MAIT cells 
have similar cytokine profile regardless of their tissue location. 
We also showed that stimulated MAIT cells released more IFNγ and TNF than IL-
4, IL-17 or IL-13 in culture supernatant. This was similar to a previous study that also 
used PMA & ionomycin to stimulate MAIT cells from PBMCs of patients with colorectal 
cancer 69. Therefore, intracellular cytokine expression by stimulated MAIT cells 
correlated well with analysis of culture supernatants.  
Our results indicated that MAIT cells had maintained their functional capacity, but it was 
interesting that more cytokine positive CD8+ MAIT cells were found than CD8- cells 
from patients, especially in blood cancers. This implies that CD8 defined MAIT cell 
subsets may have subset specific functional roles. It will be important to study these 
subsets using MR1 tetramer to measure their heterogeneity and TCR diversity. A similar 
magnitude, but non-significant, trend was observed for patients with solid cancer, 
indicating further study may be useful. This subset bias has not been previously studied, 
as many past studies have investigated MAIT (CD161+Vα7.2TCR+CD3+) cells with or 
without reference to CD8 expression, but not at once 68,69,197. However, there is already 
evidence of functionally distinct subsets in a mouse model study, where MAIT cell subset 
based on differential expression of retinoic acid-related orphan receptor γt (RORγt) 
expressed IFNγ or IL-17 54.  
We were unable to compare responses of cells from tumour and non-diseased 
tissues of patients, so we could not determine if the MAIT cells in solid tumours were 
similar in function to those in non-diseased tissue in patients or healthy donors 68. 
Interestingly, when MAIT cell subsets in patient tissue samples were compared to healthy 
donors, CD8+ MAIT cells showed no significant difference in responses, but CD8- MAIT 
cells sometimes had a reduced IFNγ or TNF response in patient tissue samples compared 
to healthy donors. 
IL-4 is often associated with immunosuppression and a past study reported that 
increased IL-4 expression in MAIT cells with aging 53. Our results showed low IL-4 
expression in all samples but it is important to note that most patient groups had a higher 
mean age than healthy donors. Interestingly, our own studies did not show any correlation 
between MAIT cell frequency and age for healthy PBMCs or patient tissue samples. 
Therefore, our data suggests aging has no impact on the frequency and functional 
capacity of MAIT cells, but further studies should take the earlier findings into account 
(data not shown). 
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Collectively, this is the first study to investigate MAIT cells from patient tissue 
samples that include tumours, bone marrow and blood from multiple patient groups. We 
showed that MAIT cells have mostly maintained their capacity to produce cytokines such 
as IFNγ and TNF indicating that function is intact much like healthy individuals. 
 
Table 13. Overview of cytokine expression by stimulated MAIT cells from patients with 
solid cancer. MAIT cells from blood and tumours of patients with solid cancer were 
assayed for expression of IFNγ, TNF and IL-4 after stimulation. Different colours 
indicate whether the frequency of cytokine positive MAIT cells from patient tissue 
samples was higher or lower than PBMCs of healthy donors. As a point of comparison, 
results from non-MAIT T cell populations are also shown. Green represents significantly 
higher frequency for cells from healthy donors, red represents significantly lower 
frequency and blue represents statistically similar outcomes.  
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Table 14. Overview of cytokine expression by stimulated MAIT cells from patients with 
blood cancers. MAIT cells from blood and bone marrow of patients with blood cancer 
were assayed for expression of IFNγ, TNF and IL-4 after stimulation. Different colours 
indicate whether MAIT cells from patient tissue samples had a higher or lower frequency 
of cytokine positive cells compared to PBMCs of healthy donors (healthy blood). As a 
point of comparison, results from non MAIT T cell populations are also shown. Filling 
with green indicates significantly higher frequency for healthy donors, red represents 
significantly lower frequency and blue represents statistically similar outcomes. 
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Table 15. Overview of results describing the patient group matched frequency of MAIT 
cells with intracellular cytokine expression in patients with solid cancer. The frequency 
of MAIT cells with expression of IFNγ, TNF and IL-4 in patient grouped (but non-patient 
matched (NP)) blood (PBMCs) or tumours (TILs) of patients with solid cancer was 
compared. As a point of comparison, non MAIT T cells were also investigated. Different 
colours indicate whether the frequency of cytokine positive MAIT cells was statistically 
different between patient grouped blood and tumours. Orange represents significantly 
higher frequency in TILs, purple represents significantly higher for PBMCs, blue 
represents statistically similar frequency. As a point of comparison, results from other T 
cell populations are also shown. 
  
160 
 
Table 16. Overview of results comparing cytokine expression for patient group matched 
MAIT cells for patients with blood cancer. The frequency of MAIT cells expressing IFNγ, 
TNF or IL-4 in patient grouped (but non-patient matched (NP)) blood (PBMCs) or bone 
marrow (BM) of patients with blood cancer was compared. Non MAIT T cells were also 
investigated as a point of comparison to MAIT cells. Different colours describe whether 
the frequency of cytokine positive MAIT cells was higher in patient PBMCs or BM. 
Orange indicates significantly higher for BM, purple indicates significantly higher 
PBMCs, blue indicates statistically similar frequency.  
 
II. NKT Cells. Earlier functional studies of NKT cells in patients with cancer have often 
been limited by low NKT cell numbers and many only examined patient PBMCs 160,204,240. 
Some studies reported that NKT cells from patients produced lower amounts of IFNγ and 
this often correlated with an overall numerical deficiency. These are interesting studies 
because they suggest there are systemic defects in these patients, however, few studies 
have investigated the functional capacity of NKT cells from patient tumours, which may 
give a direct insight into how NKT cells function in close proximity to tumour cells. 
Therefore, we have compared cytokine production by NKT cells in patient PBMCs and 
TILs to responses by MAIT cells from healthy PBMCs. 
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NKT cells from most patient samples produced cytokines and we were surprised to find 
some instances where a higher proportion of NKT cells in patient PBMCs expressed IFNγ, 
TNF or IL-4 compared to NKT cells from PBMCs of healthy donors (Table 17). We 
could not determine if this impacted anti-tumour immunity, but nevertheless we have 
definitively established that reduced cytokine production by NKT cells is not a 
widespread characteristic of patients with cancer (Table 17). The possible increased IFNγ 
or TNF response was most often seen in CD4-CD8- (DN) NKT cells, which was 
interesting considering that this subset is regarded as the most important for effective 
anti-tumour responses.  
One of the challenges with NKT cells is a lack of tumour samples with sufficient 
cell numbers to conduct functional analysis due to the overall rarity of this cell type and 
the further deficiency that affects these patient groups. Therefore, only PMA and 
ionomycin mediated stimulation was used. We were not always able to definitively 
measure cytokine responses by NKT cells in patient TILs, but we did confirm that these 
cells could produce IFNγ, TNF and IL-4 and therefore conclude that NKT cells in patient 
tumours appear to maintain their functional capacity. Although not currently feasible, it 
would be useful to also examine more cytokines to better define and compare their overall 
cytokine profiles.  
Taken together, our findings strongly suggest that NKT cells in patients with solid 
cancer retain the capacity to express IFNγ and TNF and that the magnitude of the 
response may even be increased in some groups. Our study did not address whether this 
has a meaningful impact on anti-tumour immunity, but the results show that the cells 
retain the capacity to release cytokines in they are activated.  
Our analysis of supernatants confirmed NKT cells secreted cytokines when 
stimulated, although it would be interesting to examine the effect of different mode of 
stimulation on the cytokine profiles. This is not technically feasible, but would be helpful 
to better understand the functional capacity of NKT cells in patients with cancer. 
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Table 17. Overview of results describing the frequency of NKT cells with intracellular 
cytokines. NKT cells from blood and tumours of patients with solid cancer were assayed 
for expression of IFNγ, TNF or IL-4 after stimulation. Different colours indicate whether 
the frequency of cytokine positive NKT cells from patient tissue samples was higher or 
lower than from PBMCs of healthy donors. As a point of comparison, results from non-
NKT T cell populations are also shown. Green represents significantly higher frequency 
of healthy donors, red represents significantly lower frequency and blue represents 
statistically similar outcomes. 
 
III. γδ T cells. Previous studies have reported that reduced overall frequency and 
cytokine production of γδ T cells could be associated with reduced anti-tumour capacity 
183,186 but only a few studies have been conducted and those have mostly examined cells 
from blood and not TILs. We investigated the cytokine expression of γδ T cells in patient 
PBMCs or TILs and found statistically similar IFNγ or TNF expression in patients with 
solid cancer and PBMCs of healthy donors (Table 18). We also directly compared patient 
PBMCs and TILs and no significant differences were identified (Table 19). Therefore, 
any anti-tumour capacity of γδ T cells in patient blood or tumours mediated by cytokines 
was likely to be intact, although the role of these cells has not yet been determined. Like 
MAIT cells or NKT cells, γδ T cells assayed without in vitro activation showed no 
noticeable increase in the frequency of cytokine positive cells in patient tissue samples 
compared to healthy donors. 
The cytokine profile of γδ T cells was similar to other innate-like T cells, with 
relatively high levels of IFNγ and TNF and smaller amounts of IL-17, IL-13 and IL-4 
detected, although future studies could perhaps look at a broader array of possible 
cytokines and separately assay some recently discovered subsets. Taken together, we 
showed that γδ T cells in patient PBMCs or TILs have a relatively similar functional 
capacity to healthy donors and their cytokine production is probably not impacted in 
patients with cancer. 
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Table 18. Overview of results describing the frequency of γδ T cells with intracellular 
cytokine expression in patients with solid cancer. γδ T cells from blood (PBMCs) and 
tumours (TILs) of patients with solid cancer were assayed for expression of IFNγ and 
TNF after stimulation. Different colours indicate whether the frequency of cytokine 
positive γδ T cells from patient tissue samples was statistically higher, lower or similar to 
PBMCs of healthy donors. Green represents significantly higher frequency of healthy 
donors, red represents significantly lower frequency and blue represents statistically 
similar outcomes. 
 
Table 19. Overview of data comparing the frequency of γδ T cells with intracellular 
cytokine expression between patient blood and tumours. The frequency of γδ T cells 
expressing IFNγ and TNF after stimulation was compared for cells from blood (PBMCs) 
or tumours (TILs) of patients with solid cancer. The orange colour indicates whether the 
frequency of cytokine positive γδ T cells was significantly higher for TILs, purple 
represents higher for PBMCs, blue indicates a statistically similar frequency.  
 
Innate-like T cells from patient tissue samples appear to have mostly maintained their 
capacity to produce cytokines based on responses to PMA and ionomycin stimulation, 
highlighting that they are potentially able to participate in anti-tumour responses.  
We did not examine whether functional capacity changed throughout the disease 
and this could be an important area for future studies as there are reports that γδ T cells 
show a significant reduction in cytokine production in advanced stages of cancer. 163,240. 
Therefore, although beyond the scope of our study, a longitudinal study of γδ T cells 
responses by patients would be useful to investigate potential changes over the course of 
disease.  
Our analysis of innate-like T cell lineages has indicated that their functional 
capacity appears to be maintained in patients with different forms of cancers, although 
this does not demonstrate involvement in actual anti-tumour responses. To partly address 
this, in the final results chapter, we co-cultured innate-like T cells from patient tissue 
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samples with tumour cells, lysates and lipids from those cells to directly test for evidence 
of specific responses by these lineages against tumour antigens. 
 
 
Chapter 5: Anti-cancer response by innate-like T cells  
Many clinical studies investigating innate-like T cells have reported significant changes 
in their frequency and capacity to produce cytokines. However, there are conflicting 
findings, such as significantly lower or higher frequency of NKT cells in patients with 
different forms of cancers. For example, there are reports of reduced NKT cell frequency 
among lymphocytes infiltrating tumours in patients with hepatocarcinoma 159, and in 
PBMCs of patients with colorectal carcinoma, breast cancer, head and neck cancer, renal 
cell carcinoma or melanoma 160. In contrast are reports of increased NKT cell frequency 
in primary tumours of patients with colorectal carcinoma and intrahepatic tumours 157,161. 
These reports indicate that more extensive studies with consistent approaches to cell 
identification and assaying are required to understand the significance of innate-like T 
cells in patients with cancer. 
Our findings show that most patient groups with cancer have significantly lower 
frequencies of innate-like T cells such as NKT cells and MAIT cells than seen in healthy 
donors. However, not all innate-like T cells are affected, as γδ T cells had similar 
frequencies in patients and healthy donors.  
Interestingly, cytokine responses from innate-like T cells were similar in PBMCs 
of healthy donors and PBMCs, TILs and BM derived cells of cancer patients. Thus, the 
functional capacity of patients’ innate-like T cells to produce cytokines, including TNF, 
IFNγ and IL-4, appears intact. These findings, however, do not indicate whether the cells 
respond to cancer cells. In this final chapter, we assessed the response of innate-like T 
cells to antigens from cancer cells. 
 
5.1.1. Response of innate-like T cells to cancer cells 
MAIT cells and NKT cells respond rapidly to vitamin B metabolites from bacteria and α-
galactosylceramide (αGal-Cer) respectively 38,241. Subsets of γδ T cells also respond 
rapidly to aminobisphosphate 52,73,242. However, it is not known whether innate-like T 
cells recognize antigens derived from cancer cells. Chapter 4 showed that innate-like T 
cells from patients are capable of producing cytokines such as IFNγ and TNF that are 
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associated with anti-tumour responses. Therefore, the next step is to determine if they 
recognize and respond to cancer cells. 
To determine this, we generated lysates or purified lipids from cancer cell lines or 
patient tumours and cultured these with lymphocytes from patient PBMCs and TILs. We 
compared the responses to those of cells from healthy donors and to conventional T cells. 
In some instances, we also tested the response of cells from patient TILs to autologous 
tumour cells. To identify cells of interest, we stained single cell suspensions using CFSE 
to allow proliferation to be measured based on CFSE dilution. Unlike Chapter 4 where we 
sorted different innate-like T cells, we used heterogeneous cell suspensions to retain 
antigen presenting cells and other immune cells including cancer cells within the assay.  
We had earlier tried different readouts to determine the optimal method to 
investigate functional responses. For instance, prior to incubation of cell culture, we only 
stained lymphocytes of interest with CFSE (i.e. innate-like T cells) but not feeder cells 
(i.e. PBMCs or DCs used for antigen presentation). However, we discarded this approach 
due to the high background of feeder cells and other non-stained populations (Figure 52 
A). That approach also required higher starting numbers of immune cells to allow target 
populations to be sorted and this was a major challenge for patient tissue samples. 
Therefore, to achieve a consistent staining intensity at the start of each culture, we stained 
all cells to measure the lysate response (Figure 52 B). In addition, we routinely measured 
expression of CD25 or intracellular cytokines by innate-like T cells after culture with to 
lysates, lipids or viable autologous tumour cells (Figure 53 A-M). Positive controls using 
PBMCs (from healthy individuals or patients) activated with anti-CD3 (3 µg/ml) and 
CD28 (1 µg/ml) or IL-2 (50 U/ml) were monitored throughout this chapter (Figure 54 A-
D).  
 
Figure 52. Example of methods tested for optimal measurement of the proliferation 
response by innate-like T cells. MAIT (CD161+Vα7.2TCR+CD3+) cells were CFSE 
labelled and cultured with lysate and antigen pulsed antigen presenting cells (i.e. PBMCs 
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or DCs). (A) shows cultures with unstained feeder cells and stained MAIT cells and (B) 
shows cultures where all cells were stained. The first method (A) posed a problem upon 
proliferation, as some feeder cells were false positive for CFSE (The arrow on x axis 
represents direction of more proliferated population). The other approach (B) allowed 
easier identification of proliferation. This example shows CFSE (X axis) versus 
Vα7.2TCR+ CD161+CD3+ (MAIT) T cells (Y axis). 
Figure 53. Response of innate-like T cells to cancer cells. The figure shows an 
illustration of typical analysis from cultures testing responses to tumour antigens. We 
identified MAIT cells (A-B), γδ T cells (F) and NKT cells (J) in tissue samples from 
patients or healthy donors and measured their response to culturing with lysates and 
lipids from cancer cells or viable autologous tumour cells. We measured activation 
markers (CD25) (C, G, K) or intracellular cytokine expression (D-E, H-I, L-M). 
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Figure 54. Positive control for functional assay used to measure antigen specific 
response by immune cells. As a positive control, the proliferation of stimulated cells from 
healthy individuals or patient tissue samples (where possible if enough tissue samples 
were available) was measured (B, D). The plots illustrate typical proliferation after 
stimulation with agonists such as anti-CD3 (3 µg/ml) and CD28 (1 µg/ml) (B) or IL-2 (50 
U/ml) (D). Proliferation of unstimulated cells was also tested as a control (A, C).  
 
5.1.2. Innate-like T cell response to cancer cell lysates  
We tested the response of T cells to cell lysates from colorectal cancer tumours, sarcomas 
and LIM2407, LIM2412 and LIM2538 colorectal adenocarcinoma cell lines. Based on  
established method, samples were subjected to rapid freeze and thaw cycles using liquid 
nitrogen and a 37 °C water bath to form protein lysates. We broadly quantified the 
concentration of the lysates and typically used at concentration of 200 ug for 1x106 viable 
cells in culture (refer to methods for more details). We cultured the cells for 5 days and 
added Golgiplug 4 h prior to harvesting to enhance intracellular cytokine staining. 
We only conducted broad assays of MAIT cells and γδ T cells from patient tissue 
samples or PBMCs from healthy donors as we had heavily depleted the supply of tissue 
samples from patients for earlier chapters. We were also unable to investigate NKT cells 
due to their very low numbers in patient tissue samples.  
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We first measured the overall frequency of cultured MAIT cells and γδ T cells 
among viable T cells from PBMCs of TILs of patients with solid cancer, but no 
significant proliferative response occurred after culture with tumour lysates (Figure 55 A-
B).  
 
Figure 55. Proliferation of innate-like T cells cultured with tumour lysates. Patient 
PBMCs (B), TILs (T) or healthy PBMCs (H) were CFSE labelled and cultured with lysate 
from tumours of patients with colorectal (colon) cancer, sarcoma or from colorectal 
adenocarcinoma cell lines LIM2407 (CL1), LIM2412 (CL2) or LIM2538 (CL3). Graphs 
show the % of MAIT cells ‘A’ or γδ T cells ‘B’ among T cells that had proliferated. Each 
symbol represents one patient sample. Mann-Whitney test was conducted to determine 
statistical difference (P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
Collectively, these findings indicated that there was little proliferation of MAIT cells or 
γδ T cells from patient PBMCs or TILs when cultured with tumour lysates. However, we 
cannot exclude the possibility that responses may have been detected with greater cell 
numbers or refined lysate preparations. This was beyond the scope of our assays due to 
low cell numbers, but further investigations with greater cell numbers may allow a more 
stringent analysis of anti-tumour responses.  
It was interesting, however, to observe a reduced overall frequency of γδ T cells in 
patient tissue samples not previously identified in earlier chapter and this may require 
further investigation (Figure 55 B). Using same cultures, we also measured the frequency 
of activated (CD25+) innate-like T cells (MAIT cells or γδ T cells) by patient PBMCs or 
TILs as a measure of responses to lysates. We compared cells exposed to lysates and no 
lysate, and later compared patient tissue samples and healthy PBMCs. 
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I. Impact of lysates in patient PBMCS or TILs 
i. MAIT cells. MAIT cells from patient PBMCs and TILs cultured with tumour lysates 
showed no significant increase in CD25 expression above background (for patient 
PBMCs; ranged between 1.4% - 2.7% with lysates cf 1.8% without lysates; in patient 
TILs; 0.01% - 5.9% with lysates cf 2.5% without lysates) (Figure 56 C, E). Consistent 
with this, no significant increase was seen for cells from PBMCs of healthy donors 
(ranged between 1.3% to 1.7% with lysates cf 1.4% without lysates) (Figure 56 A). One 
exception was exposure to LIM2412 (CL2) by patient TILs, which showed significantly 
lower frequency of CD25+ MAIT cells compared to control with no lysates (0.01% cf 
2.5% ± 1.1) (Figure 56 E). Our findings showed that MAIT cells are not activated by 
lysates from patient tumours or cancer cell lines. 
 
Figure 56. The frequency of activated innate-like T cells after culturing with lysates 
from tumours or cancer cell lines. The frequency of activated (CD25+) MAIT cells or γδ 
T cells in PBMCs of healthy donors (A-B), patient PBMCs (C-D) or TILs (E-F) was 
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measured after 5 day culture with lysates from tumours of patients with colorectal (colon) 
cancer, sarcoma or from colorectal adenocarcinoma cell lines LIM2407 (CL1), LIM2412 
(CL2) or LIM2538 (CL3). Each symbol represents one sample. 0.01% includes 
measurements <0.01%. Statistical significance was tested by Wilcoxon analysis 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. γδ T cells. Using same cultures, we measured CD25+ expression by γδ T cells from 
patient PBMCs or TILs cultured with different tumour lysates. Consistent with findings 
from MAIT cells, no noticeable change in the frequency of CD25+ γδ T cells was seen 
after culture for cells from patients or healthy donors (e.g. in patient PBMCs; ranged 
between; 0.45% to 1.8% with lysates cf 1.2% without lysates. Refer to Figure 56 B, D, F).   
 
II. Comparison of responses by cells from patients and healthy donors to lysates  
i. MAIT cells. Comparing the response of cells from patient PBMCs or TILs to healthy 
donors revealed no significant difference in the frequency of activated (CD25+) MAIT 
cells regardless of exposure to different cancer lysates, including controls with no cancer 
lysates (e.g. sarcoma tumour lysate; 1.9% ± 0.6 in patient PBMCs or 5.9% ± 4.2 in 
patient TILs cf 1.5% ± 0.3 in healthy PBMCs; for other conditions refer to Figure 57 A). 
One exception was for LIM2412 (CL2) lysate where the frequency of CD25+ MAIT cells 
in cells from tumours was significantly than cells from PBMCs of healthy donors (0.01% 
cf 1.76% ± 0.48) (Figure 57 A). We noted that the frequency of CD25+ MAIT cells in 
patient TILs trended higher than healthy PBMCs in most conditions and may need further 
investigation. Taken together, MAIT cells in patient tissue samples were not activated by 
culturing with cancer cell lysates. 
 
ii. γδ T cells. We also saw no difference in frequency of CD25+ γδ T cells between 
PBMCs or TILs of patients and healthy PBMCs after culturing with lysates (e.g. colon 
tumour lysates; 0.87% ± 0.54 in patient PBMCs cf 2.4% ± 0.7 in healthy donors; for 
other conditions, refer to Figure 57 C). One exception involved the sarcoma tumour 
lysate, where patient PBMCs had a significantly lower frequency of CD25+ γδ T cells 
than in PBMCs of healthy donors (0.52% ± 0.33 in patient PBMCs cf 1.93% ± 0.6 in 
healthy donors) (Figure 57 C). While the exception is consistent with a low lysate 
specific response, the frequency in patient PBMCs was consistently lower for all 
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conditions. Therefore, our findings mostly indicate that γδ T cells in patient PBMCs were 
not activated by lysates from the tumour cells.   
 
Figure 57. The frequency of CD25+ innate-like T cells or CD3+ T cells in healthy 
donors and patients after culture with cancer cell lysates. The frequency of CD25+ 
MAIT cells (A), CD3+ T cells (B) and γδ T cells (C) from PBMCs of healthy donors (H), 
patient PBMCs (B) or TILs (T) was measured after 5-day culture with or without lysate 
from tumours of patients with colorectal (colon) cancer, sarcoma or from colorectal 
adenocarcinoma cell lines LIM2407 (CL1), LIM2412 (CL2) or LIM2538 (CL3). Each 
symbol represents one sample. 0.01% includes <0.01%. Statistical significance was 
determined by Mann–Whitney analysis (P<0.05* / P<0.01**/ P<0.001*** / 
P<0.0001****). 
 
iii. Non innate-like T cells. To our surprise, the frequency of CD25+ T cells in patient 
TILs or was not significantly different to healthy PBMCs despite trending consistently 
higher regardless of lysates exposure (e.g. colorectal tumour lysate; 5.12% ± 2 in patient 
TILs cf 1.58% ± 0.21 in healthy PBMCs; for other conditions refer to Figure 57 B). In 
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contrast to patient TILs, the frequency of CD25+ T cells in patient PBMCs was 
consistently lower than healthy donors (e.g. in sarcoma tumour lysate; 0.46% ± 0.19 in 
patient PBMCs cf 1.76% ± 0.21in healthy PBMCs; for other conditions refer to Figure 57 
B). Collectively, both innate-like T cells and broader T cell populations failed to show 
significant activation in response to lysates from cancer cells. 
 
III. Comparison between patient TILs and patient PBMCs 
i. MAIT cells. We found no significant difference in the frequency of CD25+ MAIT cells 
between patient PBMCs and TILs. This comparison was conducted in case tumour 
specific cells were enriched in tumours, but it appeared neither group were activated by 
lysates (e.g. LIM2407 lysates; 2.4% ± 1.1 in patient PBMCs cf 3.1% ± 1.1 in patient 
TILs; for other conditions, refer to Figure 57 A).  
 
ii. γδ T cells. Similar to MAIT cells, no significant difference in frequency of CD25+ γδ 
T cells was seen between patient PBMCs and TILs after culture with lysates, also 
suggesting that these populations were not responding to these antigens (e.g. 0.45% ± 
0.23 in patient PBMCs cf 0.8% ± 0.8 in patient TILs for LIM2407; for other conditions, 
refer to Figure 57 C). 
 
iii. Non innate-like T cells. The frequency of activated T cells from patient TILs was 
significantly higher than in patient PBMCs for all lysates exposure, despite not being 
significantly higher than seen for healthy PBMCs (e.g. colorectal tumour lysate; 0.43% ± 
0.22 in patient PBMCs cf 5.12% ± 2 in patient TILs; for other conditions refer to Figure 
57 B). This suggests that some conventional T cells in the tumours may have responded to 
tumour antigens in the lysate.  
 
5.1.3. Summary 
Our results revealed that lysates from different cancer sources didn’t cause a significant 
increase in CD25 expression for MAIT cells or γδ T cells, suggesting that these innate-
like T cells may not specifically recognize cancer cells. Similarly, there was no 
significant difference between patient PBMCs or TILs compared to PBMCs of healthy 
donors. Taken together, our data suggests that exposure to cancer lysates does not activate 
MAIT cells, but we note that CD25 expression by MAIT cells and γδ T cells from patient 
TILs trended higher than that of cells from healthy PBMCs, suggesting a potential 
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response that was not identified in this project. A more detailed study of fractionated 
proteins from lysates is probably warranted, although this would rely on availability of 
patient tissue samples. 
 
5.1.4. Cytokine response of innate-like T cells to cancer lysates 
The response of innate-like T cells to lysates was minimal when measured by 
proliferation and CD25 expression, but it remained possible that important functional 
outputs were not being detected. We therefore tested the cytokine response MAIT cells 
and γδ T cells from patient tissue samples to cancer cell lysates.  
 
I. Cytokine response of patient PBMCs and TILs to lysates 
i. MAIT cells. We found the TNF and IL-17 cytokine responses of MAIT cells to cancer 
cell lysates was no greater than against no lysate controls, and that PBMCs and TILs had 
similar responses. (e.g. The % of TNF+ MAIT cells ranged between; 0.01% to 2.7% with 
lysates cf 0.65% without lysates for patient PBMCs; IL-17+: 0.01% to 2.3% with lysates 
cf 0.01% without lysates for patient PBMCs. Refer to Figure 58 B-C, E-F for more data). 
We also found that MAIT cells from PBMCs of healthy donors had a similar response to 
cells from patient PBMCs and TILs (TNF+ was 0.14% to 0.71% with lysates cf 0.15% 
without lysates; IL-17+ was 0.59% to 0.74% with lysates cf 0.65% without lysates) 
(Figure 58 A, D). Collectively, MAIT cells from PBMCs and TILs of patients and healthy 
PBMCs showed little evidence of response to lysates from patient tumours or cancer cell 
lines. 
 
ii. γδ T cells. We found almost no difference in the frequency of TNF+ or IL-17+ γδ T 
cells in patient PBMCs or TILs (e.g. the % TNF+ cells ranged from; 6.2% to 7.7% with 
lysates cf 13% without lysates for patient PBMCs; % IL-17+ ranged from; 0.02% to 
0.55% with lysates cf 0.25% without lysates in patient PBMCs. Refer to 59 B-C, E-F for 
more data), or PBMCs from healthy donors, following culture with or without lysates 
(TNF expression ranged between 0.6% to 2% with lysates cf 1.5% without lysates; IL-17 
expression ranged between; 0.01% to 0.06% with lysates cf 0.18% without lysates) 
(Figure 59 A, D). One exception was the significantly lower % of TNF+ γδ T cells in 
PBMCs of healthy donors when exposed to LIM2412 compared to no lysate (0.46% ± 
0.21 cf 1.5% ± 0.48) (Figure 59 A), although we do not believe this is meaningful in 
terms of the likely in vivo responsiveness. Taken together, we conclude that lysates from 
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cancer cell lines or patient tumour cells do not induce a TNF or IL-17 response from γδ T 
cells in patient PBMCs or TILs.  
    
Figure 58. The frequency of TNF+ or IL-17+ MAIT cells after culture with lysates 
from tumours or cancer cell lines. The frequency of TNF+ or IL-17+ MAIT cells was 
measured culturing PBMCs of healthy donors (A, D), patient PBMCs (B, E) or patient 
TILs (C, F) for 5 d with or without (Ctrl) lysates derived from patient tumours or 
colorectal cancer cell lines. Golgiplug was added 4 hour before harvest. Tumour lysate 
was from patients with colorectal (colon) cancer, sarcoma or from colorectal 
adenocarcinoma cell lines LIM2407 (CL1), LIM2412 (CL2) or LIM2538 (CL3). 0.01% 
includes < 0.01%. Statistical significance was determined by Wilcoxon analysis 
(P<0.05*/ P<0.01**/ P<0.001***/ P<0.0001****). 
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Figure 59. The frequency of TNF+ or IL-17+ γδ T cells after culture with lysates from 
tumours or cancer cell lines. The frequency of γδ T cells expressing TNF or IL-17 in 
PBMCs of healthy donors (A), patient PBMCs (B) or TILs (C) was measured with or 
without (Ctrl) lysates from patient tumours or cancer cell lines. Tumour lysate was from 
patients with colorectal (colon) cancer, sarcoma, or from colorectal adenocarcinoma cell 
lines LIM2407 (CL1), LIM2412 (CL2) or LIM2538 (CL3). Each symbol represents one 
sample. 0.01% includes <0.01%. Statistical significance was determined by Mann–
Whitney analysis (P<0.05* / P<0.01**/ P<0.001*** / P<0.0001****). 
 
II. Comparison between PBMCs of patients and healthy donors 
i. MAIT cells. We next compared the cytokine response of MAIT cells from PBMCs of 
patients and healthy donors to tumour lysates. The frequency of TNF+ or IL-17+ MAIT 
cells was similar in most conditions (e.g. in control; 0.85% ± 0.4 cf 0.14% ± 0.07 TNF+; 
0.3% ± 0.15 cf 0.6% ± 0.1 IL-17+. Refer to Figure 60 A, C for other conditions). One 
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exception was involved LIM2407 lysates, in which the frequency of TNF+ or IL-17+ 
MAIT cells in patient PBMCs was significantly lower than for PBMCs of healthy 
individuals (0.11% ± 0.1 cf 0.5% ± 0.1) (Figure 60 A). The proportion of responding cells 
was low for cells from patients and healthy donors. There was minor variation, including 
lower TNF responses to LIM2407 lysates by patient blood cells, but no strong evidence 
of lysate specific response.  
 
Figure 60. The TNF and IL-17 response of MAIT cells or MAIT-like T cells to cancer 
derived lysates. The expression of TNF (A) and IL-17 (C) by MAIT cells or MAIT-like 
(CD161-Vα7.2TCR+CD3+) T cells (B, D) was assayed for PBMCs of healthy donors (H) 
and PBMCs (B) or TILs (T) from solid cancer patients after 5 day culture with lysates 
from tumour cells. GolgiPlug was added 4 h before harvest. Tumour lysate was from 
colorectal (colon) cancer, sarcoma or colorectal adenocarcinoma cell lines LIM2407 
(CL1), LIM2412 (CL2) or LIM2538 (CL3). Each symbol represents one sample. 0.01% 
(10-2) includes <0.01%. Statistical significance was determined by Mann–Whitney 
analysis (P<0.05* / P<0.01**/ P<0.001*** / P<0.0001****). 
 
  
177 
ii. γδ T cells. There was no significant change in the frequency of TNF+ γδ T cells after 
culture with lysates. (e.g. TNF expression after culturing with colon tumour lysates; 7.5% 
± 4.6 in patient PBMCs cf 1.7% ± 0.45 in healthy PBMCs; for other conditions refer to 
Figure 61 A). One exception was that the frequency of TNF+ γδ T cells in patient PBMCs 
was higher than healthy PBMCs (13% ± 8 cf 1.57% ± 0.4) (Figure 61 A).  
Similar to TNF+, there was no significant difference in the frequency of IL-17+ γδ 
T cells after culturing with cell lysates to suggest lysate specific response (e.g. in colon 
tumour lysates; 0.09% ± 0.07 in patient PBMCs cf 0.06% ± 0.05 in healthy donors; for 
remaining conditions, refer to Figure 61 B).  
 
iii. Non innate-like T cells. Cell lysates had no impact on TNF or IL-17 expression of 
MAIT-like T cells (CD161-Vα7.2TCR+CD3+) (e.g. when exposed to colorectal tumour 
lysates; 0.67% ± 0.24 cf 0.21% ± 0.14 TNF expression; 1.3% ± 0.6 cf 0.74% ± 0.15 for 
IL-17 expression; refer to Figure 60 B, D for remaining conditions for TNF or IL-17 
expression). 
Consistent with this trend, T cells from PBMCs of patients also showed little TNF 
or IL-17 response. (e.g. 1.6% ± 1.5 cf 0.08% ± 0.01 in control; for remaining conditions 
refer to Figure 61 C-D) with minor exceptions involving low magnitude responses and 
appearing unlikely to be physiologically important.) (Figure 61 C).  
It is possible that low magnitude responses were still important and this would be 
useful to investigate in later studies, but given the semi invariant specificity of MAIT 
cells in particular, this pilot investigation was mostly aimed at determining if large 
proportions of cells were responding. Based on our data, this does not appear to be 
occurring.   
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Figure 61. TNF and IL-17 cytokine profile of γδ T cells or CD3+ T cells after culture 
with lysates. Single cell suspensions from PBMCs of healthy donors (H) and patient 
PBMCs (B) or TILs (T) were cultured with cancer cell lysates and assayed for TNF and 
IL-17 after 5 d culture. GolgiPlug was added 4 hours prior to harvesting cells. The 
frequency of cytokine positive γδ T cells (A-B) or their cytokine expression in overall T 
cells (C-D) were investigated. Tumour lysate was extracted from tumours of patients with 
colorectal (colon) cancer, sarcoma or from colorectal adenocarcinoma cell lines 
LIM2407 (CL1), LIM2412 (CL2) or LIM2538 (CL3). Each symbol represents one sample. 
0.01% includes <0.01%. Statistical significance was determined by Mann–Whitney 
analysis (P<0.05* / P<0.01**/ P<0.001*** /P<0.0001****). 
 
III. Comparison between patient TILs and PBMCs of healthy donors 
i. MAIT cells. For thoroughness, we compared responses of patient TILs and healthy 
donors to cancer lysates, but as expected, we saw no significant in TNF or IL-17 
expression between them (e.g. in control; 0.9% ± 0.9 cf 0.14% ± 0.07 TNF expression; 
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0.01% cf 0.65% ± 0.14 for expression of IL-17; refer to Figure 60 A, C for the frequency 
of TNF+ or IL-17+ MAIT cells in different conditions).  
 
ii. γδ T cells. The frequency of TNF+ and IL-17+ γδ T cells in patient TILs showed no 
significant difference from PBMCs of healthy donors regardless of lysate exposure (e.g. 
in colorectal tumour lysates; 3.3% ± 1.5 TNF+ in patient TILs cf 1.6% ± 0.44 in healthy 
PBMCs; for other conditions refer to Figure 61 A). Minor exceptions did not seem to 
indicate important responses (e.g. when exposed to LIM2407 lysate; 0.01% IL-17+ in 
patient TILs cf 0.03% ± 0.02 in healthy PBMCs; for other conditions Figure 61 B). 
 
iii. Non innate-like T cells. We did observe some responses from T cells and MAIT-like 
T cells. In patient TILs, we saw significantly higher frequency of TNF+ T cells for 
control and colorectal tumour lysates compared to healthy PBMCs (1.9% ± 1.4 cf 0.08% 
± 0.01 in control; 1.1% ± 0.69 cf 0.04% ± 0.01 in colorectal tumour lysate) (Figure 61 C). 
Interestingly, the frequency of IL-17+ T cells in patient TILs was consistently lower for 
all conditions with or without lysates compared to PBMCs of healthy donors (e.g. in 
control; 0.06% ± 0.04 cf 0.1% ± 0.01; refer to Figure 61 D for remaining conditions). 
These findings indicate some T cells in patient TILs can mount a TNF response to lysates. 
Little or no response was seen for MAIT–like T cells from patient TILs and no 
significant difference was found when these were compared to cells from PBMCs of 
healthy donors (e.g. in conditions with LIM2412; 0.01% cf 0.3% ± 0.16 for expression of 
TNF; refer to Figure 60 B, D for other conditions including IL-17). Overall, we conclude 
that although some T cell populations from patient TILs responded to tumour lysates, no 
such impact was observed for MAIT cells or γδ T cells. 
 
IV. Comparing response of T cell from patient PBMCs and TILs to lysates 
i. MAIT cells. We assayed MAIT cells from patient TILs and PBMCs after culturing with 
different cell lysates but found no difference in the frequency for TNF+ or IL-17+ cells 
(e.g. TNF+; 0.85% ± 0.47 for patient PBMCs cf 0.92% ± 0.9 for TILs for control with no 
lysate; IL-17+; 0.01% cf 0.3% ± 0.15 in control; refer to Figure 60 A, C TNF or IL-17 
expression in other conditions). Consistent with our previous results, we conclude there is 
no specific response of MAIT cells to lysates. 
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ii. γδ T cells. The results were similar for γδ T cells with no significant difference 
between groups after culturing with cancer lysates for TNF+ or IL-17+ γδ T cells (e.g. for 
LIM2412; 7.7% ± 5.8 in patient PBMCs cf 5.6% ± 3.7 in patient TILS LIM2412 for TNF 
expression; 0.3% ± 0.23 in patient PBMCs cf 0.01% in patient TILs for expression of IL-
17; for other conditions refer to Figure 61 A-B). One exception was that LIM2538 lysates 
induced a significantly higher frequency of TNF+ γδ T cells from patient PBMCs than 
from patient TILs (7.4% ± 5.5 cf 0.01%) (Figure 61 A). A similar trend (i.e. patient 
PBMCs trended higher than patient TILs) was consistently observed. 
 
iii. Non innate-like T cells. Consistent with innate-like T cells investigated, we found no 
significant difference between the responses of MAIT-like (CD161- Vα7.2TCR+CD3+) 
T cells from patient PBMCs and TILs (e.g. in sarcoma tumour lysates; 0.7% ± 0.5 in 
patient PBMCs cf 0.01% in patient TILs for TNF expression; 0.7% ± 0.38 in patient 
PBMCs cf 0.01% patient TILs for IL-17 expression; refer to Figure 60 B, D for TNF or 
IL-17 expression in other conditions). Similar results were seen for the TNF+ response of 
conventional T cells (e.g. in control; 1.6% ± 1.5 cf 1.9% ± 1.4 for TNF expression; refer 
to Figure 61 C for TNF expression in other conditions), but the frequency of IL-17+ T 
cells was significantly higher in patient PBMCs than in patient TILs (e.g. in colorectal 
tumour lysates; 0.06% ± 0.01 cf 0.01%; refer to Figure 61 D for significant differences 
found in other conditions). In this instance though, the data still indicated very low 
responses irrespective of where the cells were located. 
Collectively, we concluded there was little difference between cytokine responses 
of MAIT cells from patient PBMCs and TILs after culturing with lysates and thus no 
significant difference in the responses of cells from different tissues. 
 
5.1.5. Summary 
Our findings indicated that exposure to cancer cell lysates had little impact on expression 
of cytokines such as TNF and IL-17 by innate-like T cells from both blood and tumours.  
 
5.2.1. Response of innate-like T cells to viable tumour cells 
The exposure to cancer cell lysates did not induce significant responses by MAIT cells or 
γδ T cells from patient tissue samples.  In this section, we tested the response of 
autologous tumour cells and T cells to viable autologous tumour cells. We pre-
conditioned patient TILs with 100 U/mL of IL-2 for 10 days before putting them into two 
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separate wells. At day 10, cells were cultured for 5 d with or without autologous tumour 
cells with 20 U/mL of IL-2. Golgiplug was added 4 h before harvest and cells were then 
assayed for intracellular cytokine expression. We first measured the frequency of overall 
MAIT cells or γδ T cells among divided (proliferated) or non divided (non proliferated) 
population but no noticeable difference was identified (Figure 62 A-B). In the next 
section, we measured the TNF or IL-17 response in the presence of autologous tumours 
among overall MAIT cells or γδ T cells.  
  
Figure 62. The frequency of overall innate-like T cells in patient TILs with or without 
re-challenge with autologous tumours after IL-2 stimulation. The frequency of divided 
(proliferated) or non divided MAIT cells (A) or γδ T cells (B) was investigated using 
patient tumours. A change to concentration of CFSE was used as a determining factor for 
proliferation. IL-2 stimulated MAIT cells in a single cell suspension from TILs in patients 
with solid cancer were cultured for 10 days before subsequent challenge with or without 
autologous tumour single cell suspension for 5 days. GolgiPlug was added 4 hours prior 
to harvest for measuring cytokine response (refer to Figure 62). Each symbol represents 
one sample. Statistical significance was determined by Mann–Whitney analysis (P<0.05 
*/ P<0.01**/ P<0.001*** / P<0.0001****). 
 
In this section, both MAIT cells and γδ T cells from patient TILs showed no significant 
TNF or IL-17 response to autologous tumours (e.g. TNF expression; 19.3% ± 9.2 with IL-
2 stimulation cf 45.7% ± 24.1 with IL-2 and re-challenge with autologous tumour cells in 
MAIT cells; 37.8% ± 35.5 with IL-2 cf 49.1% ± 45 with IL-2 & autologous tumour cells in 
γδ T cells. Refer to Figure 63 A-B) IL-17 expression; 1.8% ± 0.8 with IL-2 stimulation cf 
3.6% ± 3.1 with IL-2 and re-challenge with autologous tumour cells) (Figure 63). Given 
the difference in TNF response by MAIT cells in patient TILs (i.e. the raw values were 
higher for cultures with tumour cells), further study with more patient tumours are 
required to investigate whether responses are occurring. Furthermore, no significant 
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difference was also identified for non innate-like T cell populations (Figure 63 C-D). 
These findings indicate that autologous tumour cells do not induce a proliferative or 
cytokine response from innate-like T cells derived from patient TILs. However, given the 
large disparity in raw values of the TNF responses, further study of MAIT cells from 
patient TILs is warranted.  
 
Figure 63. The frequency of cytokine positive MAIT cells in TILs from patients with 
solid cancer. The frequency of TNF+ and IL-17+ positive MAIT cells was measured after 
MAIT cells from TILs of patients with solid cancer were cultured for 10 days with patient 
tumour cells. Cells were cultured for 5 d with IL-2 before challenge with autologous 
tumour single cell suspension. GolgiPlug was added 4 hours prior to harvest. Each 
symbol represents one sample. Statistical significance was determined by Mann–Whitney 
analysis (P<0.05 */ P<0.01**/ P<0.001*** / P<0.0001****). 
 
5.2.2. Summary 
Our study was a pilot investigation using small number of samples, and there was no 
significant response measured for MAIT cells and γδ T cells cultured with IL-2 and 
autologous tumour cells, but the TNF expression by these cells suggested further 
investigation with more samples and patient tumours is required.  
Similarly, no significant change was seen in MAIT-like T cells or T cells found in 
patient TILs. These findings indicate that MAIT cells or γδ T cells are responding to 
tumour cells similarly to other T cell populations, but the trend of higher responses in 
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cultures with tumour cells suggests the possibility of tumour specific responses by MAIT 
cells cannot be excluded and that further studies are warranted. 
 
5.3.1. Identification of lipids  
Our analysis of anti-tumour responses by innate-like T cells had involved tumour cell 
lysates and viable cells. NKT cells recognize lipid antigens presented by CD1d so we 
therefore prepared lipids from different tumour sources. The isolation of lipids was 
achieved using a lipid extraction kit and we used thin layer chromatography (TLC) to 
confirm lipids were present in extracts from colorectal adenocarcinoma cell lines 
LIM2407 and LIM2538. 
Lipid antigens from tumours have not been identified for NKT cells and we 
therefore considered the full range of different types, including phospho- and glyco-lipids. 
NKT cells have been shown to respond to some phospholipids 243 and there are 
phospholipids expressed by cancer cells 244,245.  We identified phospholipids in extracts 
using thin layer chromatography (TLC) 246. A mixture of acetone and sulfuric acid 
(orcinol) was used to stain TLC sheets after acidic or basic solvents were used to isolate 
phospholipids from extracts in control and test samples. Although we didn’t isolate 
individual phospholipids, an adaptation of this approach could be used to isolate specific 
lipids of interest in the future. 
We used known phospholipids as a reference point for testing samples, including 
1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PE), 1-stearoyl-2-oleoyl-sn-
glycero-3-phosphate (PA), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (PC), L-α-
phosphatidylinositol (PI), 1-stearoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (PS) or N-
nervonoyl-D-erythro-sphingosylphosphorylcholine (S). For test samples, we tested a wide 
variety of source material, including mouse hybridoma DK-1 (A), human colorectal 
cancer cell lines (LIM2407 & LIM2538) (B), human colorectal cancer ascites (C) and a 
serum from a patient with colorectal cancer (D) (Figure 64). We tested different extracts 
to confirm that lipids had been extracted. 
Our results confirmed that mouse hybridoma, colorectal cancer cell lines and 
colorectal ascites all contained phospholipids similar to reference points and some 
unknown phospholipids (Figure 64). Given this, we considered our lipid extraction was 
working. Patient serum (D) was distinct from the reference samples, suggesting these 
extracts had different phospholipids to positive control or they were not at high enough 
concentration to show all bands.  
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Figure 64. Identification of phospholipid using TLC. Lipid extracts from cancer cell 
lines and tumours were tested to assess lipid extraction. The lanes from left to right are 1) 
1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine(PE), 2) 1-stearoyl-2-oleoyl-sn-
glycero-3-phosphate(‘PA’ label on membrane) , 3) (PC) 1-stearoyl-2-oleoyl-sn-glycero-
3-phosphocholine (PC), 4) L-α-phosphatidylinositol(PI), 5)1-stearoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (PS), 6) N-nervonoyl-D-erythro-
sphingosylphosphorylcholine (S) (Note PS and S were used as reference points). For test 
samples, we used 7) a mouse hybridoma (A), 8 colorectal cancer cell lines (LIM2407 and 
LIM2538) (B), 9) ascites (patients with colorectal cancer) (C), and 10) patient serum (D). 
Test and control lipids were extracted using dichloromethanol and chloroform solution at 
a concentration of 100 mg/ml and spotted onto each lane on TLC plates based on position 
marked by pencil along horizontal line. To separate phospholipids, TLC plate was placed 
into glass chamber consisting of acidic condition (chloroform, methanol and acetic acid) 
or basic condition (chloroform, methanol and ammonium). We sealed glass chamber and 
left the TLC plates in glass chamber until solvent front was just below the top of TLC 
plates. Once TLC plate was removed, we dried using heat gun and sprayed acetone and 
sulfuric acid mix (orcinol) to stain TLC plates.  
 
5.3.2.  Innate-like T cell response to cancer cell lipids 
NKT cells stimulated by αGal-Cer release cytokines that can induce responses against 
cancer cells 200 and defects in NKT cells are associated with reduced anti-tumour 
immunity. One explanation is that lipid antigens from tumour cells can be recognized by 
NKT cells, however there is limited direct evidence. Exposure to different types of 
phospholipids can generate weak stimulation of NKT cells 247 and many cancer cells 
express CD1d, so we reasoned lipid antigens from cancer cells may  potentially stimulate 
ACID BASIC 
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NKT cells in local cancer cell microenvironment 198. Identification of natural cancer 
antigens could enhance the potential for targeting NKT cells as a therapeutic option.  
We considered NKT cells to be the most likely responder cell in these assays. 
Like NKT cells, MAIT cells have semi-invariant TCR restricted by non-MHC antigen 
presenting molecules and produce cytokines rapidly upon stimulation 15,37,61, but while 
NKT cells respond to lipids, most MAIT cells appear to respond to vitamin B metabolites 
37,248. Furthermore, γδ T cell antigens are poorly defined, although some are stimulated by 
a unique antigen, aminobisphosphate, inducing production of cytokines such as IFNγ 
52,73,242. However, subsets of γδ T cells have been identified that interact with CD1d 241 
and are therefore potential candidates to mount a lipid specific response.  
In this section, we cultured lipids extracted from colorectal cancer 
adenocarcinoma cell lines (LIM2407 and LIM2538 combined) with different innate-like 
T cells to test whether this induced an antigen specific response. 
We used PBMCs from healthy donors as a source of innate-like T cells and 
cultured these with extracted lipids from cancer cells at 200 ug of lipid per 1x106 cells for 
6 days with or without IL-2 (10 U/ml) stimulation. We used PBMCs from healthy donors 
because patient samples had been depleted in other experiments and our aim was to test 
typical responses rather than those form patient groups where defects in innate-like T 
cells would complicate analysis. We used an equivalent volume of 0.1% DMSO 
concentration in control cell culture media as DMSO was used to dissolve the lipids. Non 
innate-like T cell populations such as CD161+ T cells and MAIT-like (CD161-
Vα7.2TCR+CD3+) T cells were also used as prospective responder cells. 
Our results showed statistically similar overall frequencies of NKT, MAIT and γδ 
T cells (Figure 65 A-C) regardless of their exposure to lipids and little proliferation was 
detected (data not shown for proliferation).  
 
Figure 65. The frequency of innate-like T cells after culture with lipids from cancer 
cells. The frequency of overall innate-like T cells such as MAIT cells (A), NKT cells (B) or 
γδ T cells (C) was measured after 6d culture of PBKCs from healthy donors with lipids 
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(LIPID) and/ or IL-2 (10 U/ml). Wilcoxon test was used to test statistical significance 
(P<0.05* / P<0.01**/ P<0.001***/ P<0.0001****). 
 
I. Impact of lipids on the activation (CD25+) of different T cell populations  
i. Innate-like T cells. Our results showed no significant change in CD25 expression by 
NKT cells after culturing with cancer cell lipids, suggesting that NKT cells were not 
responding to the lipid extracts (e.g. 10.8% ± 1.5 with no lipids cf 12.6% ± 5 with lipids; 
13% ± 4 with IL-2 cf 16.2% ± 2.4 with IL-2 & lipids) (Figure 66 A). Similarly, the 
frequency of CD25+ MAIT cells or CD25+ γδ T cells also remained statistically 
unchanged regardless of exposure to lipids (e.g. CD25+ MAIT cells; 4.2% ± 1 with no 
lipids cf 3.5% ± 0.7 with lipids; CD25+ γδ T cells; 2.6% ± 0.75 with no lipids cf 2.2% ± 
0.6 with lipids. Refer to Figure 66 A-C for other condition). 
 
ii Non innate-like T cells. The proportion of activated (CD25+) T cells, CD161+ T cells 
and MAIT-like T cells was not significantly changed after culture with cancer cells 
derived lipids (e.g. for MAIT-like T cells; 7.3% ± 1.7 with DMSO cf 7% ± 1.7 with lipids; 
16.7% ± 5.3 with IL-2 cf 12.7% ± 4.5 with IL-2 & lipids. Refer to Figure 67 A-C for more 
details.). Collectively, our results showed that innate-like T cells in healthy PBMCs did 
not appear to respond directly to lipids isolated from cancer cell lines. 
 
Figure 66. CD25 expression by innate-like T cells after culture with cancer derived 
lipids. We cultured PBMCs of healthy donors with cancer-derived lipids for 6d with or 
without IL-2 (10 U/ml) and then measured the frequency of CD25+ MAIT cells (A), 
CD25+ NKT cells (B) or CD25+ γδ T cells. Wilcoxon test was used to assess statistical 
significance (P<0.05* / P<0.01**/ P<0.001***/ P<0.0001****). 
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Figure 67. CD25 expression by different non innate-like T cells after culture with 
cancer cell derived lipids. We cultured PBMCs of healthy donors with cancer-derived 
lipids for 6d with or without IL-2 (10 U/ml) and then measured the frequency of CD25+ 
MAIT-like (CD161-Vα7.2TCR+CD3+) T cells (A), CD161+ T cells (B) and T cells (C). 
Wilcoxon test was used to determine statistical significance (P<0.05* / P<0.01**/ 
P<0.001***/ P<0.0001****). 
  
II. Cytokine response of different T cell populations 
i. Innate-like T cells. We investigated the expression of TNF and IL-17 by NKT cells 
after exposure to the lipids, but there was no significant difference between cells exposed 
to cancer cells derived lipid extracts and controls with no lipids (e.g. for TNF+ NKT cells; 
4.1% ± 1 with no lipids cf 6.2% ± 3.7 with lipids; 8.9% ± 3.3 with IL-2 cf 7.4% ± 3.3 with 
IL-2 & lipids; for the frequency of IL-17+ NKT cells, refer to Figure 68 A-B). Likewise, 
MAIT cells or γδ T cells showed no TNF or IL-17 response to cancer cell derived lipids 
(e.g. TNF+ γδ T cells; 0.52% ± 0.16 with no lipids cf 0.48% ± 0.19 with lipids; 0.96% ± 
0.27 with IL-2 cf 1.2% ± 0.36 with IL-2 & lipid; for IL-17 expression; for TNF+ MAIT 
cells; 0.7% ± 0.23 with no lipids cf 0.46% ± 0.18 with lipids; for TNF expression in other 
conditions or IL-17 expression with or without lipids, refer to Figure 68 C-F).  
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Figure 68. The frequency and TNF and IL-17 cytokine profile of innate-like T cells 
from PBMCs of healthy donors after culture with cancer cell derived lipids. The 
frequency of TNF+ or IL-17+ NKT cells (A-B), MAIT cells (C-D) or γδ T cells (E-F) from 
healthy donors was measured after culture with (or without) colorectal cancer cell line 
derived lipids and with or without IL-2 (10 U/ml) was determined. Golgiplug was added 4 
h before harvest. Wilcoxon test was used to determine statistical significance (P<0.05* / 
P<0.01**/ P<0.001***/ P<0.0001****). 
 
ii. Non innate-like T cells. Broader T cell populations, such as CD161+ T cells and 
conventional T cells, also gave similar results (e.g. TNF+ CD161+ T cells; 0.3% ± 0.03 
with no lipids cf 0.5% ± 0.09 with lipids; 1% ± 0.23 with IL-2 cf 0.74% ± 0.18 with IL-2 
& lipids; for IL-17+ CD161+ T cells, refer to Figure 69 A-B). Similarly, MAIT-like T 
cells also showed no significant change in expression of TNF or IL-17 after culture with 
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cancer cells derived lipids (e.g. TNF+ MAIT-like T cells; 1% ± 0.4 with DMSO cf 0.8% ± 
0.4 with lipids; for expression of TNF or IL-17 by MAIT-like T cells or CD3+ T cells, 
refer to Figure 69 C-F). These findings indicate that NKT cells and other T cells did not 
respond to lipid extracts from the cancer cells. 
  
Figure 69. The frequency and TNF and IL-17 cytokine profile of non innate-like T 
cells from PBMCs of healthy donors after culture with cancer cell derived lipids. The 
frequency of TNF+ or IL-17+ CD161+ T cells (A-B), MAIT-like (CD161-
Vα7.2TCR+CD3+) T cells (C-D) or CD3+ T cells (E-F) from healthy donors was 
measured after culture with (or without) colorectal cancer cell line derived lipids and 
with or without IL-2 (10 U/ml) was determined. Golgiplug was added 4 h before harvest. 
Wilcoxon test was used to determine statistical significance (P<0.05* / P<0.01**/ 
P<0.001***/ P<0.0001****). 
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 5.3.3. Summary  
We chose to test the response of innate-like T cells from PBMCs of healthy donors to 
lipids from cancer cells. Our primary interest was in the response of NKT cells because 
they are CD1d restricted and are known to recognize lipids and have an important role in 
anti-tumour immunity. However, we saw no evidence of a significant response by NKT 
cells or other T cells when cultured with lipids derived from cancer cells. Our sample 
sizes were low and lipids from only a few cancer lines were tested, but based on our 
assaying of TNF, IL-17 and CD25 responses, our data does indicate that NKT cells from 
healthy donors do not universally detect lipids from cancer cells.  
 
5.4. Chapter 5 discussion 
A key question of this project was whether innate-like T cells in cancer patients directly 
respond to cancer cells or their antigens. Previous studies have shown that innate-like T 
cells from patients with cancer have the capacity to induce anti-cancer response through 
production of cytokines upon stimulation with various stimulants 73,171,231 and our results 
particularly from Chapter 4 also confirms this as functional capacity to produce cytokines 
associated with anti-tumour response such as IFNγ and TNF were maintained by innate-
like T cells in tissues from patients with blood or solid cancers when compared to healthy 
PBMCs.  A key trait of innate-like T cells is their rapid response to stimuli, including 
αGal-Cer, vitamin B metabolites and aminobisphosphate for NKT cells, MAIT cells and 
γδ T cells, respectively 52,172,249. However, these antigens are not cancer-derived and it is 
unclear whether innate-like T cells can recognize cancer-derived antigens.  
To investigate this, we cultured lymphocytes with cancer-derived lysates or lipids 
to measure the proliferative and cytokine responses of innate-like T cells. Where possible, 
we also tested whether innate-like T cells could induce response specifically to 
autologous tumour cells but this was limited by not investigating patient matched PBMCs 
as we exhausted PBMCs to conduct experiments on previous chapters. Unlike Chapter 4, 
we used whole single cell suspension from patient tissue samples or healthy PBMCs and 
no sorting of certain cell population (i.e. innate-like T cells) was involved. This allowed 
for innate-like T cells to potentially engage with cancer cells or other immune cells such 
as antigen presenting cells (APCs) so that we could better understand the dynamics if we 
detect anti-tumour response. Also, this form of assay allowed us to investigate different 
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innate-like T cell populations using single cell suspension from each patient tissue 
samples. 
 
I. MAIT cells. MAIT cells have been previously reported to increase their anti-tumour 
capacity by producing more IFNγ, TNF or IL-17 when in direct contact with cancer cell 
line after stimulation with PMA and ionomycin compared to MAIT cells with only PMA 
and ionomycin stimulation 69. Furthermore, another study showed that MAIT cells in 
patient PBMCs co-incubated with E.coli infected THP-1 cell line (a cancer cell line 
developed using acute monocytic leukaemia) was capable of activation with increased 
expression of granzyme B, perforin or CD107a compared to MAIT cells co-incubated 
with non-E.coli infected THP-1 cell line 197. These studies help to highlight possibilities 
of using cancer cells to stimulate MAIT cells and induce anti-tumour response or use 
stimulated MAIT cells to enhance anti-tumour response. However, no studies have 
reported whether MAIT cells are able to induce anti-tumour response specifically to 
antigens derived from cancer cells with limited or no supplements to condition MAIT 
cells (i.e. use of IL-2 in culture).  
To measure the anti-tumour response, we have measured key indicators such as 
changes to activation (CD25), cytokine expression or proliferation, the latter was based 
on changes to dilution of CFSE. When we tested the functional response of MAIT cells 
from patient PBMCs and TILs against lysates from patient tumours or colorectal cancer 
cell lines, our data showed little evidence of a response to lysates including proliferation. 
Lack of specific response was also highlighted by statistical outcomes and trend in the 
frequency of activated or cytokine positive populations from patient tissue samples. For 
instance, when patient tissue samples and healthy PBMCs was separately investigated for 
cancer cell specific response by comparing lysate exposed cells and control with no lysate 
exposure, no significant frequency difference was identified for activation (CD25) or 
intracellular cytokine expression (TNF or IL-17) in innate-like T cells. Furthermore, the 
trend of activated or cytokine positive innate-like T cells in patient tissue samples were 
mostly consistent between lysate exposed and non-lysate exposed cells when compared 
between patient tissue samples (i.e. PBMCs or TILs) to healthy PBMCs (Table 20-21). 
These findings together suggest that innate-like T cells in patient tissue samples or 
healthy PBMCs didn’t induce lysate specific response. Reflecting the trend observed in 
innate-like T cells, we also showed that broader non innate-like T cell populations such as 
CD161+ T cells also showed similar trends and statistical outcomes suggesting that 
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systemically, promotion of lysate specific response was less likely in patient tissue 
samples and healthy PBMCs. 
 
Table 20. Statistical outcomes measuring response of different T cell populations to 
lysates derived from patient tumours or cancer cell lines. The frequency of innate-like T 
cells and broader T cell populations in patient PBMCs, TILs or healthy PBMCs were 
investigated for response to exposure of lysates derived from patient tumours or cancer 
cell lines. In each assay Golgiplug was added 4 h prior to harvest after conditioned with 
or without lysates for 5 days. Tumour lysate was extracted from tumours of patients with 
colorectal (colon) cancer, sarcoma or from colorectal adenocarcinoma cell lines 
LIM2407, LIM2412 or LIM2538. Functional markers; CD25, TNF or IL-17 were 
measured among overall population and statistical results comparing between patient 
tissue samples and healthy PBMCs were colour coded based on statistical outcomes. 
Green represents significantly higher frequency of healthy donors compared to patient 
PBMCs or TILs, red represents significantly lower frequency of healthy donors and blue 
represents statistically similar outcomes.  
 
Table 21. Statistical outcomes measuring response of different T cell populations to 
lysates derived from patient tumours or cancer cell lines comparing patient PBMCs and 
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TILs. The frequency of innate-like T cells and broader T cell populations in patient 
PBMCs and TILs were compared for the functional response to exposure of lysates 
derived from patient tumours or cancer cell lines. In each assay Golgiplug was added 4h 
prior to harvest after conditioned with or without lysates for 5 days. Tumour lysate was 
extracted from tumours of patients with colorectal (colon) cancer, sarcoma or from 
colorectal adenocarcinoma cell lines LIM2407, LIM2412 or LIM2538. Functional 
markers; CD25, TNF or IL-17 were measured among overall population and statistical 
results comparing between patient PBMCs and TILs were colour coded based on 
statistical outcomes. Orange represents significantly higher frequency of patient TILs 
compared to patient PBMCs, purple represents significantly higher frequency of patient 
PBMCs compared to patient TILs and blue represents statistically similar outcomes.  
 
Since our data from Chapter 3 showed significantly higher frequency of CD25+ MAIT 
cells particularly in patient tumours compared to healthy donors, we next measured a 
potential functional response specific to viable cancer cells by innate-like T cells and 
broader T cell populations using cells assayed with or without exposure to autologous 
tumour cells. When we compared MAIT cells in patient TILs with or without re-
challenge with autologous single cell suspension from patient TILs with IL-2 supplement, 
we couldn’t statistically establish changes based on cytokine expression to suggest that 
MAIT cells in patient TILs induced a significantly different response when re-challenged 
with autologous tumour cells. There were large differences in the raw TNF expression 
data between re-challenged and non re-challenged MAIT cells from patient TILs and 
while not statistically significant, this observation may warrant further investigation with 
greater statistical power (Table 22). The difference found for TNF+ MAIT cells in patient 
TILs did show different trend to broader T cell populations, the latter showed very similar 
proportion of cytokine positive populations regardless of re-challenge with autologous 
tumour cells. Due to use of high IL-2 concentration (100 U/ml), we didn’t investigate 
changes to CD25 expression. We also investigated overall frequency and proliferation but 
no noticeable difference was identified indicating that tumour cells specific response was 
triggered. Therefore, our findings supported that MAIT cells in patient TILs are less 
likely to induce specific response in the presence of tumour cells. However, this 
investigation was limited by lack of patient tissue samples and more access to patient 
tissue samples including PBMCs (patient matched) will be important for better statistical 
power to provide more definitive conclusion and perhaps answer whether systemic 
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impact is present in patients with solid cancer if functional capacity to induce anti-tumour 
response was identified. 
 
Table 22. Statistical outcome comparing functional response of different T cell 
populations with or without re-challenge with autologous tumour cells. The cytokine 
positive frequency of innate-like T cells and broader T cell populations in patient TILs 
were compared with or without viable autologous tumour cells.  The tumour cells and 
lymphocytes (including different T cell populations) was cultured with IL-2 (100U/mL) 
for 10 days before rechallenging with or without freshly thawed autologous single cell 
suspension (consisting tumour cells) for further 5 days with 10 U/mL IL-2. Each assay 
was added with Golgiplug 4 h prior to harvest. Functional markers; CD25, TNF or IL-17 
were measured among overall population and statistical results comparing between 
patient tissue samples and healthy PBMCs were colour coded based on statistical 
outcomes. Green represents significantly higher frequency was identified in cells re-
challenged with autologous tumour cells compared to non re-challenged cells, red 
indicates significantly lower frequency was identified in cells re-challenged with 
autologous tumour cells and blue indicates statistically similar outcomes. 
 
In conjunction with assaying for other innate-like T cells such as NKT cells, which we 
discuss later, we tested whether MAIT cells would respond to lipids from colorectal 
cancer cells lines. Since it was previously reported that lipids such as different forms of 
phospholipids are identified in cancer cells from patients with colorectal cancer 245, it was 
relevant in context to this chapter to investigate whether MAIT cells could potentially 
induce response to lipids derived from cancer cells. We expected that MAIT cells would 
not respond to lipids given their recognition of vitamin B metabolites of bacterial origin 
via MR1 dependent manner 248, whereas other innate-like T cells such as NKT cells were 
more likely given their reactivity to lipids via CD1d 37. Indeed, MAIT cells did not 
respond to the exposure of cancer cells derived lipids as no significant difference or 
different trend was identified for proliferation or overall frequency of MAIT cells. In 
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addition, CD25 expression or intracellular cytokine expression of TNF or IL-17 also 
revealed no significant difference (Table 23). Despite the lack of statistical significance, 
the disparity in the raw data for IL-17 production by MAIT cells when comparing lipid 
exposed cells and control cells without lipid exposure which may warrant further 
investigation. We have exhausted patient tissue samples, we only managed to investigate 
healthy PBMCs. 
Taken together, our study showed that MAIT cells from patient tissue samples 
were not directly responding to cancer cells or their antigens in lysates or lipids. We 
cannot exclude the possibility of responses to different antigens. 
  
Table 23. Statistical outcome comparing functional response of different T cell 
populations with or without lipids extracted from colorectal cancer cell lines. The 
cytokine (TNF/IL-17) positive or activated (CD25) frequency of innate-like T cells and 
broader T cell populations in healthy PBMCs were compared with or without viable 
autologous tumour cells.  Each assay was added with Golgiplug 4 h prior to harvest after 
conditioned with or without lipids for 6 days and we also conducted similar comparison 
with low concentration of IL-2 (10 U/ml) as supplement to cell culture. Functional 
markers; CD25, TNF or IL-17 were measured among overall population and statistical 
results comparing between patient tissue samples and healthy PBMCs were colour coded 
based on statistical outcomes. Green represents significantly higher frequency of cells 
identified when exposed to lipids compared to cells conditioned with no lipids regardless 
of IL-2 supplement, red represents significantly lower frequency of cells identified when 
exposed to lipids compared to cells conditioned with no lipids regardless of IL-2 
supplement and blue represents statistically similar outcomes. 
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II. NKT cells. The importance of NKT cells for inducing anti-tumour response was first 
reported in Jα281 gene targeted mouse study, which showed that NKT cells without any 
external stimulation were able to protect against spontaneous tumours generated by 
injection of chemical carcinogen (methylcholanthrene) 99.  While other studies described 
anti-tumour capacity of NKT cells after stimulation with αGal-Cer, it is not clear how 
NKT cells respond and regulate immune response in patients with cancer. In humans, past 
reports showed that NKT cells have functional abnormalities including reduced 
proliferation in patients with cancer 162,163 and therefore, requires further investigation to 
better understand the impact on anti-tumour response generated by NKT cells in patients 
with cancer.  
NKT cells can respond to phospholipids 247,250,251 and we therefore tested whether 
phospholipids from colorectal cancer cell line could induce a NKT cell response. We 
didn’t have sufficient NKT cell number in patient tissue samples so only healthy PBMCs 
were used. Our results showed that the frequency of activated (CD25+) NKT cells or their 
intracellular TNF or IL-17 expression among overall population was unaffected 
regardless of culturing with the lipids (Table 23). We did detect a small proportion of 
NKT cells responding in the presence of lipids, so it would be interesting to examine the 
response to lipids from other cancers. 
Our findings were similar to some past studies, which identified small proportions 
of NKT cells responding to lipids in vitro. In a study using lipids extracted from serum of 
multiple myeloma patients, most CD1d restricted T cells that responded were Vα24-
Vβ11- T cells while other studies showed that Type 2 NKT cells, and not NKT cells were 
responsive to phospholipids 243,252. Supporting these findings, another study showed that 
NKT cells are able to respond to different forms of phospholipids but the proportion of 
NKT cells responding was low for most phospholipids 247.  
In our project, we didn’t see any noticeable differences in response based on 
activation or cytokine expression non NKT cells, even though past studies reported that 
lipid responding T cells were mostly Vα24-Vβ11- T cells 252. While we did not 
specifically investigate Vα24-Vβ11- T cells, other T cell populations also did not respond 
to lipid extract. 
Taken together, the response by NKT cells to cancer cell-derived lipids were weak 
and suggest NKT cells were not directly recognizing these lipids. It is possible NKT cells 
are activated by other means (e.g. IL-12) but it would be valuable to conduct more studies 
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of NKT cell responses to phospholipids extracted from cancer cell lines. Perhaps, further 
purification of lipids is required for this type of study. 
 
III. γδ T cells. Like NKT cells, γδ T cells are associated with anti-tumour response. Past 
studies have reported that tumours develop and progress when γδ T cells are reduced or 
depleted 175,176 and in an ex vivo mouse model of human breast cancer, adoptively 
transferred γδ T cells migrated to tumour sites and induced an anti-tumour response 177. 
The anti-tumour response of γδ T cells is proposed to be mediated through a direct 
cytotoxic response or by producing cytokines such as IFNγ 236. Although 9γ2δ T cells can 
induce anti-tumour responses when stimulated with aminobisphosphate or spontaneous 
lysis of leukemic cells 236,253,254, studies are limited and questions remain regarding their 
capacity to directly respond to tumours. We showed here that in the presence of lysates 
from patient tumours or cell lines, there was no significant impact on the frequency of 
activated γδ T cells, including their expression of cytokines, TNF or IL-17 when 
compared to control with no lysates among patient PBMCs or TILs. We also showed that 
γδ T cells from patient PBMCs and TILs or healthy PBMCs did not respond specifically 
to different lysates and similar observation was made when patient PBMCs and TILs 
were compared for tissue specific impacts (Table 20-21). Collectively, our results suggest 
that γδ T cells from both patients and healthy donors were not being activated specifically 
by lysates derived from cancer cells.  
We next measured the response of γδ T cells to autologous tumour cells. 
Consistent with our results with lysates, no significant difference in frequency or cytokine 
expression (Table 22) was seen following culture with autologous tumour cells. A past 
study reported spontaneous killing of autologous leukemic cells in vitro 253, but we didn’t 
identify a similar response. While it is possible that the low number of γδ T cells we used 
impacted the sensitivity of the study, overall, it seemed that γδ T cells were not activated 
by lysates or intact tumour cells.  
Lastly, we tested whether γδ T cells from PBMCs of healthy donors could respond 
to lipids derived from colorectal cancer cell lines. Previously, some subsets of γδ T cells 
were reported to respond to αGal-Cer, a form of lipid presented through CD1d 15,70. We 
observed that γδ T cells maintained their functional capacity in the presence of extract 
derived from cancer cell line, but did not appear to respond specifically (Table 23).  
Taken together with other results in this chapter, we showed that MAIT cells, NKT 
cells and γδ T cells have maintained their functional capacity to be activated or to express 
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cytokines in the presence of lysates, lipids or even in the presence of autologous tumours 
cells. However, we didn’t identify a response to suggest that innate-like cells are capable 
of specifically recognizing cancer cells.  
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Chapter 6: Concluding remarks 
Innate-like T cells are well established as a distinct T cell population with unique 
phenotypical and functional features. They have restricted TCR specificities and respond 
to stimulation with a rapid release of cytokines 37,52,255. Their TCRs recognize antigens 
presented by non-MHC antigen presenting molecules. Classic examples of such antigens 
include αGal-Cer and vitamin B metabolites presented by CD1d and MR1 to NKT cells 
and MAIT cells respectively 38,200. Although we have some insights into the importance 
of these T cells, there are still many questions about their role in cancer immunity. The 
recent emergence of MAIT cells as a distinct lineage of innate-like T cells with 
similarities to NKT cells further emphasises the need to better understand the potential 
roles of innate-like T cells in patients with cancer. 
In cancer, animal studies have established that innate-like T cells can play 
important roles in promoting immune responses against cancer cells. Such findings led to 
clinical trials targeting innate-like T cells, but these have not always provided consistent 
results and there is still uncertainty about the frequency and functional capacity of innate-
like T cells in patients with cancer.  
One obstacle to a better understanding of innate-like T cells in patients with 
cancer has been that previous studies have used quite different experimental designs, 
including how the different subsets were identified. A limited access to human tissue 
samples has often been a limiting factor of this type of study as well.  
The frequency of innate-like T cells is significantly lower than for conventional T 
cells and this poses significant challenges for our studies as it has as in previous studies. 
For example, the frequencies of innate-like T cells in PBMCs of healthy donors are 
0.01% - 5% (NKT cells), 1% - 4% (MAIT cells) and 1% - 10% (γδ T cells) 53,226,256. 
Given that abnormally reduced frequency reported for innate-like T cells from patients 
with cancer, conducting expression and functional research on innate-like T cells using 
patient tissue samples of usually <20 ml whole blood were very challenging 182,198.   
This PhD project was the first to characterize a large number of tissue samples from 
many different patient groups with cancer. Over 200 tissue samples were assayed from 
over 120 cancer patients to address key questions about the importance of innate-like T 
cells in cancer and anti-cancer immunity. They included the following questions: 
 
  
200 
1. Is the frequency of innate-like T cells (and their subsets) in cancer patients 
comparable to healthy people? Previous studies have mostly focussed on one T 
cell lineage and/or one patient group, but we assayed all of the most important 
innate-like T cell lineages and their expression of important markers such as CD4, 
CD8 and NK surface receptors that help mediate some functions and also identify 
subsets. While most previous studies had focussed on blood of patients we tested 
blood and tumour samples that were often patient-matched to determine if the 
immune activity in tumours correlated with that in blood. This enabled an 
assessment of whether the tumour microenvironment was influencing the local 
immune activity.   
2. Are innate-like T cells from patients with cancer defective in their cytokine 
production? The immune regulatory activities of innate-like T cells are mostly 
attributed to their cytokine production and defects have been previously reported 
for some patient groups. We stimulated innate-like T cells and measured their 
cytokine production as well as relevant surface antigens such as activation 
markers. 
3. Do innate-like T cells in cancer patients respond to cancer cells? Innate-like T 
cells are thought to enhance anti-tumour responses, but it is not clear how or 
where this happens. We directly measured the response of innate-like T cells from 
both the blood and tumour of patient groups to tumour cells and antigens.  
 
MAIT cells. MAIT cells had been identified in neuroblastoma and renal tumours and a 
deficiency of MAIT cells had been reported in a study of colorectal cancer patients, but 
few other groups had been studied 160,197,257.  In Chapter 3, we identified deficiencies in 
several patient groups that were more severe than the deficiencies that were sometimes 
seen in broader T cell populations. The deficiency appeared to affect CD8+ and CD8- 
subsets equally as no changes in distribution were identified.  
 We also report for first time that CD25 expression (activation) by MAIT cells was 
significantly higher in cells from patients with blood or solid cancer compared to cells 
from PBMCs from healthy donors, indicating a possible functional involvement in 
patients with cancer. An increase in activation was also identified in broader T cell 
populations, however, the increase in MAIT cell activation was usually higher than for T 
cells, particularly in tumours, perhaps suggesting a specific response. Interestingly, CD8+ 
MAIT cells were more activated than the CD8- subset in both PBMCs and TILs of 
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patients with colorectal cancer suggesting this subset may be preferentially responding to 
tumour cells. It is not clear from our data how increases in activation impacted patients 
and these warrants further study. 
Previous studies have shown a reduced cytokine response by innate-like T cells 
from patients with cancer 160,197. Most studies examined NKT cells, although one of the 
few studies to assay cytokine responses by MAIT cells found lower than normal cytokine 
responses by MAIT cells in patients with colorectal cancer 68. In contrast, our study of 
MAIT cells from many different patient groups showed that MAIT cells from blood, 
tumours and bone marrow had mostly maintained their capacity for IFNγ, TNF and IL-4 
expression after stimulation. This included patients with colorectal cancer and suggests 
that MAIT cells in patients are as capable of mounting a cytokine response as those from 
healthy donors. It is important to note that we stimulated cells using PMA and ionomycin 
to enable detectable responses from small numbers of cells, so we cannot exclude the 
possibility that more subtle defects could be identified in antigen or cytokine mediated 
activation assays 258. Taken together, our findings indicate that cytokine expression from 
MAIT cells in patients with cancer was normal, although we cannot rule out more subtle 
defects 160,162,180.  
 Stimulated MAIT cells cultured with cancer cells have previously been reported to 
produce more IFNγ, TNF or IL-17 than MAIT cells stimulated without cancer cells 69. 
MAIT cells from patient PBMCs co-incubated with E.coli infected THP-1 cell line had 
increased expression of granzyme B, perforin and CD107 compared to MAIT cells co-
incubated with non- E.coli infected THP-1 cell line 197, which shows that MAIT cells can 
be stimulated in culture with tumour cells, but these studies used stimulants unrelated to 
cancer cells. We cultured MAIT cells with tumour cells or their lysates, including lipids 
to test for responsiveness of the overall MAIT cell pool or of subsets. In this project, we 
could not detect a MAIT cell response to these tumour derived antigens, which suggests 
the increase in activation observed in patients may be due to another stimulus, such as IL-
12, although further testing of possible cancer specific responses by MAIT cells may be 
worthwhile.  
 Our finding of a MAIT cell deficiency in many patient tissue samples requires 
further investigation as we mostly investigated one time point per patient. It is therefore 
difficult to know if the deficiency was caused by the cancer, or if it preceded and perhaps 
predisposed to it. A longitudinal study would help to better understand the causes and 
kinetics of changes in MAIT cell frequency in patients with cancer. Another limitation of 
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our study was that we didn’t have access to non-cancerous tissues from patients to 
directly compare the frequency of MAIT cells. A previous study reported significant 
increase in tumour infiltrating MAIT cells in patient with colorectal cancer in comparison 
to non-affected colon patient tissue samples and it would be interesting to extend this to 
other groups to determine how the MAIT cell frequency is affected by tumours 68.  
Collectively, we have studied several important characteristics of MAIT cells in 
patients with cancer. We have extended earlier studies by analysing patient groups with 
solid forms of cancer other than colorectal cancer and we have investigated patients with 
blood cancers such as CLL, NHL and MM. Our findings that many of these patient 
groups have a deficiency in MAIT cells indicates that these defects may be associated 
with the cancer and more studies are now needed to define the natural role of these cells.  
 
II. NKT cells. NKT cells have been more widely studied than MAIT cells and other 
innate-like T cells. The importance of NKT cells for anti-tumour responses was first 
reported in NKT cell deficient mice, which showed that NKT cells are important for 
protection against spontaneous tumours induced by injection of methylcholanthrene (a 
chemical carcinogen) 99. The importance of NKT cells is well established in animal 
studies but studying their importance in patients with cancer has been challenging due to 
their 100-fold lower frequency in humans compared to mice 36. In fact, NKT cells have 
the lowest frequency of the innate-like T cells we studied in PBMCs of healthy donors 
197,226,259,260, which poses technical challenges for investigating them. In Chapter 3, we 
showed that the overall frequency of NKT cells was consistently deficient in patients with 
blood or solid cancers, which supports the hypothesis that reduced NKT cell frequency 
may predispose to cancer, as suggested in animal studies. We found that many patient 
groups had a significant deficiency of NKT cells more severe than that of broader T cell 
populations. However, unlike some earlier studies, the deficiency did not impact the 
relative proportion of CD4+ and CD4- NKT cell subsets, which was comparable between 
patients with cancer and PBMCs of healthy donors. Interestingly, we didn’t identify a 
significantly increased proportion of activated (CD25+) NKT cells in patients as we did 
for MAIT cells. This was unexpected as several animal studies have indicated that NKT 
cells with no external stimulants could protect host from chemically induced cancer 99.  
In Chapter 4, we measured the functional capacity of sorted NKT cells to produce 
cytokines when stimulated with PMA and ionomycin. Interestingly, we showed that 
stimulated NKT cells in patient PBMCs were not deficient and in fact sometimes showed 
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increased capacity to produce IFNγ or TNF. The increase was especially evident for CD4-
CD8- (DN) subset which was interesting given the DN subset is regarded as more 
important for anti-tumour immunity because of their Th1 profile for producing cytokines 
such as IFNγ and TNF157. As patient TILs and PBMCs appeared to maintain their 
capacity to produce cytokines, this suggests that reduced overall NKT cell frequency 
rather than functional defects could be the most important abnormality for NKT cells in 
patients with cancer. It is not clear why some other studies have reported defects in 
cytokine release, although there have been several conflicting studies in this area. A 
possible explanation is the means of stimulating the cells as some other studies have used 
PHA and αGal-Cer as a stimulant. Nevertheless, our study shows the functional capacity 
of NKT cells appears to be intact for patients with solid cancer. 
We were not able to directly test whether NKT cells are able to respond directly to 
cancer cells or lysates, or in the presence of autologous tumour cells, but we did test their 
response to lipids extracted from colorectal cancer cell lines. We established that these 
extracts contained phospholipids from tumour cells but, no significant evidence of 
stimulation was found. 247.  
Taken together, we showed that NKT cells from patients with cancer had a 
deficiency in NKT cells, but had retained their cytokine response to stimulation with 
PMA and ionomcycin. We saw no direct evidence to suggest that NKT cells could 
recognize tumour antigens. 
 
III. γδ T cells. The precise function of γδ T cells is still poorly understood but they can 
contribute to immune surveillance against cancer cells, with past studies reporting 
increased development and progression of tumours when γδ T cells are reduced or 
depleted in animal cancer models  175,176. Like NKT cells, there have been conflicting 
reports about γδ T cell frequency in patients with cancer. For example, it was reported 
that breast cancer patients exhibit higher frequency of γδ T cells in blood compared with 
healthy counterparts 206, while melanoma patients had a lower frequency of γδ T cells 180. 
In contrast to MAIT cells or NKT cells, we showed that the frequency of γδ T cells was 
comparable in patients and healthy donors. One earlier study 213 identified opposing 
changes in subsets of γδ T cells, as the frequency of tumour infiltrating γδ T cells in rectal 
cancer showed an increase in the δ1 subset of γδ T cells while the δ2 subset decreased. 
We did not examine these subsets, but interestingly we found a higher proportion of 
activated γδ T cells in patient TILs suggesting that γδ T cells could have a functional role 
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in patients with cancer.  Our study was designed to example the population as a whole, so 
further investigation of subsets would be informative. 
We found γδ T cells from PBMCs or TILs of patients with solid cancers were 
similar in their responses to stimulation as PBMCs of healthy donors. This was different 
to some previous studies that showed conflicting results in different solid cancers. For 
instance, IFNγ and TNF expression was lower in γδ  T cells of patients with melanoma 
was lower 180 whereas cells of patients with breast cancer had significantly higher TNF 
expression than in cells when respective patient PBMCs were compared to PBMCs of 
healthy donors and comparable IFNγ expression 186. Once again, the fact that these 
studies used different stimulation methods complicates interpretation but our study 
suggests that γδ T cells frequency and cytokine productivity was normal in these patient 
groups. 
In the third results chapter, we asked whether γδ T cells could respond to cancer 
cells derived lysates, lipids or autologous tumour cells. Past studies have showed some 
evidence that γδ T cells are capable of responding to cancer cells but to date, only non-
tumour antigens have been identified including microbial derived (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMB-PP) and αGal-Cer 187,241. There is also evidence 
that γδ T cells can mount spontaneous cytotoxic response to autologous leukemic cells or 
myeloma cell lines 185,261, however, our cultures of γδ T cells with cancer cell lines or 
patient tumour derived lysates or autologous tumour cells showed no significant evidence 
of activation. As described earlier, one study reported that γδ T cells could respond to the 
NKT cell lipid antigen αGal-Cer through interaction with CD1d 241, but we saw no 
response of γδ T cells to lipids extracted from colorectal cancer cell lines.  
Taken together, we showed in this project that γδ T cells in patient PBMCs or 
TILs had normal frequency and cytokine responses when compared to PBMCs of healthy 
donors suggesting they were not impacted by the presence of cancer cells and we saw no 
evidence that γδ T cells mount a direct response to cancer cells.  
Our examination of responses to cancer cells and antigens by innate-like T cells 
was intended to be broad and more refined methods may identify more subtle defects or 
differences. These approaches could include analysis of separate γδ T cell subsets and 
separately assaying the response against individual proteins and lipids extracted from 
cancer cells grouped by the size or by structural properties such as non-polar or bipolar 
lipids. This may enable responses to be detected against relatively rare antigens that may 
otherwise be masked. Another factor to consider is use of antigen presenting cells such as 
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monocyte derived dendritic cells to enhance the antigen presentation to innate-like T cells. 
However, this approach requires a significant amount of patient tissue samples with large 
number of viable immune cells.  
This is difficult to achieve with patient samples due to the challenges in coordinating 
clinicians and donors and the competing need for samples to be used in patient care by 
pathology laboratories for clinical care of the patient.  Past studies have highlighted the 
availability of tissue samples as an obstacle to experimental research . In my PhD project, 
the rarity of the cell populations and the relatively small patient samples restricted the 
type and statistical power of experiments, so we often used groups sizes of ~5, which 
usually allowed for meaningful analysis of more than one type of assay. Experiments that 
were most impacted were patient matched samples (i.e. CLL), assays of cell function 
(cytokine and antigen specific response) and molecular studies. , however our studies 
represented a significant step forward because they had often never been conducted 
previously or involved smaller group sizes. Therefore, while technical advances may be 
required before more detailed analysis is possible, the data we generated represents an 
important advance. One limitation resulting from small sample numbers is that groups 
could not be separated into subpopulations. For example, the CLL group includes patients 
at different stages of disease progression and there are other factors including age, sex 
and treatments that could potentially impact the results. The number of samples prevented 
this depth of analysis, however the primary aim of my project was to identify broad 
defects within patient groups that could then be studied in more detailed research. Indeed, 
my research has already led to the appointment of new PhD students who are studying 
MAIT cells in CLL and colorectal cancer and will be able to examine these variables 
because we have access to more samples because of the interesting pilot studies.  
One of our key findings was a deficiency of innate-like T cells such as NKT cells 
and MAIT cells in patient tissue samples compared to healthy PBMCs. The effectiveness 
of anti-tumour responses can sometimes be reduced where there are defects of innate-like 
T cells, which may be due to reduced levels of cytokines such as IFNγ and TNF that are 
associated with anti-tumour responses. This can directly affect anti-tumour immunity, but 
also impact the overall immune surveillance and hence make patients more vulnerable to 
development and progression of the disease.  Regardless of whether the deficiency is a 
risk factor or caused by disease itself, these innate cell defects may lead to a reduced 
capacity for anti-tumour responses and resolving this appears to be one of the challenges 
shared across different forms of cancer that could be addressed by targeting innate like T 
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cells in new treatments. Interestingly, we showed that patients with the lowest frequency 
of NKT cells or MAIT cells as a proportion of T cells) didn't equate to the lowest 
frequency of broader T cell populations (data not shown). While both innate-like T cells 
and broader T cell populations were deficient, patients with the lowest frequency of T 
cells did not always have a lower proportion of innate-like T cells.  
Studying expression of CD1d and MR1 in patients with cancer could provide us 
with better understanding of the different characteristics of these cells. It is well 
established that innate-like T cells such as NKT cells and MAIT cells interact with CD1d 
and MR1 respectively and that these are expressed on cancer cells 197,262. Interestingly, 
increased expression of CD1d on malignant cells in PBMCs of patients with CLL was 
associated with a  poor clinical outcome 198 but most other different forms of cancer have 
not been investigated for CD1d and MR1 expression. This analysis was beyond the scope 
of this project but it would be interesting to determine whether the expression of CD1d 
and MR1 correlates with different clinical stages of disease with changes to frequency of 
innate-like T cells. 
As far as functional roles of innate-like T cells are concerned, there are many  
different transcriptional factors expressed by innate-like T cells (especially for NKT cells) 
that are lined to specific functional roles 15,263,264, but many of these have not been 
examined in cancer and perhaps further investigations could be helpful in establishing the 
nature of the defects of these cells. Similarly, it may be worthwhile examining the 
expression of the various NK markers expressed by innate-like T cells because these are 
often associated with activation (e.g. NKG2D) or inhibition (e.g. NKG1A) of cytotoxic 
responses 265. Investigating these NK markers may help reveal the capacity of innate-like 
T cells from patient groups to respond to cancer cells, although this was not possible for 
this project. 
Collectively, this project investigated innate-like T cells with consistent and 
rigorous approaches for cell identification and functional analysis. This project has 
provided an overview of innate-like T cells in humans with cancer that identifies cells and 
patient groups where one or more of the innate-like T cell lineages is different from what 
is seen in healthy donors. We used predominantly treatment free tissue samples to 
conduct the research that minimized variability when interpreting data. To our knowledge, 
this is the first study to investigate NKT, MAIT and γδ T cells concurrently across 
different cancer groups in humans. We have especially expanded the knowledge base of 
MAIT cells in cancer by using patient groups where MAIT cells had never previously 
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been studied, in conjunction with detailed analysis of MAIT cells from patients with 
colorectal cancer where some defects had been identified. Our project highlighted that 
innate-like T cells are generally deficient in patients with cancer but that they retain a 
comparable functional capacity to healthy controls. The deficiency of NKT cells and 
MAIT cells in particular could mean a predisposed risk to cancer as there is significant 
evidence they can impact anti-tumour responses. It is critical to now determine whether 
these defects are present before the onset of cancer or are a result of it. This knowledge 
will help determine if innate-like T cells can be used as biomarkers to identify at risk 
individuals, or as targets of new immune based therapies to promote effective immunity 
by restoring innate-like T cell numbers and function. 
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